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ABSTRACT 
Mohamed A. Zayed: CIB1 Mediated Regulation of Endothelial Cells and Pathological 
Angiogenesis 
 
(Under the direction of Leslie V. Parise, Ph.D.) 
 
 
Calcium and integrin binding protein 1 (CIB1), a 22kDa EF-hand containing protein, 
that was originally identified to bind the platelet integrin αIIb, can also bind and regulate 
various other proteins.  Among the newly identified CIB1-binding partners is the p21-
activated kinase 1 (PAK1), which is known to regulate ECs and contribute to angiogenesis in 
vivo.  Since CIB1 is present in highly vascularized tissue and is expressed in various types of 
ECs, we hypothesized that it may also have an important role in vascular tissue.  The work 
described herein is a collection of studies that for the first time investigates the role of CIB1 
in EC signaling, function, and angiogenesis. 
 
Pathological angiogenesis contributes to various ocular, malignant, and inflammatory 
disorders, emphasizing the need to understand this process on a molecular level.  We 
demonstrate here that CIB1 is necessary for various EC functions such as migration, 
proliferation, tubule formation, and monolayer permeability.  CIB1 also regulates PAK1 
activation, as well as downstream ERK1/2 phosphorylation and MMP-2 expression.  
Depletion of CIB1 in ECs attenuates their response to angiogenic growth factors such as 
VEGF and bFGF.  In ex vivo and in vivo assays, CIB1-KO tissue also has an attenuated 
 iii
response to growth factors, demonstrating that CIB1 is necessary for a robust angiogenic 
response.  Moreover, although we confirm that CIB1-KO mice have no defects in 
developmental vasculogenesis and angiogenesis, we demonstrate that CIB1 is essential for 
ischemia-induced and tumor-induced pathological angiogenesis.  These findings are 
important since they differentiate between physiological and pathological forms of 
angiogenesis and identify CIB1 as novel target for pro- and anti-angiogenic therapy.   
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CHAPTER 1 
 
 
 
General Overview 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 The circulatory system 
 
All except the most primitive animals must have a circulatory system in order to 
insure adequate distribution of essential elements necessary for survival.  Even in organisms 
as diverse as mollusks, arthropods, and fish, the hierarchical branching of circulatory vessels 
and their inflowing blood facilitates the transport of nutrients, respiratory gases, hormones, 
metabolic products, and components of the immune system(1).  In humans, the circulatory 
system is composed of a four-chambered heart that pumps blood to two fully separated 
circulations through the pulmonary and aortic trunks.   The pulmonary trunk branches into 
the pulmonary arteries and carries blood to the lungs, while the aorta branches into the 
systemic arteries, which distribute blood to all other organs of the body(2).  Within all 
perfused organs further branching of the blood vessels occurs, creating millions of tiny 
arteries that give rise to billions of downstream capillaries.  These capillaries are microscopic 
in size, form vast networks, cover a large surface area, and connect the arterial and venous 
circulations (Figure 1-1).  Remarkably, the most vital functions of the circulatory system 
occur in the microvasculature and are greatly dependent on the events that occur at the 
capillary level(3).   
 
1.2 Microvascular capillaries 
 
Microvascular capillaries are entirely responsible for the diffusion of water, small 
solutes, and lipid soluble molecules in the circulatory system(4).  Furthermore, in the adult, 
microvascular   capillaries   are  the  site  where  new  blood  vessels  are  first  formed  to 
 2
  
 
 Fi
gu
re
 1
-1
.  
C
ap
ill
ar
ie
s a
re
 a
n 
es
se
nt
ia
l c
om
po
ne
nt
 o
f t
he
 c
ir
cu
la
to
ry
 sy
st
em
.  
(A
) T
he
 c
irc
ul
at
or
y 
sy
st
em
 is
 c
om
po
se
d 
of
 
an
 a
rte
ria
l a
nd
 v
en
ou
s 
ci
rc
ul
at
io
n.
  T
he
 h
ie
ra
rc
hi
ca
l b
ra
nc
hi
ng
 o
f v
es
se
ls
 a
llo
w
s 
fo
r p
ro
pe
r d
is
tri
bu
tio
n 
of
 b
lo
od
 a
nd
 n
ut
rie
nt
s 
to
 a
ll 
or
ga
ns
 o
f t
he
 b
od
y.
  M
aj
or
 a
rte
rie
s 
st
em
 fr
om
 th
e 
he
ar
t a
nd
 it
s 
co
nd
ui
t v
es
se
ls
 a
nd
 b
ra
nc
h 
in
to
 a
rte
rio
le
s. 
 A
rte
rio
le
s 
ar
e 
fu
rth
er
 p
ar
tit
io
ne
d 
to
 y
ie
ld
 sm
al
le
r v
es
se
ls
.  
Ev
en
tu
al
ly
 th
ey
 fo
rm
 si
ng
le
 c
el
l t
ub
ul
ar
 c
ap
ill
ar
ie
s a
nd
 a
re
 p
rim
ar
ily
 li
ne
d 
by
 E
C
s 
(B
). 
 T
he
 s
tru
ct
ur
al
 in
te
gr
ity
 o
f 
th
es
e 
ca
pi
lla
rie
s 
is
 a
ls
o 
m
ai
nt
ai
ne
d 
by
 e
nv
el
op
in
g 
la
ye
rs
 o
f 
EC
M
.  
C
ap
ill
ar
ie
s 
ca
n 
co
al
es
ce
 
in
to
 v
en
ou
s 
st
ru
ct
ur
es
.  
Th
es
e 
st
ru
ct
ur
es
 g
iv
e 
ris
e 
to
 v
en
ul
es
 w
hi
ch
 th
en
 g
iv
e 
ris
e 
to
 v
ei
ns
 th
at
 fa
ci
lit
at
e 
th
e 
re
tu
rn
 o
f b
lo
od
 to
 
th
e 
he
ar
t. 
 E
C
, e
nd
ot
he
lia
l c
el
l; 
EC
M
, e
xt
ra
ce
llu
la
r m
at
rix
; R
B
C
, r
ed
 b
lo
od
 c
el
l. 
 3
facilitate vascular expansion(5).  Depending on the microenvironment, the vast majority of 
newly formed capillaries are referred to as continuous capillaries.  These are structurally 
simple tubes, approximately 8µm in diameter, and are held together by cellular tight 
junctions(3).  Continuous capillaries are also enveloped by a delicate layer of basement 
membrane composed primarily of extracellular matrix (ECM) proteins such as collagens, 
laminins, elastin, fibronectin, and vitronectin(6).  This layer of ECM proteins is essential for 
maintaining the structural integrity of the microvascular capillary.   
 
In addition to continuous capillaries, there are also fenestrated (or discontinuous) 
capillaries that contain pores that span the lining of the vessel and allow for a more rapid 
exchange of water and solutes(3).  Fenestrated capillaries can occur physiologically and are 
naturally found in anatomical structures such as the brain choroids plexus and the kidney 
glomeruli.  However, they are also a hallmark of the microvasculature in pathological tissue 
(such as in rapidly expanding tumors)(7).  In either case, capillaries, both continuous and 
fenestrated, function as units of a dynamic vascular plexus that are highly sensitive to an 
array of local and external stimuli(8).    
 
1.3 The endothelium 
 
Capillaries are also almost entirely composed of endothelial cells (ECs), which are 
the cellular units that form the endothelium – the inner lining of all the vessels and the 
heart(4).  Forming the interface between blood and tissue, at first glance the endothelium can 
be overlooked as a simple tissue that only serves an inert barrier function.  However, with the 
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advent of in vitro primary culture of ECs, and more recently, with the use of genomic and 
proteomic techniques, ECs have been found to have a diverse topology and serve various 
complex functions(9;10).  It is now accepted that in addition to its barrier function, the 
endothelium participates in various other functions including vascular permeability, vascular 
tone, trafficking of nutrients, leuckocyte recruitment and transmigration, inflammation, 
maintenance of blood fluidity, vascular morphogenesis, and vascular expansion (see Table 1-
1 for a partial list of endothelial functions)(11).  All these functions no doubt contribute to 
vascular homeostasis and are necessary for the survival and function of multiple types of 
tissue and organs. 
 
1.4 ECs and angiogenesis 
 
In the past few decades, several major breakthroughs were reached in our 
understanding of the signaling mechanisms that regulate ECs and their role in vascular 
expansion and new blood vessel growth.  Much of this progress can be attributed to 
‘knockout’ mouse models, where in vivo homologous recombination techniques are used to 
selectively delete genes and determine their purpose in the vasculature.  As a result, knockout 
mouse models have helped to uncover a large number of essential genes that can regulate the 
endothelium and its various functions.  One of these functions is angiogenesis, which is an 
EC-dependent process that is defined as the formation of new blood vessels from a pre-
existing capillary network(12).  Disregulation of angiogenesis can yield deleterious effects 
and can even be fatal in animal models(13-15).  Furthermore, overstimulation and 
understimulation  of  angiogenesis  are  hallmarks  of  a myriad of clinical disorders(5;16;17).   
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 Table 1-1.  EC functions in vascular biology. 
Function Protein Specific Role Reference
    
Permeability 
barrier 
PECAM1 Cell-to-cell adhesion (18) 
 VE-Cadherin Cell-to-cell adhesion (19) 
 Integrin α2β1 Cell-to-cell adhesion and cell-
to-matrix adhesion 
(20;21) 
    
Trafficking of 
nutrients 
Caveolin 1 Forms trans-endothelial 
caveolae 
(22) 
    
Vasoactive 
factors 
NO Vasodilating agent (23) 
 adenine metabolites Vasodilating agent (24) 
 endothelin Vasoconstricting agent (25) 
    
Blood fluidity PGI2 Antithrombotic agent (26) 
 Factor VIIIa (vWF) Prothrombotic agent (27) 
 thrombomodulin Anticoagulant (28) 
 Tissue Factor procoagulant (29) 
 Tissue plasminogen 
activator 
Fibrinolytic agent production (30) 
    
Inflammation IL-1 Expressed to mediates 
inflammation 
(31) 
    
Leukocyte 
recruitment 
ICAM-1 Bind leukocytes and facilitates 
transmigration 
 (32;33) 
    
 6
Growth inhibition Heparin Inhibits EC proliferation (34) 
    
Growth 
stimulation 
bFGF Stimulates EC proliferation (35) 
 PDGF Stimulates EC proliferation (36;37) 
    
Blood cell 
production 
 
blood cell colony-
stimulating factor 
Regulates granulopoiesis (38) 
Abbreviations: PECAM1, platelet/endothelial cell adhesion molecule 1; VE-Cadherin, 
vascular endothelial cadherin; NO, nitric oxide; PGI2, prostacyclin; vWF, von 
Willebrand Factor; ICAM, intracellular adhesion molecule 1; bFGF, basic fibroblast 
growth factor; PDGF, platelet derived growth factor.
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Therefore, in recent years interest has heightened to exploit this process as means to treat 
patients with angiogenesis-dependent diseases.   
 
1.5 The promise of angiogenesis-based therapy 
 
It is predicted that over the coming decades more than 500 million patients will 
benefit from therapy that targets the endothelium to either inhibit or stimulate 
angiogenesis(39).  As such, more than $4 billion has been invested in the research and 
development of novel angiogenesis-based medicines, making it one of the most highly 
funded areas of medical research today (The Angiogenesis Foundation; 
http://www.angio.org).  To date, approximately 300 molecules that regulate angiogenesis 
have been discovered.  However, only a subset of these molecules has progressed to clinical 
trials, and even a smaller subset has demonstrated clinical benefit in patients. 
 
Nevertheless, the rate of progress in the development of new angiogenesis-based 
therapies has been very rapid.  In a relatively short time, 7 angiogenesis-based medicines 
have been FDA approved to treat of a limited, yet diverse set of clinical disorders 
(http://www.angio.org).  The recent success of some of these agents has prompted Phase IV 
clinical trials to determine whether these agents can also improve patient outcomes in other 
disease states.   Similarly, results from Phase I and Phase II clinical trials testing new 
angiogenesis-based therapies are eagerly awaited (http://cancertrials.nci.nih.gov/).  Hence, 
over the coming years it will be interesting to observe the enormous growth in this field and 
the emergence of angiogenesis-based medicines as agents of first-line therapy.  
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 1.6 Goal of this research 
 
The goal of this research is multifaceted.  First, we wanted to expand our knowledge 
and understanding of the important regulatory protein calcium and integrin binding protein 1 
(CIB1; see Chapter 3 for an overview of this protein).  Despite its previously reported 
important functions in different cell types(40), its role in vasculature and in ECs has never 
been explored.  Second, we wanted to determine whether CIB1 played a role in angiogenesis.  
We hypothesized that it would, since CIB1 was previously shown to regulate the activity of 
established angiogenic kinases(41;42).  Finally, although CIB1-KO mice are viable and 
develop normally(43), we postulated that CIB1 may still have an important role in 
pathological and/or adaptive forms of angiogenesis.  We tested this in various in vivo 
settings, and we report herein that CIB1 is involved in at least two forms of pathological 
angiogenesis (ischemia-induced angiogenesis and tumor-induced angiogenesis).  We believe 
this research is substantial since it identifies a previously unknown role for CIB1, and since it 
delineates new differences between physiological and pathological forms of angiogenesis.  
By understanding these differences more thoroughly, a new generation of more selective and 
effective angiogenesis-based therapies can be developed to alleviate human disease. 
 
1.7 Overview of thesis 
 
Chapter 2 will briefly introduce the process of angiogenesis and its importance in 
human health and disease.  This chapter will also summarize standard methods for modeling 
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and studying angiogenesis, as well as provide a non-exhaustive overview of essential 
molecular signals that regulate angiogenesis.  Chapter 3 is an extension of the introduction 
and will primarily focus on CIB1 and its currently known roles in vascular biology. 
 
In Chapter 4, data exploring the critical role of CIB1 in EC function and signaling 
will be presented.  Specifically, the data will show that the loss of CIB1 in ECs leads to a 
decrease in migration, proliferation, nascent tubule formation, and monolayer permeability.  
We propose that these functional defects are at least in part due to the attenuated activation of 
p21-activated kinase 1 (PAK1) and ERK1/2 in CIB1-KO ECs.  Furthermore, we show that 
CIB1 is essential for angiogenic growth factor-induced matrix metalloproteinease-2 (MMP2) 
expression, which ordinarily contributes to various pathophysiological conditions.   
 
To expand these findings further, Chapter 5 will present data collected from two 
distinct in vivo murine ischemia-induced angiogenesis models.  In summary, we demonstrate 
that CIB1 knockout (CIB1-KO) mice have a reduced capacity for pathological and adaptive 
neovascularization, despite demonstrating normal retinal vascular development. In this 
chapter, we also show that associated with decreased angiogenesis, CIB1-KO mice also have 
significantly reduced tissue recovery following ischemic insult.   
 
In Chapter 6, we provide further evidence that implicates CIB1 in pathological 
angiogenesis.  First we demonstrate that CIB1-KO tissue is stimulated less by angiogenic 
growth factors and as a result forms less microvessels ex vivo and in vivo.  In addition, we 
explore the role of CIB1 in tumor-induced angiogenesis in two different xenograft tumor 
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models.  Collectively these studies demonstrate that CIB1-KO mice develop tumors that are 
smaller in size, necrotic, and less vascularized.  These observations are also corroborated by 
preliminary findings that demonstrate that CIB1-KO mice, that are also transgenic for the 
Polyomavirus middle T (PyV-mT) oncogene, have a sizably decreased tumor burden.   
 
Finally, in Chapter 7, we conclude with a summary of the data presented in this thesis 
and highlight future experiments.  We also make conclusions regarding the differences 
between physiological and pathological angiogenesis, and we speculate about the molecular 
signals that differentially regulate each process.  We propose that targeting pathological 
forms of angiogenesis may yield better results in patients afflicted with angiogenesis-
dependent diseases and suggest CIB1 as a novel target for anti- and pro-angiogenic therapy. 
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CHAPTER 2 
 
 
 
Role of Angiogenesis in Vascular Expansion 
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2.1 The basic model of angiogenesis 
 
Angiogenesis is a dynamic multi-step process that is highly dependent on EC 
signaling and function, and is defined as the formation of new blood vessels from pre-
existing vascular networks(1;2).  In addition to contributing to the expansion of the primitive 
vasculature in the embryo, angiogenesis is the primary mechanism by which most new blood 
vessels are formed in adult tissue during both physiological and pathological situations(3).  
Thus understanding the mechanisms that can inhibit or enhance angiogenesis may have 
significant implications for human health and disease. 
 
Under normal conditions, in adult mammalian tissue the endothelium (which is 
derived from embryonic hemangioblasts) is thought to be quiescent and angiogenesis is 
assumed to be static.  In fact, in the normal adult it is estimated that at any given time only 1 
in every 10,000 ECs is undergoing cell division(4).  However, in response to appropriate 
stimuli, quiescent ECs become activated and facilitate the growth of new capillaries, or 
regress and undergo apoptosis(5;6).  Thus EC regulation is complex and often multifaceted 
due to the various physiological and pathological stimuli, cytokines, hormones, and growth 
factors that can determine the activation state of ECs(7;8).  The delectate balance between 
the factors that activate ECs and stimulate angiogenesis (pro-angiogenic factors), and the 
factors that halt ECs and inhibit angiogenesis (anti-angiogenic or angiostatic factors) is often 
referred to as the ‘angiogenic switch(4).’  This basic model suggests that when angiogenic 
growth factors in the EC microenvironment surpass a specific threshold, angiogenesis will 
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proceed.  On the other hand, if angiostatic agents dominate, or cell-cell and cell-matrix 
interactions are not in place, ECs will be inhibited and angiogenesis will not occur(9).    
 
In 1984, basic-fibroblast growth factor (bFGF; also known as FGF-2) became the first 
angiogenic growth factor to be discovered(10;11).  Since then, many such growth factors 
have been identified, including vascular endothelial growth factor (VEGF), placental growth 
factor (P1GF), PDGF, and transforming growth factor-β (TGF-β) (for a partial list of 
endogenously expressed pro- and anti-angiogenic factors see Table 2-1)(12-14).  These 
growth factors have the capacity to activate vascular ECs via their respective cell-surface 
receptors.  Upon EC activation, vessel permeability is increased, the secretion of proteolytic 
enzymes is induced, and the degradation of surrounding extracellular matrix occurs.  This 
process facilitates the release of additional growth factors from the ECM and stimulates EC 
proliferation(15).  Activated ECs also respond to gradients of growth factors in their 
environment through the extension of cellular processes (filopodia and lamellipodia)(16;17).  
These extensions allow EC sprouting to take place, which then determines the directionality 
of EC chemotatic migration(17;18).  Similarly, activated ECs can also engage in haptotatic 
migration, which is migration toward ECM proteins such as fibronectin, collagen, and 
vitronectin.  This process of haptotaxis requires the expression of specific adhesion receptors, 
such as integrins, on the surface of ECs(19;20).  For both chemotatic and haptotatic 
migration, the trail set forth by sprouting ECs establishes the location of future capillaries.  
At these sites EC invade and implant into the ECM.  This allows them to eventually envelop 
one another and form lumens of what later becomes nascent tubules (Figure 2-1). 
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Table 2-1.  Examples of endogenously expressed pro- and anti-angiogenic factors. 
Etiology Protein Reference 
 
Pro-angiogenic Factors: 
Growth factors VEGF-A, -B, -C, -D                                     (21) 
 aFGF, bFGF                                                 (22) 
 P1GF (23) 
 PDGF (24) 
 TGFα, TGFβ                                                (25) 
 IGF-I, -II (26) 
 HGF (27) 
   
Hormones Estrogens (28) 
 Leptin (29) 
 hCG (30) 
 proliferin (31) 
   
Inflammatory cytokines IL-8 (32) 
   
 
Anti-angiogenic factors: 
Secreted peptides Thrombospondin                                          (33) 
 Endostatin                                                    (34) 
 Angiostatin                                                  (35) 
   
Hormones Prolactin (36) 
 
Abbreviations: VEGF, vascular endothelial growth factor; FGF, fibroblast growth 
factor; P1GF, placental growth factor; PDGF, platelet-derived growth factor; TGF, 
transforming growth factor; IGF, insulin growth factor; HGF, hepatocyte growth factor; 
hCG, human chorionic gonadotropin. 
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 In the resolution phase of angiogenesis, newly formed nascent tubules undergo 
stabilization, maturation, and remodeling to become actual capillaries(37).  This process is 
facilitated by the recruitment of mesenchymal cells and is highly dependent on the origin, 
location, and function of the newly formed capillary.  Studies have also shown that molecules 
such as PDGF-β, PDGF-β receptor (PDGFR)-β, sphingosine-1-phosphate-1 (SIP1), and 
endothelial differentation sphingolipid G-protein-coupled receptor-1 (EDG1) are essential 
components to this process(38;39).  Molecules such as these also facilitate new vessel 
branching, expansion, and pruning in order to meet local tissue demands.  Finally, 
surrounding mesenchymal cells differentiate to give rise to smooth muscle cells, pericytes, 
and fibroblasts which, in turn secret additional ECM proteins and facilitate further 
stabilization of the maturing newly formed capillaries(37). 
 
2.2 Other mechanisms of vascular expansion 
 
2.2.1   Vasculogenesis 
 
One of the most important ECs functions is the formation of new blood vessels during 
embryogenesis(40).  In the embryo the circulatory system develops shortly  after  gastrulation  
and  is  the  first  functioning  organ  system(41).   At this stage the vascular primordia forms 
clusters of progenitor cells, known as hemangioblasts, and arise in blood islands in the yolk 
sac between the embryonic mesoderm and endoderm(42).  Through a programmed sequence 
of events these hemangioblasts differentiate de novo into peripheral cells, which become 
either angioblast ECs or short-lived primitive hematopoetic stem cells (HSCs)(43;44).  Due 
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to their lineage association, these newly formed and spatially segregated ECs and HSCs share 
several surface expression markers including the VEGF receptor 2 (VEGFR-2; Flk-1), TEK 
tyrosine kinase (Tie2), and CD34(45;46).  Further differentiation of these hemangioblast-
derived cell types marks the beginning of vasculogenesis and is a highly conserved process.  
 
Unlike angiogenesis, vasculogenesis facilitates vascular expansion de novo (for a 
comparison between angiogenesis and vasculogenesis see Table 2-2)(47).  As embryonic 
development progresses, newly formed ECs in the visceral yolk sac rapidly divide and form a 
primitive vascular plexus.  This plexus coalesces with a system of EC tubules that originates 
independently within the parenchyma of the embryo(48).  At this stage ECs start to assume 
their primary barrier function by maintaining the interface between blood and tissue.  
Remarkably, the primitive vascular plexus derived by vasculogenesis is highly ordered, with 
channels having the same width and separated by approximately similar distances(40).  
Therefore, it is not surprising that any disruption of this highly ordered system often results 
in death by embryonic day (ED) 9.5 to ED 12.5 in mouse embryos(49).  For instance, gene 
deletion of molecules that facilitate VEGF and Notch signaling cause death in ED 9.5 - 10.5 
mouse embryos(50).  These findings, in various other murine gene knockout studies, have 
been instrumental in the identification of genes that are important for proper vessel 
development and remodeling. 
 
In some circumstances post-natal vasculogenesis has been suggested to also occur in 
the adult(51).  One of the first studies to suggest this demonstrated that endothelialization of 
prosthetic devices in adult  canines  can  occur  via  differentiation  of  circulating endothelial 
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Table 2-2.  General comparison between vasculogenesis and angiogenesis. 
 Vasculogenesis Angiogenesis 
   
Method of new 
blood vessel 
formation 
De novo From pre-existing capillaries 
Depends on 
what cell types 
Progenitor cells 
(hemangiocytes/angioblasts) Mature ECs in capillary bed 
Occurs in adult 
vs. embryo Primarily in the embryo In the embryo and adult 
Regulation Highly ordered process 
Not as tightly regulated, 
especially during pathological 
conditions 
If impaired Frequently leads to lethality 
Deceased wound healing, 
ischemia, and vascular 
insufficiency 
If excessive Frequently leads to lethality 
Causes vascular malformations, 
contributes to tumor growth, and 
facilitates inflammation 
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progenitor cells (EPCs) that are CD34-positive(52).  Similarly, Asahara et al. showed that 
adult circulating EPCs can differentiate into mature ECs in vitro and contribute to ischemia-
induced new blood vessel formation in vivo(53).  Other investigators also showed that human 
cord blood EPCs also have clear vasculogenic properties following hind-limb ischemia(54).  
Thus the contribution of EPCs in adult vasculogenesis is becoming a more commonly 
accepted concept.  
 
2.2.2 Circulating progenitor ECs  
 
In addition to their contributions in post-natal vasculogenesis, EPCs also contribute to 
other forms of neovascularization, particularly in the context of rapidly growing 
tumors(55;56).  One hypothesized source of EPCs is from the bone marrow.  In vitro, EPCs 
derived from the bone marrow can be enriched and differentiated into ECs(57;58).  In vivo, 
bone marrow-derived ECs were found at sites of neovascularization in athymic nude mice 
that were transplanted with bone marrow derived from transgenic mice constitutively 
expressing β-galactosidase via an endothelial cell-specific promoter (Tie2/lacZ)(59).  
Additional studies confirmed the presence of bone marrow-derived ECs at the sites of 
neovascularization post-myocardial ischemia, hind-limb ischemia, wound healing, 
atherosclerosis, and retinal neovascularization(51).  However, despite agreement on their 
presence, some reports claim up to 95% of the neovascularization can be attributed to bone 
marrow-derived ECs(60), but other studies report contributions ranging between 3.5 to 
10%(61). Thus, it is still debated to what extent bone marrow-derived ECs can contribute to 
the formation of new blood vessels. 
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Like the bone marrow, hematopoietic stem cells (HSCs) are also hypothesized to 
yield ECs and contribute to neovascularization(51).  This was originally hypothesized since 
ECs and hematopoietic cells have a close lineage in the blood islands of the developing 
embryo.  Moreover, hematopoietic cells and ECs are derived from a common hemangiocyte 
progenitor cell.  Evidence to support this comes from findings that show that both 
hematopoietic cells and ECs express common putative markers such as Flk-1, Tie2, and 
CD34(62;63).  Furthermore, Jin et al. recently showed that cytokine release of stromal-
derived factor 1 (SDF-1) can mobilize to sites of neovascularization a population of non-
endothelial hemangiocytes that express CXCR4 (the receptor for SDF-1) and VEGFR-1(64).   
 
Additionally, contributions from endothelial-derived circulating cells (EDCCs) in 
vascular expansion have also been reported.  It is hypothesized that these cells result from a 
shedding process involving the delamination of ECs from pre-existing vasculature, or 
generated as a result of injury or mechanical disruption(51).  However, Segal et al. recently 
reported that the number of EDCCs observed in the blood stream following myocardial 
infarctions cannot account for total EDCC levels(65).  Furthermore EDCCs are found in the 
circulation even under normal physiologic conditions.  Thus it is not entirely clear how 
EDCCs are generated and whether their fate is exclusively restricted to ECs(51). 
 
2.2.3 Non-sprouting angiogenesis 
 
In addition to sprouting angiogenesis, non-sprouting angiogenesis can also form new 
blood vessels from pre-existing vessels.  One such process is referred to as 
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intussusception(66).  This mechanism of vascular growth is somewhat unique because it 
occurs through the formation of intra-vascular transendothelial cell bridges, whereby 
interstitial ECs form columns within in vessels and partition the vessel lumen.  Circulating 
ECs (i.e. EPCs and EDCCs) are postulated to contribute to this process.  Reinforcement of 
the newly formed EC bridges occurs by the recruitment of smooth muscle cells and pericytes.   
Remodeling of the newly formed bridges also takes place to stabilize the newly formed 
lumens and leads to vessel maturation(67).  Although it is reported that this type of vascular 
expansion frequently occurs in rapidly growing tumor vasculature(68), little is actually 
known about the frequency, extent, and molecular basis of intussusception in vivo.  
 
2.2.4 Arteriogenesis and mechanical-induced forces 
 
It is well documented that blood vessels have the capacity to adapt to altered flow 
situations(69).  Arteriogenesis describes this process and is defined as the remodeling of pre-
existing collaterals between arteries of adjacent vascular beds(70).  Unlike angiogenesis, 
which is regulated by hypoxia and angiogenic growth factors, arteriogenesis is instead 
primarily regulated by physical forces that occur in and around the vasculature(71).  In fact, 
in vivo fluid sheer stress is known to be one of the strongest experimental triggers for 
arteriogenesis(72).   In such models, shear stress in the collaterals is increased upon stenosis, 
occlusion, or ligation of conduit arteries, and is transmitted to endothelial, stromal, and 
mesenchymal cells on a molecular and cellular level.  For example, stretch of ECs may be 
sensed by integrins that are anchored to ECM, as well as tyrosine kinases and ion channels 
on the EC surface(73).  These effects can induce rearrangements of the cytoskeleton and 
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induce MAP kinase (MAPK) signaling, which in turn transmit signals to the nucleus(74).  To 
date, a large number of genes have been reported to be transcriptionally up-regulated by 
promoters containing shear stress responsive elements(71).  Among those reported to be 
increased, is the expression and secretion of plasminogen activators and MMPs.  These 
factors degrade and remodel the ECM, therefore enabling cell proliferation and 
migration(15).  Thus mechanical forces, including fluid shear stress, can induce complex 
cascades of molecular and cellular events that lead to larger vessel lumens and increased wall 
thickness. 
 
2.3 Physiological angiogenesis 
 
2.3.1 Wound healing 
 
In addition to its role in the development of the embryo, physiological angiogenesis is 
also important for rare events in the adult.  For example, physiological angiogenesis plays an 
important role in healing, which is essential for the recovery from fractures or wound 
injuries(3).  It is not only critical for repair, but it also restores tissue strength and is 
necessary for resistance from infection and further external insults.   
 
The process of wound healing is based on three phases of healing(75).  First, 
inflammatory cells migrate into the wound.  This is called the lag phase and it occurs over the 
span of several of days following the injury.  Neutrophils predominate in the wound for 
approximately 1-2 days, and then macrophages become active by approximately the third 
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day.  The abundance of inflammatory cells leads to the secretion of various cytokines and 
inflammatory mediators forming a significant chemoattractant gradient in the surrounding 
tissue.  This positive gradient induces the next phase of wound healing, which is called the 
proliferative phase.  During this 4-5 week phase, fibroblasts and ECs migrate into the wound, 
fibroblasts lay down a collagen matrix, and angiogenic ECs form nascent capillary loops 
from the adjacent venules at the wound margin.   The newly formed capillary buds are highly 
permeable and grow across the wound to supply the fibroblasts with oxygen and nutrients.  
Both of the capillaries and the surrounding fibroblasts are critical components for facilitating 
tissue binding and ultimately wound strength.  Evidence for this comes from patients with 
Vitamin C deficiencies, who have less efficient synthesis and cross-linking of collagen, 
which as a result impedes capillary formation and neovascularization of a wound(76). 
 
2.3.2 Reproduction and pregnancy 
 
The cyclic development of new vasculature plays a critical role in the reproductive 
tract of all mammalian females and is involved in endometrial growth, embryo implantation, 
and placentation(14).  In the ovary, follicular growth, and subsequently, during ovulation and 
formation of the corpus luteum, a vascular network emerges within the ovarian thecal cell 
layer(77).     Similarly, the endometrial vasculature in humans undergoes dramatic cyclic 
changes, and in both the proliferative and secretory phases of the menstrual cycle, the 
endometrium undergoes dramatic vascularization(78;79).  This relatively rapid 
transformation in endometrial vasculature is characterized by an increase in length, branching 
and coiling of the uterine spiral arteries.  The changes observed in both the ovary and uterus 
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are highly regulated by the actions of several angiogenic growth factors and hormones.  For 
example, VEGF message levels increase almost three-fold during the secretory phase of the 
menstrual cycle(80).  Similarly, angiopoitein 1, and 2 (Ang1 and 2) secretion is increased up 
until menstruation and then decreases during the proliferative phase of the menstrual 
cycle(81).   
 
Physiological changes in the uterine circulation are also hormonally regulated.  For 
example, recent studies have shown that the ovarian hormones progesterone and estrogen can 
induce significantly uterine stromal cell expression of VEGF, and progesterone can 
upregulate endometrial bFGF secretion(82;83).    Similarly, uterine angiogenesis can also be 
induced by hCG, a hormone secreted by the corpus luteum that is normally responsible for 
maintaining pregnancy-induced changes and the formation of the placenta.  It is suggested 
that hCG mediates its effects by activating protein kinase C (PKC) and MAPK (ERK1/2) 
signaling(14).  Independently, studies also demonstrate that hCG can induce angiogenesis by 
stimulating the migration and capillary sprouting of uterine ECs(84). 
 
During pregnancy, an adequate nutrient and substrate supply is essential for the 
normal growth and development of an intrauterine fetus.  In order for such fetal demands to 
be met, the uterine vasculature must adapt accordingly.  The endometrium, uterine decidua, 
and placenta are rich sources of angiogenic growth factors like VEGF, bFGF, and PIGF, 
which collectively induce dramatic changes in the endometrium(14).  First, vasodilation is 
stimulated to increase the blood volume that participates in the process of fetal gas 
exchange(77).  Second, pre-existing maternal uterine vessels become more permeabiable, 
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thus allowing for more rapid nutrient/waste exchange(78).  Lastly, angiogenesis is stimulated 
by the signaling mechanisms initiated by activated growth factor receptor tyrosine 
kianses(85).   
 
This process of new blood vessel formation is especially important at the earliest 
stages of pregnancy (7-11 days post conceptionem).  During early pregnancy intracellular 
signals propagated from activated growth factor receptors induce proliferation, chemotatic 
migration, and invasion of ECs into the endometrium.  As a result intact capillaries grow 
around the fertilized ovum syncytiotrophoblast layer(78).  These newly formed capillaries 
form a plexus that then connects into the emerging placenta and give rise to a primitive 
vascular system that supplies the embryo.  Profound changes in vascular patterning occur 
deeper in the uterine tissue, yielding permanent changes even following pregnancy(14).  Due 
to its complexity, it is still not entirely clear, how the level of angiogenesis in the 
endometrium and placenta is tightly regulated throughout pregnancy to prevent both over- 
and under-stimulation of new blood vessel growth – which in either case would be 
detrimental to both the mother and fetus.     
 
2.4 Pathological Angiogenesis 
 
2.4.1 Ischemic diseases 
 
In contrast to physiological angiogenesis, pathological angiogenesis underlies the 
pathophysiology of a myriad of clinical diseases, which include ischemia-related clinical 
 30
disorders(3;86).  Upon induction of ischemia, tissues become metabolically stressed due to 
decreased nutrient and oxygen levels, and increased waste levels.  Eventually this leads to 
hypoxia and activation of the hypoxia inducible factor-1 (HIF-1) transcription factor, which 
induces the expression of various angiogenesis-related growth factors and their receptors(86).  
These growth factors in turn facilitate an adaptive angiogenic response in the ischemic tissue 
as an attempt to restore proper blood perfusion.  Often however, this rapid induction of 
angiogenesis can be excessive and as a result can lead to aberrant blood vessel growth and 
permanent tissue damage.   This type of ischemia-induced pathological angiogenesis is 
commonly observed in different types of retinopathies, including diabetes mellitus 
retinopathy, central retina vein occlusion-induced retinopathy, and retinopathy of 
prematurity(87-90).  In each one of these conditions retinal neovascularization is in part 
stimulated by the upregulation of hypoxia-induced VEGF.  In agreement with this, elevated 
VEGF levels have been detected in both the aqueous and vitreous fluids of patients with 
proliferative and non-proliferative forms of retinopathy(91).  Rodent models have also 
established the role of VEGF signaling in ischemia-induced retinopathy of 
prematurity(89;92).   
 
The goal for patients afflicted with retinopathies is to inhibit ischemia-induced 
pathological angiogenesis as much as possible.  However, in patients afflicted with ischemic 
heart disease and peripheral vascular disease, the induction of ischemia-induced angiogenesis 
can be of great clinical benefit for alleviating disease symptoms(93).  This field of study is 
obviously immensely important since each year in the United States diseases of the heart are 
reported to account for 30% of all deaths (http://www.americanheart.org), and an estimated 
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7.4 million people develop critical limb ischemia(86).  Surgical revascularization techniques 
and pharmacological treatments are available to treat these conditions; however they only 
benefit a subset of patients.  Thus, for the majority of patients suffering from ischemic 
diseases, therapeutic angiogenesis may be of great clinical benefit.   
 
2.4.2 Genetic diseases 
 
Vascular deformities and anomalies may have an inherited predisposition, often 
resulting from genetic mutations in cellular and molecular components that regulate ECs and 
smooth muscle cells(94).  Hemangiomas are vascular tumors and are common vascular 
deformities that are angiogenesis dependent(95).  The most common type of hemangioma is 
infantile hemangioma and it is characterized by increased bFGF and Tie2 expression, 
enhanced response to Ang1, and disregulated Ang2 expression(96).  In addition to arising 
from somatic mutations in angioblasts during development, infantile hemangiomas are also 
hypothesized to possibly be derived from immobilized placental vascular cells that become 
dislodged into the fetal circulation during gestation or after birth(97).   
 
Many mutations have also been identified in different genes that encode essential 
angiogenic products.  Often these mutations are found to lead to severe clinical conditions.  
For example, mutations in the Tie2 receptor gene at locus 9p21, leads to an autosomal 
dominant condition known as coetaneous-mucosal venous malformation that is characterized 
by decreased smooth muscle cell recruitment to the venous circulation(98;99).  Mutations in 
endoglin and ALK1, which are critical components of TGF-β signaling,  predispose  patients  
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 to develop arteriovenous malformations that manifest in syndromes that are clinically 
referred to as hereditary hemorrhagic telengiectasia (HHT)-1 and HHT-2(97).  Mutations 
also in Notch3, a gene implicated in interactions between ECs and smooth muscle cells, leads 
to a condition called cerebral autosomal dominant arteriophaty with subcortical infarcts and 
leucoencephalopathy (CADASIL)(100).   
 
2.4.3 Pregnancy associated disorders 
 
Vascularization of the human embryo takes place very early in pregnancy and 
depends highly on proper vascularization of the maternal placental chorionic villi(14).  If 
placental chorionic villus varscularization is even slightly compromised, conditions such as 
preeclampsia, eclampsia, and intrauterine embryonic death can occur(101).  In these events, 
chorionic villi were found to have a significantly reduced vascular density, constricted 
vessels, increased fibrosis, and hydorpic degradation.  Recently, it was also reported that the 
decidual endothelium of placentas associated with idiopathic spontaneous abortions had 
diminished placental trophoblastic VEGF immunoreactivity, reduced placental torphoblastic 
Tie1 and Tie2 expression, and reduced VEGFR-1, VEGFR-2, Tie1 and Tie2 
expression(102).  Therefore, a growing body of evidence suggests that reduced placental 
blood vessel density is associated with poor pregnancy outcomes and likely has an important 
role in maternal fetal health. 
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2.4.4 Inflammatory diseases 
 
Prolonged and excessive angiogenesis is a characteristic of various common 
inflammatory disorders(68;93).   This effect is mediated by tissue macrophages and blood-
borne monocytes, platelets, mast cells, and other leukocytes that release a myriad of 
angiogenesis factors such as VEGF, Ang1, bFGF, TGF-β, PDGF-β, IGF-1, tumor necrosis 
factor α (TNFα), HGF, and monocyte chemoattactant protein-1 (MCP-1)(103;104).  These 
growth factors in turn activate ECs, stromal cells, and tissue resident macrophages, which 
secrete ECM proteinases such as MMP2, MMP7, MMP9, and MMP12(105).  This process 
leads to degradation of anatomical barriers and facilitates neovascularization.  Moreover, 
inflammatory cytokines such as TNFα also upregulate EC expression of adhesion molecules 
such as ICAM-1 and VCAM-1, which promote further inflammation-induced angiogenesis 
by promoting ECs and leukocytes interactions. 
 
One of the most common inflammatory conditions is rheumatoid arthritis, which is a 
chronic systemic inflammatory disease of unknown etiology that occurs worldwide with a 
prevalence of 1%(106).  In this condition, the number of tissue macrophages that are derived 
from CD34 positive bone marrow progenitors is increased in synovial membranes and 
pannus of joints(93).  The activation of macrophages (which is demonstrated by the 
macrophage surface overexpression of major histocompatilibity complex class II molecules) 
induces secretion of growth factors, MMPs, cytokines, and chemokines that alter the normal 
balance between pro- and anti-angiogenesis factors in the synovium and stimulate 
neovascularization(107).   
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 Psoriasis is another chronic inflammatory disorder that affects 2-3% of the Caucasian 
population, and is characterized by aberrant angiogenesis in the skin(108).  Forty percent of 
psoriasis patients also have inflammatory arthritis (psoriatic arthritis), which form the second 
most common diagnostic category after rheumatoid arthritis in synovitis clinics(109).  
Although it is accepted that this condition develops due to abnormal activation of T cells and 
dentritic cells, as well as the abnormal secretion of inflammatory cytokines, the molecular 
alterations that underlie this disease are still not fully understood.  Recently, genetically 
modified mice have revealed additional clues and have demonstrated that disregulated blood 
vessel growth contributes to the progression and severity of this disease(110).  For example, 
when VEGF is overexpressed in the basal layer of the epidermis, mice develop psoriatic skin 
lesions that are hyperplastic, inflammed, and have epidermal thickening (110;111). 
 
2.4.5 Oncogenic diseases 
 
Pathological angiogenesis is a hallmark of tumorgenesis and is a discrete event in 
solid tumor formation(4;68).  The observation that angiogenesis occurs around tumors was 
made nearly 100 years ago, and later, diffusible substances were hypothesized to emerge 
from a tumor to stimulate the growth of surrounding blood vessels(112).  Now that many of 
these factors have been identified, it is widely accepted that various metabolic and 
mechanical stresses in tumors indeed induce the secretion of many factors and cause an 
imbalance in the so called angiogenic switch, to favor angiogenesis(4).  Some of these 
metabolic stresses such as low pO2, low pH, and hypoglycemia are induced when tumors 
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grow beyond 1cm3 and become hypoxic(113).  These events activate key transcription 
factors, such as the heterodimeric transcription factor HIF-1, which can induce expression of 
a vast array of gene products (almost 2% of all human genes) to control energy metabolism, 
survival, and angiogenesis.   Among the most highly regulated genes by HIF-1 are the genes 
encoding VEGF, VEGFR-1, and the glucose transporter GLUT-1(68).  
 
Unlike physiological angiogenesis, the pathological induction of angiogenesis in 
tumors is temporally and spatially disregulated.  As such, newly formed tumor vasculature is 
structurally and functionally abnormal.  In contrast to normal vessels, tumor vessels are 
highly disorganized, tortuous, dilated, and have excessive branching and shunts(68).  The 
endothelium that lines tumor vessels is also abnormal.  Tumor ECs assume a different 
morphology, with absent or widened inter-endothelial junctions that sometimes project into 
vessel lumens(114).  Some tumors vessels are not even lined with ECs, and are instead 
mosaic in nature and lined primarily with cancer cells that mimic the role of ECs.  Vessel 
wall diameters are also uneven, have numerous openings and fenestrations, and often have a 
discontinuous basement membrane(115).  Consequently, the heterogeneity and leakiness in 
vasculature leads to highly chaotic and variable blood perfusion within the tumor.  This 
induces further hypoxia and acidosis, which in turn induces additional vessel and tumor 
growth(68;115).  As a result tumor-induced angiogenesis facilitates a self-perpetuating 
vicious cycle of tumor growth that can ultimately lead to cancer metastasis.  For this reason it 
is hypothesized that therapeutic targeting of tumor-induced angiogenesis may prevent 
progression of disease and diminish tumor growth.  
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Beyond solid tumor growth, disregulated angiogenesis is also observed in 
haematological malignancies and hemangiomas(68).  For example, the relatively simple bone 
marrow vasculature in normal individuals is altered with complex branching in leukemic 
patients(116).  Evidence suggests that malignant haematopoietic cells express and secrete 
factors like VEGF and Ang1, which induce these alterations, and perpetuate the progression 
of disease in the bone marrow(117).  Similarly, VEGF signaling has been implicated in 
hemangioma growth, which is induced by genetic alterations (as mentioned earlier under 
genetic diseases) or viral infections.  Human immunodeficiency virus type-1 (HIV-1) 
activates VEGFR-2, α5β1, and αvβ3 to give rise to Kaposi’s sarcoma, a type of malignant 
hemangioma(118).  Since these types of cancers are also dependent on angiogenesis, it is 
currently being determined whether anti-angiogenic therapy may be a useful adjunct to 
reduce the mortality and morbidity associated with these conditions. 
 
2.5 Commonly used tools to study angiogenesis 
 
2.5.1 In vitro assays 
 
After approximately three decades of studies, investigators in the fields of vascular 
biology, and its major branch of angiogenesis research, have derived reliable and 
standardized methods that can be used to assess EC function and angiogenesis(119).  Perhaps 
the most commonly used techniques are in vitro methods that can assess EC signaling and 
function.  These techniques are low cost, reproducible, and simple compared to other 
angiogenesis assays.  However, central to all in vitro assays is the ability to isolate and 
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culture ECs.  This process requires a careful assessment of what EC cell-type should be 
isolated and how they should be cultured.  As demonstrated in the literature, not all ECs are 
alike and differences do exist between macrovascular and microvascular ECs, EC obtained 
from different organs, and ECs isolated from different sites within a single organ(120).  In 
addition, ECs used in vitro are by the very nature of being cultured, different from ECs that 
comprise the quiescent endothelium in the mammalian vasculature.  To this effect, cultured 
ECs can both gain and lose attributes found in cells in vivo(121).  Nevertheless, in vitro 
techniques have been instrumental for screening for anti-angiogenic factors and for testing 
various in vitro EC functions such as migration, two-dimensional and three-dimensional 
tubule formation, growth, proliferation, permeability, sprouting, and invasion. 
 
2.5.2 Ex vivo assays 
 
Angiogenesis involves not only ECs, but also other vascular cell types, including 
smooth muscle cells, fibroblasts, pericytes, and other mesynchemal cell types.  This has led 
investigators to develop techniques that can readily assess angiogenesis in whole tissue.  The 
rat and mouse aortic ring organ culture system is the most commonly used technique used for 
this purpose(122).  This technique has also become more popular with the discovery of 
Matrigel (a matrix-rich product prepared from Engelbreth-Holm-Swarm (EHS) tumor cells 
whose primary component is laminin(123)), which can facilitate the growth and extension of 
microvessels from whole tissue organ cultures.  However, one disadvantage of an aortic ring 
organ culture assay is that forms microvessels that are macrovascular in nature(120).  Since 
angiogenesis is primarily a microvascular event, other tissue (such as hind-limb muscle 
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tissue) which contains microvessels can also be used to corroborate findings from aortic ring 
organ cultures. 
 
2.5.3 In vivo assays 
 
 Depending on what is being investigated and what the experimental design entails, in 
vivo, ex vivo, and in vitro techniques can be used to complement one another.  However, due 
to the cellular and molecular complexities of angiogenic interactions, in vivo studies are 
generally accepted to be the most informative(120).  Indeed, in the preclinical setting, in vivo 
angiogenesis assays present the investigator with unique advantages to assess angiogenic 
processes in response to various types of stimuli, treatments, or trauma that are both physical 
or chemical in nature.  Meanwhile, in vivo techniques also have some biological, technical, 
and economical limitations associated with them and therefore are not appropriate for all 
situations. 
 
 For evaluating both pro- and anti-angiogenic responses, in vivo assays such as the 
rodent corneal micropocket, the rodent mesentery, the chick chorioallantoic membrane, and 
the zebrafish system have been commonly used(124).  Similarly, neovascularization of 
artificial implants can also be tested in vivo by implanting rodents with subcutaneous 
Matrigel plug impregnated with tumor cells or angiogenic agents.  In such assays the extent 
of new blood vessel formation in a non-cellular matrix can be highly formative(124).  
Furthermore, in vivo assays can also be modified to test specific forms of pathological or 
adaptive angiogenesis.  For example, ischemia can be induced in a rodent retina or hind-limb 
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muscle tissue to investigate processes that contribute to post-ischemic recovery and 
ischemia-induced pathological angiogenesis(125).  Using the same paradigm, tumor- and 
inflammation-induced angiogenesis can also be assessed in vivo(119).   
 
2.6 Molecular regulation of angiogenesis 
 
 In 1971, Folkman proposed a model whereby tumor growth and metastasis are 
angiogenesis-dependent(126).  Hence, it was hypothesized that blocking angiogenesis could 
be an effective strategy for arresting tumor growth.  Since then the field of angiogenic 
signaling has become an intense area of study.  In recent years, our understanding of how 
new blood vessels develop during physiological and pathological situations has been 
significantly enhanced, and much of this progress could be attributed to homologous 
recombination techniques in murine mouse models.  A partial list of ‘knockout’ mouse 
models used over the past two decades to study angiogenesis in vivo is provided in Table 2-3. 
As demonstrated in this table, the deletions of a significant subset of genes do not yield lethal 
phenotypes.  This is despite the fact that some of these genes contribute to adult and 
pathological forms angiogenesis.  Hence, this demonstrates that angiogenic signaling is 
complex and is differentially regulated by multiple molecular mechanisms. 
 
In general angiogenic signaling molecules can be sub-divided into six main 
categories: i) growth factors and their receptors, ii) integrins, cadherins, and other cell surface 
adhesion receptors, iii) matrix degrading proteineases, iv) chemokines, hormones, and small  
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Table 2-3.  A partial list of vasculogenesis and angiogenesis-related knockout mouse 
models. 
Classification Protein Lethal Description Reference 
     
Matrix Metalloproteniases (MMPs)  
 MMP2 No 
Mild phenotype with minor defects 
in the skeleton and joints.  Tumor-
induced angiogenesis and tumor 
growth is highly reduced. 
(133;134) 
 MMP9 No 
Show delayed visualization and 
ossification of hypertrophic zones 
in cartilage.  Have decreased 
atherosclerosis and less aneurysm 
formation. Otherwise viable with 
only minor defects. 
(135-137) 
 MT1-MMP No 
Have severe skeletal abnormalities 
and do not mature sexually.  Also 
have abnormal lung alveolar 
formation and decreased alveolar 
surface area.  
(138;139) 
 MMP2 & MT1-MMP Yes 
Death occurs immediately after 
birth due to respiratory failure, 
abnormal blood vessels, and 
immature muscle fibers. 
(140) 
 MMP2 & MMP9 No 
Mice are normal but one report 
suggests a defect in transepithelial 
chemokine gradient formation. 
(141;142) 
 TIMP1 No 
Has increased susceptibility to 
atherosclerosis-induced aneurysm 
formation. 
(143;144) 
 TIMP2 No Has impaired proMMP2 activation and altered nerve branching. (145;146) 
 TIMP3 No Has impaired lung development and dilated cardiomyopathy (147;148) 
Growth Factors    
 PDGF-β Yes Embryonic lethality due to lack of (149;150) 
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pericytes recruitment which causes 
the formation of microvascular 
aneurysms. 
 Edg1 Yes 
Like PDGF-β mice.  Embryonic 
lethality due to lack of pericytes 
recruitment. 
(151) 
 VEGF-A Yes 
Homozygous and heterozygous 
mice have defective 
vasculogenesis, decreased number 
of cells in the yolk sac blood 
islands, less vessel invasion in the 
forebrain, reduced number of ECs, 
and defective vascular patterning. 
(129;153) 
 bFGF No 
Mice are normal with only 
decreased vascular tone and low 
blood pressure. 
(154) 
 Ang1 Yes 
Die during embryo development 
embryonic day (ED) 12.5 due to 
poor vascular remodeling and 
defects in EC adhesion and 
spreading. 
(155) 
 Ang2 Yes 
Lethal with eye, lymphatic, and 
kidney defects.  Lymphatic defect 
can be rescued by Ang1 cDNA, but 
not the eye phenotype. 
(156) 
 Semaphorin 3E Yes 
Same phenotype described for 
Plexin D1-KO mice. (157) 
 ephrinB2 Yes 
Mice die at mid-gestation from 
vascular anomalies and lack of 
remodeling. 
(158;159) 
Growth Factor receptors   
 endoglin Yes 
Normal vasculogenesis but are 
embryonically lethal as a result of 
defective vascular remodeling and 
smooth muscle cell differentiation. 
(152) 
 PDGFR-β Yes 
Embryonic lethality due to lack of 
pericytes recruitment which causes 
the formation of microvascular 
(160) 
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aneurysms. 
 VEGFR-2 Yes Haemangioblasts fail to differentiate into ECs. (161;162) 
 VEGFR-1 Yes 
Vascular lethal defect that is due to 
an increase in the number of 
haemangioblasts. 
(163;164) 
 FGFR-1 or -2  Yes 
Leads to embryonic lethality prior 
to gastrulation. (165;166) 
 FGFR-3 No Mice have skeletal abnormalities and deafness. (167) 
 Tie2 Yes 
Mice die between ED 9.5 and 12.5 
due to lack of remodeling of the 
primary capillary plexus.  The 
heart also appears to have defects 
with poor associations between 
ECs and underlying matrix. 
(168;169) 
 Tie1 Yes 
Mice die between ED13.5 and the 
immediate post-natal period due to 
severe hemorrhages and edema 
suggesting defective vessel 
integrity.  Mice also have increased 
vessel density. 
(168) 
 Neuropilin1 Yes 
Deletion leads to abnormal 
vascular development and poor 
branching in the brain 
subventricular zone. 
(170) 
 Plexin D1 Yes 
Abundant branching in the 
intersomitic vessels with loss of 
normal vascular patterning. 
(171) 
 EphB4 Yes 
Mice die at mid-gestation from 
vascular anomalies and lack of 
remodeling. 
(158;159) 
Intracellular kinases    
 PKG No Mice have decreased adult ischemia-induced angiogenesis. (172) 
 ShcA Yes Lethal due to defect in Ras-MAPK pathway. (173) 
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 Ras-GAP Yes Lethal due to defect in Ras-MAPK pathway. (174) 
 MEK kinase 3 Yes 
Lethal due to defect in Ras-MAPK 
pathway. (175) 
 Src No 
Viable but have impaired VEGF-
induced permeability and 
angiogenesis. 
(176) 
 Yes No 
Viable but have impaired VEGF-
induced permeability and 
angiogenesis. 
(176) 
 Fyn No Mice are normal. (176) 
 Etk No 
Mice are normal but have impaired 
hind-limb ischemia-induced 
angiogenesis and arteriogenesis. 
(177) 
 PAK1 No Mice are normal. Unpublished
Matrix proteins    
 fibronectin Yes 
Mice die by ED 9 due to defects in 
somitogenesis and vascular 
development.  Very similar to α5-
KO mouse phenotype. 
(178) 
Integrins     
 α1 No Viable and fertile and wound healing is not altered. (179) 
 α2  No 
Viable and fertile, however 
pathological angiogenesis is altered 
(tumor growth and tumor-induced 
angiogenesis is reduced). 
(180) 
 α3 Yes 
Lethal phenotype within hours 
after birth due to aberrant basement 
membrane organization.  They also 
have dilated and reduced kidney 
glomeruli. 
(181;182) 
 α5 Yes 
Mice die at ED10-11 because yolk 
sac and embryonic vascular 
network fails to properly form. 
(183) 
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 α6 Yes 
Lethal phenotype within hours 
after birth due to aberrant basement 
membrane organization.  Also have 
severe epidermal blistering. 
(184) 
 α3 & α6 Yes 
Double knockout has severe skin 
blistering but no known blood 
vessel defects. 
(185) 
 αv Yes 
Developmental vasculogenesis and 
angiogenesis proceed normally 
until ED9.5.  Between ED10.5 and 
ED11.5, 70% of embryos die due 
to a placental defects.  By E12.5, 
the surviving embryos develop 
cerebral hemorrhage and die soon 
after birth. 
(186) 
 β1 Yes 
Mice die during the early post-
implantation period prior to 
vascular development. 
(187) 
 β3 No Viable and fertile. (188) 
 β4 No 
Severe epidermal blistering defects 
but no defect in either 
developmental vasculogenesis or 
angiogenesis. 
(189) 
 β5 No Viable and fertile. (190) 
 β3 & β5 No 
Double knockout is viable and 
fertile and has normal 
developmental angiogenesis.  
Interestingly, mice demonstrate 
increased pathological 
angiogenesis. 
(189;191) 
 β8 Yes Very similar to αv.  Mice die due to impaired blood vessel support.  (192) 
Adhesion molecules   . 
 VE-cadherin Yes 
Lethal during early days of 
development.  ECs form primitive 
vascular plexus but vascular 
remodeling is missing.  ECs detach 
from one another causing vessels 
(193) 
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to regress and collapse. 
 PECAM1 No Viable and fertile.  Also have altered coronary circulation. (194) 
 ICAM1 No 
Viable and demonstrates decreased 
growth factor-induced 
angiogenesis. 
(195) 
Transcription factors    
 HIF1α Yes 
Mice die by ED11 due to extensive 
vascular defects and cardiovascular 
malformation. 
(196) 
 HIF2α Yes & No 
Mixed results, but generally mice 
die in utero or shortly after birth 
due to bradycardia, respiratory 
distress, or improper vascular 
connections. 
(197;198) 
Other     
 Retinoic Acid Yes 
Capillary plexus formation occurs, 
but capillary plexus remodeling 
and later stages of vessel assembly 
are disrupted. 
(199) 
 
Abbreviations: TIMP, tissue inhibitor of matrix metalloproteinase; MT-MMP, 
membrane associated matrix metalloproteinase; VEGFR, vascular endothelial growth 
factor receptor; FGFR, fibroblast growth factor receptor; PKG, cGMP dependent protein 
kinase; Etk, epithelial tyrosine kinase; PAK1, p21 activated kinase. 
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protein fragments v) transcription factors, and vi) intracellular kinases and proteins.  It is 
beyond the scope of this section to discuss all of these classes in detail; however these 
reviews provide an overview of these signaling components(15;37;127;128).  Only a few key 
growth factors, integrins, MMPs, and intracellular kinases that regulate angiogenesis will be 
briefly discussed. 
 
2.6.1 VEGF 
 
VEGF-A (commonly referred to as VEGF) is a heparin-binding, EC-specific growth factor 
that has been extensively studied and demonstrated to have an essential role in development 
and proper patterning of new and immature vasculature(129-131).  It was originally 
discovered as vascular permeability factor (VPF), for its ability to induce localized edema 
and increased permeability(132).  Since all VEGF isoforms contain eight conserved cysteine 
residues they are also considered to be members of the PDGF family(12).  The isoforms in 
this family include VEGF (VEGF-A through VEGF-E, which are highly homology), PDGF, 
and P1GF.  VEGF isoforms are active as homodimers, but some evidence also suggests that 
they can be active as heterodimers.  The isoform VEGF-A, and to a lesser extent VEGF-B 
and VEGF-C, have been widely implicated in vasculogenesis and the development of 
primitive vasculature(12).  Expressed throughout the embryo except in ECs, VEGF specifies 
where the primordial dorsal aorta and other major vessels will form during embryogenesis.  
VEGF gene deletion in vivo induces a lethality that demonstrates the essential role of VEGF 
in vascular development(129).  Examination of VEGF-KO mutant embryos reveals that 
normal vasculogenesis is severely impaired and vitelline veins do not coalesce with the de 
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novo circulation in the yolk sac (Table 2-3).  The requirement for VEGF also appears to be 
dose-dependent since heterozygous mutant embryos also fail to induce vascular pattering and 
form yolk sac blood islands(153).   
 
The biological effects of VEGFs are mediated via three specific cell surface 
receptors, VEGFR-1 (Flt-1), VEGFR-2 (KDR or Flk-1) and VEGFR-3 (Flt-4)(12).  All three 
consist of an extracellular domain comprising seven Ig-like domains, a transmembrane 
domain, and a cytoplasmic kinase domain.  While VEGFR-3 is primarily expressed in the 
lymphatic system, VEGFR-1 and VEGFR-2 are mainly expressed on ECs, although other 
cell types of hematopoietic origins can also express these receptors.  Disruption of genes 
encoding VEGFR-1 and VEGFR-2 leads to disrupted vascular development and embryonal 
death(161;164).  In the absence of VEGFR-2, haemangioblasts fail to differentiate into ECs.  
However, in the absence of VEGFR-1, the vascular defect is instead due to an increase in the 
number of EC progenitors, suggesting that the biological function of VEGFR-1 is to suppress 
vasculogenesis and sequester VEGF (Table 2-3). 
 
VEGF ligand binding to VEGFRs induces receptor dimerization and 
autophosphorlyation of cytoplasmic catalytic tyrosine kinase domain.  Various signaling 
molecules can interact with the newly phosphorylated receptor residues, which in turn leads 
to a cascade of signaling events (reviewed in (12;200)).  Molecules such as focal adhesion 
kinase (FAK), Src family non-receptor tyrosine kinases, Shc-like protein (Sck), 
phospholipase C-γ (PLC-γ), the MAPK p38, and phosphoinositide kinase-3 (PI3K), are 
among those that are directly activated by phosphorylated VEGFR-2.  As illustrated in Figure 
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2-2, many of these molecules have the capacity to activate other molecules in the cell, which 
subsequently induce a variety of unique cellular events.  Among those reported including 
gene expression, altered cytoskeletal dynamics, cell proliferation, cell migration, and 
differentiation(12;21).  Furthermore, VEGFR can also associate with integrins to potentate 
adhesion-induced angiogenic signaling.   For instance, VEGF activation of VEGFR-2 can in 
turn activate Src and potentate αvβ5 integrin signaling.  This cooperation in signaling not 
only induces angiogenesis in vivo, but also protects cells from the extrinsic apoptosis 
pathway, thus enhancing cell survival(201).   
 
2.6.2 bFGF 
 
Basic-FGF, also known as fibroblast growth factor-2, was the first pro-angiogenic molecule 
to be identified(11).  At present, the FGF family consists of at least 20 factors that are nearly 
identical in their primary amino acid sequences.  Surprisingly, the classical FGFs, acidic-
FGF (aFGF) and bFGF, lack cytoplasmic sequences for extracellular export, in contrast to 
most other angiogenic growth factors(12).  Furthermore, FGFs bind with high affinity to 
heparin sulfate proteoglycans (HSPGs) that are located on the surface of most cells and in the 
ECM.  These bound FGFs are among a pool of other growth factors that can be released in a 
regulated manner by the action of heparanases and ECM proteases. 
 
There are several similarities between VEGFs and FGFs.  For example, like VEGFs, 
FGFs also mediate their biological effects by interacting with their four structurally related  
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 Figure 2-2.  VEGF signaling in ECs.  VEGF ligands facilitate VEGF receptor 
typrosine kinase dimmerization and autophosphorlyation.  Phosphorylated receptors 
activate downstream signaling molecules such as FAK, PKC, PI3K, and Src.  FAK is 
essential for forming EC focal adhesion complexes and facilitating adhesion, 
migration, and gene expression via Ras/Raf/MEK/ERK signaling.  ERK activation 
can also induce prostacyclin production to induce vascular permeability.  PI3K 
activation induces Akt survival pathways, and stimulates eNOS production to 
facilitate proliferation and permeability.  Moreover, activated VEGF receptors can 
both directly and indirectly interact with integrins and cell adhesion molecules, such 
as VE-Cadherin, to further facilitate EC adhesion, migration, and permeability.  PI3K, 
phosphoinositide-3 kinase; PLA2, prostacyclin LA2; eNOS, endothelial nitric oxide 
synthase. 
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receptor tyrosine kinases FGFR-1, -2, -3, and -4.  These receptors and their splice variants 
are widely expressed and display different ligand interactions(202).  Like VEGFRs, gene 
knockout studies have revealed that both FGFR-1 and FGFR-2 are essential for the 
development of the vasculature in the mouse embryo (Table 2-3)(165;166).  Moreover, FGFs 
dimmers also can complex with their dimmerized FGFRs to induce receptor intermolecular 
autophosphorylation.  These events in turn lead to activation of molecules like Src, Ras, p38, 
PLCγ, and PI3K (reviewed in (12;200)).  Finally, both bFGF and VEGF can induce 
angiogenesis in vivo in the chicken chorioallantoic membrane, are secreted at high levels by 
many tumor cell lines, and are elevated in the serum of a large subset of cancer patients who 
have solid tumors(68;203;204). 
 
However, FGFs also differ from VEGFs in various ways.  For example, unlike the 
embryonic lethality induced by the loss of VEGF, genetic ablation of bFGF yields mice that 
are essentially normal, with only slightly reduced vascular tone and blood pressure(154).  
This suggests that there are significant redundancies among the FGF protein family that may 
compensate for the loss of bFGF during vasculogenesis and angiogenesis(12).  Furthermore, 
bFGF and VEGF can both induce the Ras-MEK-MAPK signaling cascade, but in some 
instances through exclusive pathways.  For instance, Hood et al. report that unlike VEGF 
which potentiates αvβ5-induced MAPK signaling through FAK, bFGF instead facilitates 
αvβ3-induced MAPK signaling through PAK1 activation(201).  Similar studies also 
demonstrate that bFGF can mediate cell survival by protecting cells from the intrinsic 
apoptosis pathway, while VEGF protects cells against the extrinsic apoptosis pathway(205). 
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2.6.3 Angiopoietins 
 
In addition to VEGFs and FGFs, angiopoietins comprise another important group of 
angiogenic growth factors that can also regulate EC signaling and angiogenesis.  Ang1-4 are 
very similar in peptide sequence and protein structure and they can regulate angiogenic 
remodeling in a context-dependent manner(206).  These growth factors induce their cellular 
effects through the Tie2 receptor, a receptor tyrosine kinase that is mainly expressed on ECs.  
Ang2 is expressed and stored in ECs, but its Tie2 mediated signals are contextual (sometimes 
it acts as an agonist and sometimes as an antagonist)(207;208).   On the other hand, Ang1 is 
primarily expressed by non-endothelial mesenchymal cells, can be incorporated into the 
ECM, and is an agonist for Tie2 signaling(209).  In addition to Tie2, Tie1 is another Tie 
receptor which can induce ligand-independent intracellular signals that mimic Tie2 
signaling(206).  However, it is disputed whether any of the angiopoietins can bind to 
Tie1(209;210).  In both cases, signaling through the Tie receptors has been shown to regulate 
multiple steps in vessel development, maturation, and angiogenic remodeling. 
 
The importance of angiopoietins and their receptors in vascular development, as well 
as in mediating cell-cell and cell-matrix interactions, is highlighted by the embryonic mouse 
lethal phenotypes induced in mice lacking either the Tie receptors or angiopoietin ligands 
(see Table 2-3).     Although vasculogenesis in these mice proceeds normally, the essential 
angiogenic remodeling and maturation steps that follow are severely impaired(206).  As a 
result, angiopoietin and Tie2 deficient mice present with severe hemorrhages, edema, poorly 
remodeled vasculature, and significant defects in EC adhesion and spreading.  Interestingly, 
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Ang2-KO mice also demonstrate defects in their lymphatic vessels, as well as in their eyes 
and kidneys, which suggests that angiopoietin signaling is also likely to be important for 
other systems(156). 
 
In addition to their critical functions during vascular development, angiopoietins and 
the Tie receptors also play an important role in EC signaling in the adult.  Upon angiopoitein 
binding, the Tie-2 receptor dimerizes and its cytoplasmic tyrosine kinase domain undergoes 
autophosphorlyation (reviewed in (206)).  Activated Tie2 can associate with other cell 
surface molecules (like integrin α5β1) as well as a number of cytoplasmic proteins, including 
Dok-R, GRB2, and PI3K, which in turn activate downstream signals(206;211).  For example, 
Dok-R activates PAK1, GRB3 facilitates Ras-MAPK activation, and PI3K induces the 
activation of other intracellular kinases such as FAK, Akt, and ERK1/2.  These multiples and 
diverse signaling pathways are responsible for facilitating angiopoietin-induced EC survival, 
migration, sprouting, tube formation, maturation, and remodeling.  Furthermore, through the 
mechanisms are not fully understood, signaling through Tie2 can also up- or down-regulate 
gene expression.  For example, angiopoitiens can induce vessel remodeling by increasing 
metalloprotease and plasmin expression(212;213), can mediate anti-inflammatory effects by 
inducing decreased ICAM-1, VCAM-1, and IL-8 expression(214;215), and can increase 
vessel permeability by inducing PECAM-1 and VE-cadherin expression(216).   
 
2.6.4 Integrins 
 
Integrins  are  a  family  of  heterodimeric,  transmembrane  glycoproteins  that  are primarily 
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involved in cell-to-ECM adhesion and signaling(127).  They are composed of a single α-
subunit that is not-covalently associated with a single β-subunit.  In mammals, there are 8 
different types of β-subunits and 18 types of α-subunits(217).  Of these subunits, only 6 α-
subunits and 4 β-subunits are known to be expressed on ECs.  These surface expressed 
subunits can assemble to make at least 8 different and unique integrins, including α1β1, 
α2β1, α3β1, α5β1, α6β1, α6β4, αvβ3, and αvβ5(127) (Figure 2-3).  The heterodimer 
composition of each of these integrins confers a certain degree of ligand specificity, although 
some integrins bind similar substrates and others can bind many substrates(218).  For 
example, α1β1 and α2β1 are both relatively specific integrins that predominantly bind to 
collagen, but can also bind to laminin.  Similarly, α3β1, α6β1, and α6β4 predominantly bind 
to laminin, however α3β1 is less specific in its binding and can also bind to 
thrombospondin(127).  Finally, α5β1, αvβ3, and αvβ5 can bind to ECM via an arginine-
glycine-asparagine (RGD)-binding site (reviewed in (217;219)).  Thus ECM matrix proteins, 
like fibronectin, that contain an RGD sequence, will bind to these integrins.  However, of this 
group only α5β1 selectively binds fibronectin.  Integrin αvβ5 instead binds a similar protein 
called vitronectin, and αvβ3, in addition to binding to both fibronectin and vitronectin, also 
binds to vWF, thrombospondin, osteopontin, and denatured collagen(127).   
 
Moreover, results from gene knockout studies of integrin subunits that are expressed 
on ECs have been both compelling and complex.  First, certain integrin subunits clearly have 
an  essential  role  in  development.   Accordingly, genetic deletion of the α-subunits α3(181),  
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Figure 2-3.  EC integrin subunit pairing and classification.  ECs express different 
α and β integrin subuinits that can assemble into at least 8 different integrins.  EC 
integrins can bind a wide range of ECM proteins.  For example, αvβ3, αvβ3, and α5β1 
are classified as RGD receptors because they bind ECM proteins such as fibronectin 
and vitronectin.  Integrins α1β1 and α2β1 primarily bind collagen, but can also bind 
laminin, while α3β1, α6β1 and α4β6 primarily bind to laminin. 
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α5(183), α6(184), and αv(186), and the β-subunits β1(187) and β4(189), all yield lethal 
phenotypes in mouse embryos (Table 2-3).  However, of these subunits, only α3, α5, αv, and 
β1-KO mouse embryos demonstrate impaired blood vessel development.  Integrin α6 and β4-
KO mice may also have impaired developmental angiogenesis, but so far the lethal 
phenotype is thought to be due to a distribution of the basement membrane integrity.  
Moreover, mice null for α1(179), α2(180), β3(188), and β5(190) are all viable and fertile, 
suggesting that these integrin chains are not essential for developmental angiogenesis.  
Interestingly, when pathological angiogenesis is invoked in these seemingly normal mice, a 
range of observations have been reported.  In α2-KO mice, no difference is reported, and 
again these mice appear to be respond identical to their wildtype control(180).  However, in 
α1-KO mice, pathological tumor growth and tumor-induced angiogenesis are dramatically 
reduced(220).  On the other hand, pathological angiogenesis in β3- and β5-KO mice is 
augmented in response to ischemia and tumors(191).  Thus, collectively it is clear from these 
gene knockout studies that the role of integrins in angiogenesis is complex.  Furthermore, it 
is important to note that integrin subunits that are not essential for development, may still 
contribute to pathological forms of angiogenesis. 
 
            The complexity associated with integrins is also apparent in the molecular signals 
they transduce in ECs.  Under normal conditions, integrins on ECs are generally thought to 
be in the ‘off’ state.  In fact, expression of integrins αvβ3, αvβ5, and α2β1 is barely 
detectable in the quiescent endothelium, and is upregulated various fold upon EC sprouting 
(221).  Integrin αvβ3 and α5β1 expression is also upregulated upon stimulation of ECs with 
growth factors and during angiogenesis(219).  On the molecular level, activation of ECs 
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induces changes in integrin conformation, which in turn allows it to bind ECM.  This 
phenomenon is often referred to as integrin inside-out signaling(218).  As reviewed in 
(127;218), upon binding to ECM, integrins can cluster and induce a variety of cellular events, 
including the recruitment and activation of various important cytoplamsic signaling 
molecules (i.e. FAK, Rho family GTPases, Src).  As illustrated in Figure 2-4, these 
molecules in turn transduce intracellular signaling cascades that involve the activation of 
cytoplasmic kinases such as PAK1 and components of the MAPK signaling cascade.  
Additionally, integrins can also stimulate lipid metabolism (e.g. phosphatidylinositol-4,5-
biphosphate (PIP2) synthesis),  induce ion transfer (e.g. Na2+/H+ transfer, and Ca2+ influx), 
change intracellular pH, and alter EC morphology through interactions with the actin 
cytoskeleton via proteins such as paxillin, vinculin, and talin (except for integrin α6β4 which 
instead affects EC morphology by linking to intermediate filaments)(127;218;222).  All of 
these alterations have repeatedly been demonstrated to be essential for proper EC adhesion, 
migration, growth and differentiation.   
 
A large body of evidence also indicates that integrins not only signal on their own but 
also facilitate growth factor receptor signaling(223;224).  For example, Hood et al. 
demonstrate that αvβ3 preferentially mediates bFGF signaling through FAK and PAK1 
activation, while αvβ5 preferentially mediates VEGF signaling through FAK activation(201).  
Similarly, α5β1 is necessary for optimal activation of Tie2 by its ligand Ang1(225).  The 
selectivity in integrin/receptor tyrosine kinase associations may be a result of direct binding.  
For example,  the  α5β1  integrin   co-immunoprecipitates   with   Tie2,  while  αvβ3  integrin  
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Figure 2-4.  Integrin-mediated EC signal transduction.  Upon ECM binding, EC 
integrins can activate several intracellular kinases.  For example, integrins can directly 
activate Src, which can in turn activate Rho GTPases such as Rac/Cdc42.  
Alternatively, integrins can stimulate the formation of focal adhesion complexes that 
are composed of talin, vinculin, paxilin, FAK, and actin.  Downstream to these events 
PAK1 is activated and induce various signaling pathways, including MAPK signaling.  
Collectively, integrin signaling induces various EC functions, including adhesion, 
migration, proliferation, and differentiation. 
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associates with the PDGF receptor(225;226).  In either of these cases, the integrin interaction 
appears to be essential in mediating growth factor-induced EC signaling and angiogenesis. 
 
2.6.5 MMPs 
 
MMPs are zinc-endopeptidases that are key modulators of numerous physiological 
and pathological processes.  Under normal conditions, MMPs modulate skeletal bone 
formation, coagulation, cellular migration, inflammation, wound healing, reproduction, 
growth and development, and physiological angiogenesis(227).  Pathologically, MMPs also 
play an important role in various lung diseases, atherosclerosis, aneurism, sequelae of 
myocardial infarction, inflammation, infective diseases, degenerative diseases of the brain, 
tumorgenesis, and cancer metastasis(227;228).  In humans, these effects are regulated by 24 
known members of the MMP family.  To induce their effects, these MMPs bind to an array 
of substrates, including ECM proteins, growth factors, soluble proteins, and cell surface 
receptors(228).   
 
Expression of most MMPs is tightly regulated at the transcriptional level by growth 
factors, hormones, cytokines, cell-to-cell and cell-to-matrix interactions(229).  The majority 
of MMPs are secreted as zymogens in propeptide form that require activation in order to 
cleave their substrates.  Extracellular activation of MMPs is complex, and involves chemical 
or proteolytic cleavage of the prodomain of proMMP zymogens, and most MMPs are 
mutually activated by other MMPs(227).  For example, MMP9 can be activated by other 
MMPs such as MMP2, MMP3, and MMP7(228).  In some cases, pericellular activation of 
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proMMPs may also depend upon membrane-associated MMPs (MT-MMPs).  For instance, 
both proMMP2 and proMMP13 are both activated by MT1-MMP (MMP14)(228).  
ProMMP2 activation also requires the presence of TIMP2, which forms a complex with 
proMMP2 and MT1-MMP, to yield the active MMP2 zymogen(230).  In addition, TIMPs 
(TIMP1-4) are also responsible for the inhibition of activated MMPs, and affect biological 
functions such as cell proliferation, apoptosis, and angiogenesis(228). 
 
MMPs are subdivided into different categories.  The most common classification is 
based on historical assessments of substrate specificity and cellular localization of the 
MMPs.  In this classification there are 5 main categories: i) collagenases, ii) gelatinases, iii) 
stromelysins, iv) matrilysins, and v) membrane bound MMPs (MT-MMPs).  For brevity this 
introduction will only overview gelatinases, however for a more in-depth review of all the 
MMP sub-categories see(227).   
 
There are two types of gelatinases.  MMP2 (gelatinase A) is a non-glycosylated 72-
kDa monomer enzyme that mediates most of its functions through the proteolygic 
degradation of ECM proteins such as elastin, fibronectin, laminin, and collagens IV, V, VII, 
and X(227).  It is abundantly expressed by normal ECs, fibroblasts, and epithelial cells, as 
well as many transformed cells(231;232).  In vivo, MMP2 has been detected at sites of tumor 
growth, aneurysm formation, atherosclerosis, and myocardial infarctions(233;234).  It is 
hypothesized that increased MMP2 at these sites increases ECM rapid turn-over, remodeling, 
and the accumulation of phagocytic macrophages.  Pharmacological inhibition and gene 
deletion of MMP2 can protect against these effects, reduces the incidence of lethal cardiac 
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rupture following myocardial infarctions, and protects against experimentally-induced 
abdominal aortic aneurysms. MMP2-KO mice also have reduced tumor onset and growth, 
and tumor-induced angiogenesis(134).  However, genetic deletion of MMP2 in mice leads to 
very few developmental side-effects, and mice are viable and fertile (Table 2-3).  The lack of 
a developmental phenotype suggests that other MMPs, such as MMP9 (gelatinase B), can 
compensate for the loss of MMP2 during development. 
 
MMP9 is the other member of the MMP gelatinase family.  It is a glycosylated 92-
kDa enzyme that exists in both monomer and dimer forms.  Like MMP2, it also mediates its 
effects by degrading ECM proteins such as collagen types IV, V, and XI, aggrecan, and 
elastin(227).  However, unlike MMP2 it is not expressed by ECs, and instead it is mainly 
expressed by normal leukocytes and various types of transformed cells(235).  MMP9 can 
also activate other molecules such as cytokines IL-1β and TGF-β, and convert plasminogen 
to angiostatin (a potent in vivo angiogenesis inhibitor)(220;227).  Moreover, like MMP2-KO 
mice, MMP9-KO mice are also viable, but exhibit several developmental abnormalities 
(Table 2-3).  For example during development, MMP9-KO mice have delayed and abnormal 
vascular and ossification patterning in the skeletal growth plate.  In adult mice this defect 
leads to moderate skeletal abnormalities due to delayed growth in the cartilage ossification 
hypertrophic zones(135).  In pathological states, as in MMP2-KO mice, loss of MMP9 alters 
ECM remodeling after myocardial infarctions and reduces the severity of atherosclerotic 
plaques(136;236). 
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Despite their largely overlapping functions, MMP2 and MMP9 may be differentially 
regulated, and in some cases can facilitate opposing functions.  For example, compared to 
MMP2, MMP9 is reported to be more highly upregulated upon cellular stimulation with 
molecules such as epidermal growth factor (EGF), PDGF, bFGF, VEGF, IL-1α and β, and 
TNF-α(228).  Moreover, unlike MMP2 pro-angiogenic and tumorgenic effects, MMP9 
mediates both mediate pro- and anti-tumorgenic effects.  Furthermore, MMP2 promotes 
platelet aggregation, while MMP9 does the opposite by inhibiting platelet aggregation(228). 
 
2.6.6 PAK1 
 
The serine/threonine kinase PAK1 belongs to a family that consists of six known 
members, PAK1 through PAK6(237;238).  Each member of this family is encoded by a 
distinct gene and the differences in their N-terminal regions contribute to their ability to 
recruit different intracellular molecules and activate distinct signaling pathways(239).  PAK1 
activation is regulated by small GTP-bound GTPases(240).  The Rho family GTPases Cdc42 
and Rac can cause autophosphorlyation of PAK1, and are stimulated by multiple growth 
factors (such as EGF, PDGF, HGF, VEGF, bFGF, and heregulin), as well as integrins and G 
protein coupled receptors(201;241-243).  Alternatively, PAK1 can be activated by adapter 
molecules (such as Nck and the guanine nucleotide factor Pix), AGC protein kinase family 
members (such as Akt-1, PDK1 and cAMP-dependent protein kinase), lipids (such as 
phosphorylated 3-phosphoinositid-dependent kinase 1), and sphingosine (as well as related 
long-chain sphingoid bases; reviewed in (239)).  As illustrated in Figure 2-5, activated PAK1 
also has numerous downstream substrates that affect a diverse set of cellular functions 
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(including cellular growth, proliferation, and actin cytoskeleton reorganization), thus making 
it apparent that PAK1 is likely an important signaling molecule.  For an in depth overview of 
PAK1 functions, see (237;239).   
 
Evidence to support the role of PAK1 in cellular growth and proliferation is 
demonstrated in its involvement in tumor cell proliferation and cancer progression(239).  For 
instance, Ras-mediated signaling, which induces cellular transformation and proliferation, 
also induces PAK1 activation and MAPK signaling(244).  The expression of catalytically 
active PAK1 in tumor cells can on its own also induce MAPK signaling and stimulate 
anchorage-independent growth(245).  PAK1 can also enhance cell survival by inactivating 
the pro-apototic functions of BCL2 family member proteins(246). 
 
In addition to these functions, PAK1 also plays a significant role in cellular migration 
and actin cytoskeleton reorganization(239).  It is known to facilitate these processes through 
multiple different mechanisms.  For example, PAK1 can stimulate migration through 
activation of ERK1/2 and p38(247-249).  The pro-migratory role of PAK1 can be inhibited in 
breast cancer cells by overexpression of a kinase-dead PAK1 mutant.  On the other hand, 
PAK1 can also inhibit migration.  This is mediated by PAK1 induced LIM kinase 1 
activation.  Activated LIM kinase 1 in turn phosphorylates and inactivates cofilin and induces 
actin filament depolymerization(250;251).  Therefore, this demonstrates that the effects of 
PAK1 on cellular migration depend on the context of cellular activation(252). 
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Figure 2-5.  PAK1 is an important signaling molecule that affects various 
downstream molecules.  G protein coupled receptors, receptor tyrosine kinases, and 
integrins can activate PAK1.  In turn, PAK1 can phosphorylate and affect the function 
of various downstream molecules. 
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Accumulating evidence also suggests that PAKs plays an important role in regulating EC 
signaling and angiogenesis.  Kiosses et al. provided the first evidence for this by 
demonstrating that constitutively activated and dominant negative forms of PAK both inhibit 
EC migration, therefore suggesting that proper PAK activation and signaling was essential 
for this process in ECs(250).  Subsequently, dominant negative PAK was shown to strongly 
inhibit the interaction between Nck and PAK, and caused a significant decrease in growth 
factor-induced EC migration, contractility, and three-dimensional capillary structure 
formation(253).  In this study, the disruption of the Nck/PAK interaction was also shown to 
decrease angiogenesis in vivo in a chick chorioallantoic membrane assay.    
 
The role of PAK1 in angiogenesis was also confirmed by Hood el al., as well as 
others, who demonstrated that PAK1 acts as a point of convergence between growth factor-
induced and integrin-induced angiogenic signaling(201).  In these studies, PAK1 was shown 
to mediate VEGF-induced actin cytoskeleton reorganization, and bFGF-induced EC anti-
apoptotic signaling.  PAK1 mediates these effects by preferentially acting on the Ras-Raf-
ERK1/2 MAPK signaling pathway, and by phosphorylating specific serine residues on either 
Raf1 or MEK1.  Bagheri-Yarmand et al. also showed that PAK1 can participate in 
angiogenic growth factor expression, and mediated heregulin-induced VEGF 
expression(242).   
 
2.7 Angiogenesis as a promising medicine 
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It is predicted that more than 500 million patients can benefit from anti- or pro-
angiogneic therapy in the coming decades (254).  However, proper in vivo delivery of 
therapeutics still remains an obstacle in the treatment of angiogenesis-contributing or 
angiogenesis-dependent diseases(255).  Since the vascular endothelium in these diseases is 
the central target for intervention, much effort has recently been invested in determining how 
to best target this tissue in a safe, efficient, and selective manner.   
 
2.7.1 Pro-angiogenic Therapy 
 
Myocardial ischemia and peripheral vascular disease are two major causes of 
morbidity and mortality in humans(86).  Over the past decade, advances in our understanding 
of neovascularizaiton have encouraged efforts to develop clinical interventions that may 
promote adaptive forms of angiogenesis in such cases of vascular insufficiency, wound 
healing, and tissue recovery(256).  Two main strategies have been proposed to accomplish 
this: i) angiogenic gene therapy using viral vectors, or ii) administration of growth factors 
such as VEGF and bFGF at sites of ischemia(257).  Preclinical animal models and 
preliminary clinical trials highlight the therapeutic promise associated with both of these 
strategies.  For example, in a phase I clinical trial bFGF was slowly administered over a 4-6 
week period in patients with ischemic heart disease and was found to significantly increase 
freedom from angina recurrence, increase myocardial neovasularization, and reduce 
myocardial ischemic area(258).  In dogs, pre-existing collaterals demonstrated improved 
blood flow following administration of bFGF at sites distal from experimentally induced 
coronary artery constrictions(259).  Single bolus administration of VEGF near the femoral 
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artery also alleviated experimentally induced hind-limb ischemia in mice, which models 
human peripheral vascular disease(260).  Similarly, delivery of adenovirus carrying the 
VEGF gene to the diseased coronary arteries of heart disease patients decreases the incidence 
of angina (cited in (260)).   
 
However, in order for angiogenic therapy to be more feasible and become a reliable 
method of therapy, clinical trials must demonstrate little or few acute side effects, enhanced 
specificity to targeted ischemic tissue so that unwanted angiogenesis is not stimulated, and 
sustained clinical benefit(256).  Unfortunately, so far clinical trials have demonstrated a 
significant lack of treatment specificity, suboptimal delivery, and treatment-associated acute 
side-effects(261;262).  Furthermore, delivery of VEGF and bFGF to ischemic tissue 
stimulates the growth of vessels that are morphologically and functionally less stable 
compaired to normal mature vessels(263).  It is not yet clear whether increased systemic 
levels of angiogenic growth factors can induce decreased adhesion molecule expression in 
the systemic circulation, trigger dormant tumor growth, and accelerate vessel 
atherosclerosis(257;264).  Current research is focusing on improving methods of treatment 
administration as well as optimizing viral gene transfer methods through modification of 
viral capsid proteins that enhance treatment selectivity and efficiency, and decrease host 
immunogenecity(265). 
 
2.7.2 Anti-angiogenesis Therapy 
 
Based  on  exciting  preclinical  data  that  surfaced in the 1990s(266), anti-angiogenic 
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therapy, which can alleviate aberrant forms of angiogenesis, has since been under 
development.  Anti-angiogenic targets have been developed to interfere with angiogenic 
ligands like VEGF and PDGF, their receptors, or subsequent downstream signaling in 
ECs(267).  As reviewed in (268), anti-angiogenic therapies have also been developed to 
upregulate or deliver endogenous angiogenesis inhibitors, inhibit EC integrins, neutralize 
matrix degrading enzymes, or inhibit EC-specific functions (such as proliferation, adhesion, 
migration, protease secretion, and differentiation).  Several of these medicines are currently 
in clinical trials, and a few have already been approved for combination therapy with 
conventional treatments.  See Table 2-4 for a list of agents currently being tested in clinical 
trials (http://cancertrials.nci.nih.gov/).   
 
Anti-angiogenic therapy is currently in use to treat different types of angiogenesis-associated 
clinical disorders.  For example, for the treatment of rheumatoid arthritis, anti-TNFα 
antibody infliximab (Remicade, Johnson & Johnson) not only neutralizes the effects of TNFα 
in inflammation, but also decreases angiogenesis and significantly reduces VEGF serum 
levels(269).  Anti-angiogenic effects of infliximab are also noticed in other forms of arthritis, 
such as psoriatic arthritis(270).  Similarly, becaplermin (Regranex, recombinant PDGF-β, 
Ortho-McNeil Pharmaceuticals) is FDA-approved to treat dermatological conditions such as 
diabetic neuropathic foot ulcers(271).  For retinal diseases like AMD, intravitreal 
administration of anti-VEGF therapy (using pegaptanib sodium and ranibizumab) showed in 
phase III clinical trials to reduce the progression and severity of this disease(272).   
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Table 2-4.  A partial list of anti-angiogenic agents undergoing clinical trial testing. 
Category of 
Therapy Drug Description 
Clinical 
Trial 
Phase 
 
Blocks matrix 
breakdown 
   
 Dalteparin Low molecular weight heparin II 
Blocks ECs directly    
 ABT-510 Small peptide thrombospondin-1 mimetic I & II 
 Lenalidomide Thalidomide derivative I, II, III, & IV 
 Combretastatin A4 phosphate 
Binds to tubulin and inhibits 
microtubule 
depolymerization 
I & II 
Blocks activators of 
angiogenesis    
 ADH-1 (ExherinTM) Competitively binds and inhibits cadherins I 
 AG-013736 Inhibits tyrosine kinase receptors I & II 
 
Anti-VEGF Antibody 
(Bevacizumab; 
AvastinTM) 
Binds and inhibits action of 
VEGF 
II, III, 
& IV 
 BMS-582664 Inhibits VEGFR-2 activation I & II 
Inhibits EC-specific 
integrin/survival 
signaling 
   
 ATN-161 α5β1 integrin antagonist I & II 
 EMD 121974 (CilengitideTM) Inhibits αvβ3 and αvβ5 I & II 
Undefined method 
of action    
 Celecoxib, (Celebrex®) Inhibits Cyclooxygenase-2 I, II, & III 
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Anti-angiogenic therapy has also been tested for its potential role in inhibiting tumor-
induced angiogenesis and tumor growth.  The goal of anti-angiogenic tumor therapy is to 
first effectively normalize tumor vasculature and then inhibit it all together(273).  If this can 
be achieved it is hypothesized that tumors would be starved from essential nutrients and 
oxygen, stunt tumor growth, and eventually reduce tumor progression(113).  The 
endothelium is a prime target for such therapy since unlike most tumor cells it is composed 
of cells that are diploid and genetically stable, thus making it less likely that they will 
develop resistance to therapy(68).   Second, the tumor endothelium is pathologically 
activated unlike the normal endothelium, which is normally quiescent(274).  Activated ECs 
are known to overexpress surface markers (such as integrin αvβ3, E-selectin, and Tie 
receptors) that are expressed to a lesser degree on the quiescent endothelium(68).   Such 
differences in surface marker expression provide opportunities for selective targeting of the 
tumor endothelium in order to decrease therapy associated side-effects.  Third, ECs are easily 
accessible to therapeutic agents through the blood stream(274).  This is obviously beneficial 
since it allows for more efficient drug delivery at lower effective doses(13).  Thus 
collectively, anti-angiogenic cancer therapy demonstrates enormous promise over 
conventional chemotherapy since it may overcome current problems of resistance, 
selectivity, and drug delivery(268). 
 
The recent success of the FDA-approved humanized anti-VEGF monoclonal antibody 
bevacizumab (Avastin, Genentech, Inc.) has made the option of anti-angiogenic therapy even 
more attractive.  In 2004 the FDA approved this drug for combination therapy of advanced 
colorectal cancer when in Phase III clinical trials it was found to significantly prolong 
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survival, and had a better ability to shrink tumors than standard therapy (5-fluorouracil, 
leucovorin, and oxaliplatin or ininotecan)(275).  Bevacizumab also improves outcomes for 
patients with metastatic renal, ovarian, lung, and breast cancer(268).  Furthermore, 
bevacizumab and its derivatives improve the condition of patients that have non-oncologic 
disorders.  For example, in June, 2006, the FDA approved Ranibizumab (Lucentis, 
Genentech, Inc.) which is a Fab fragment derived from bevacizumab, for the use in 
AMD(276).  Although patients that receive this therapy demonstrate significantly improved 
outcomes, the therapy so far has been prohibitively expensive(277).     
 
Despite the success of these as well as other anti-angiogenic agents, clinical trials of 
these agents have also raised various important questions.  For example, so far bevacizumab 
demonstrates an overall survival benefit in patients receiving combination therapy(268).  It is 
still unclear why monotherapy with these agents has been less effective in human cancers, 
than in rodents(278).  Second, bevacizumab causes some serious side effects, including 
increased incidence of elevated blood pressure, gastrointestinal bleeding, as well as intestinal 
perforation(279).  This suggests that at least anti-VEGF therapy is not as EC-specific as 
previously thought.  Third, clinical evidence suggests that targeting ECs in combination with 
other cell types, like stromal and hematopoietic cells, is more effective than therapies that 
target only ECs(267).  This argues that despite the genomic stability of ECs, resistance may 
still occur.  Finally, despite advances in anti-angiogenic therapy, cancer patients receiving 
angiogenesis inhibitors, even in combination with chemotherapy, still die(268).  Therefore, 
although significant advances in anti-angiogenic therapy have been made in the past decade, 
their full potential in cancer therapy still remains to be determined. 
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Role of CIB1 in Vascular Biology 
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3.1 Identification of CIB1 
 
Proper integrin function and signaling is critical for various physiological 
processes(1).  Among these processes, integrin-mediated platelet aggregation is essential for 
efficient wound healing and vascular hemostasis(2).  However, equally as important are 
pathological conditions that arise from disregulated platelet aggregation (e.g. hemorrhage, 
stroke, distal vein thrombosis, etc.)(3).  Regulation of both physiological and pathological 
platelet functions are facilitated by the platelet fibrinogen receptor, integrin αIIbβ3(4).  This 
integrin is specifically expressed in the megakaryocytic lineage, and its mechanism of 
regulation has been a subject of intense interest. 
 
In an effort to understand how platelets regulate the function of αIIbβ3, Naik et al 
screened a human fetal liver cDNA library in a yeast two-hybrid system by using the αIIb 
cytoplasmic domain as bait(5).  This screen yielded one positive clone; contained 855-base 
pairs that translated into a novel 191-amino acid, 22 kDa protein.  This protein was identified 
as CIB (for calcium and integrin-binding protein), but is now commonly referred to as CIB1.  
Previous names for CIB1 also included CIBP, calmyrin, Kip, and ISBP(3).  In subsequent 
biochemical studies, isothermal titration calorimetry (ITC) confirmed a high affinity 
association (0.7 µM) between CIB1 and αIIb(6).  The specific residues in αIIb that are 
essential for CIB1 binding were also identified, thus further confirming the CIB1/αIIb 
interaction(7). 
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Early studies also demonstrated that CIB1 is N-terminally myristolated(8).  This 
myrisotyl group appears to target CIB1 to the plasma membrane, since in lysates of nucleated 
(megakaryocytes and HeLa) and non-nucleated (platelets and erythrocytes) cells CIB1 almost 
entirely fractionates to the membrane(6).  Moreover, disruption of the myristolation site on 
CIB1 by the addition of an N-terminal myc tag induces CIB1 cytoplasmic and nuclear 
localization(8).   However, the effects of myristolation on CIB1 cellular localization are still 
not entirely clear, and it is unknown to what extent myristolation regulates the binding 
affinity of CIB1 to αIIb and other proteins. 
 
Furthermore, upon identification of CIB1, sequence homology studies indicated that 
CIB1 belongs to a family of Ca2+-binding proteins(5).  Accordingly, CIB1 is homologous to 
calcineurin B (58% similarity) and calmodulin (56% similarity), both of which are known to 
regulate a variety of cytoplasmic proteins.  Further, CIB1 sequence analysis showed that 
CIB1 contains 4 EF hand motifs, which may bind Ca2+.  Using a 45Ca2+ blot overlay assay, 
recombinant CIB1 did bind Ca2+ like its homolog calmodulin(9).  Subsequently, NMR 
studies reveled that CIB1 contains two non-Ca2+ binding EF hand motifs in addition to the 
two different EF hand motifs that bind Ca2+ in a regulatory manner(10).  The dissociation 
constants for Ca2+ binding to these motifs are 2µm and 0.5µm(10). 
 
3.2 Structure of CIB1 
 
Gentry et al. describe the crystal structure of CIB1, which confirms that CIB1 
contains four EF-hand motifs (EF1-4), two of which can bind Ca2+ (EF3 and EF4)(11).  The 
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crystal structure (illustrated in Figure 3-1) also confirms that CIB1 is significantly 
homologous to various mammalian and non-mammalian EF-hand containing proteins.  
Interestingly, sedimentation equilibrium and gel filtration studies demonstrate that CIB1 
exists as a monomeric protein.  This is in contrast to Blamely et al., who later reported that 
CIB1 forms a head-to-tail dimmer(12).  Nevertheless, CIB1 contains a hydrophobic channel 
on its surface that is preserved in other closely related EF-hand-containing proteins (e.g. 
calcineurin B and the neuronal calcium sensor (NCS) protein KChIP1), which may facilitate 
its ability to associate with various binding partners(11).   
 
3.3 CIB1 binding partners 
 
Since its discovery in platelets, CIB1 was found to be expressed in various human 
and murine cell types and tissue(6;13).  The near ubiquitous expression of CIB1 also appears 
in several cancer cell lines (Bin Zhao and Cassandra Moran, unpublished data).  The wide 
distribution of CIB1 expression prompted speculation that, like calmodulin and other EF-
hand containing proteins, CIB1 binds and regulates the function of various intracellular 
proteins.  In the past decade, nearly a dozen CIB1 binding partners have been identified 
(recently reviewed in (3)).  It is beyond the scope of this section to discuss all of the CIB1-
binding partners, but we will explore a subset of these proteins to highlight their diverse roles 
and different cellular localizations.   
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Figure 3-1.  Ribbon diagram of CIB1 crystal structure.  CIB1 contains four EF 
hand motifs, two of which bind Ca2+ (gold spheres).  The N-terminal region and EF1 
is blue, EF2 is yellow, EF3 is red, EF4 is green, and the C-terminus is purple.  This 
figure is published in the following reference: Gentry, H.R., Singer, A.U., Betts, 
L., Yang, C., Ferrara, J.D., Sondek, J., and Parise, L.V.  “Structural and 
Biochemical Characterization of CIB1 Delineates a New Family of EF-hand-
containing Proteins.” JBC, 2005. 280: 9, 8407-8415.  It is reprinted with 
permission from the American Society for Biochemistry and Molecular Biology 
Journals. 
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3.3.1 PAX3 and DNA-PKCS  
 
Immunoflorescent microscopy of CIB1-transfected cells demonstrates that CIB1 can 
localize to the nucleus(8).  Accordingly, CIB1 has been reported to bind and regulate the 
activity of several nuclear proteins that have diverse cellular functions.  For example, CIB1 
can bind PAX3, which is a homeodomain family transcription factor(14).  Binding of CIB1 
to PAX3 inhibits human and mouse primary myoblast differentiation.  Similarly, CIB1 was 
also shown to associate with DNA-dependent protein kinase (DNA-PKCS) in a yeast two-
hybrid assay only.  DNA-PKCS is a nuclear kinase that is important for the repair of double-
strand breaks(15).  Since the autophosphorylation of DNA-PKCS results in its 
inactivation(16), it is hypothesized that CIB1 binding to DNA-PKCS inhibits 
autophosphorylation and instead induces its activation(15).   
 
3.3.2 InsP3R isoforms 
 
Isoforms of the inositol 1,4,5-triphosphate receptor (InsP3R) that are localized to the 
endoplasmic reticulum (ER) are the primary cytosolic target responsible for the initiation of 
intracellular Ca2+ signaling (reviewed in (17)).  This process is important since it can affect 
apoptosis, intracellular pH, exocytosis, and gene expression.  To fulfill its effects, InsP3Rs 
interact with several ER and cytosolic proteins.  Recently, CIB1 was reported to bind all 
mammalian InsP3R isoforms in a Ca2+-dependent manner(18).  In the absence of InsP3 
ligand, CIB1 was found to activate InsP3Rs in vitro.  However, in CIB1-transfected COS-7 
and PC12 cells, CIB1 decreased InsP3R activation.   Thus these findings demonstrate that 
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CIB1 is an InsP3R protein ligand that can both stimulate and inhibit InsP3R-mediated Ca2+ 
signaling.   
 
3.3.3 Presenilin-2 
 
A few reports have also implicated CIB1 binding to presenilin-2 (PS2) in a Ca2+-
independent manner(8;19-21).  PS2 is an ER membrane protein that is mutated in early onset 
Alzheimer’s disease (AD), which is a neurodegernative disorder characterized by dementia 
(reviewed in (22)).  In a yeast two-hybrid screen, CIB1 bound to a cytoplasmic loop that is 
specific to PS2, and in cells this interaction enhanced cellular apoptosis(8).  
Immunohistochemistry of CIB1 showed that it is in part associated with diffuse and senile 
plaques in the forebrains of deceased human AD patients(20).  
 
3.3.4 PAK1 
 
CIB1 also binds and regulates the activity of various types of kinases(3).  For 
example, CIB1 can inactivate kinases such as serum-inducible kinase (Snk or polo-like 
kinase 2)(23).  On the other hand, CIB1 can also bind and activate the AGC protein kinase 
family member PDK1 (Bin Zhao, unpublished data).   Most notably however, Leisner et al. 
provided the first evidence to show that CIB1 is an essential regulator of PAK1 activity in 
several different cell types including REF52 fibroblasts(24).  In this study, CIB1 is found to 
specifically bind to the PAK1 NH2-terminus in a calcium-dependent manner at two putative 
binding sites (site I and site II).  Interestingly, site I was found to be in close proximity to the 
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NH2-terminal p21-binding domain (PBD; where Rac/Cdc42 normally bind PAK1).  Site II 
was found to be within the PAK1 NH2-terminal autoinhibitory domain.  Since the crystal 
structure of PAK1 suggests that site I is more accessible than site II for binding(25), it is 
hypothesized that CIB1 binds to PAK1 in two-stages: i) first by binding the more accessible 
site I to induce a conformational change in PAK1, ii) then binding to site II where it may 
regulate PAK1 activation.   
 
Using a series of in vitro kinase assays, Lesiner et al. demonstrate that CIB1 indeed 
regulates PAK1 activation levels and can inhibit Cdc42 binding to PAK1(24).  This study 
also showed that in a Rac/Cdc42-independent manner, overexpression of CIB1 increased 
adhesion-induced activation of PAK1 at all time points (for up to 3 hours; Figure 3-2 A).  
Upon depletion of CIB1, adhesion-induced activation of PAK1 was decreased only at early 
time points (20 and 45 minutes), but not at later time points (1.5 and 2.5 hours) which were 
primarily regulated by Rac/Cdc42 (Figure 3-2 B).  Moreover, CIB1 overexpression and 
depletion appeared to significantly affect PAK1-mediated cell migration.  In this study, 
CIB1-induced activation of PAK1 inhibited migration by promoting LIMK-dependent 
inactivation of the actin regulatory protein cofilin.  This is an interesting finding, since PAK1 
is also known to increase migration through its downstream activation of MAPK signaling.   
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A 
B 
 
 
 
 
 
 
 
Figure 3-2.  CIB1 regulates PAK1 activation in REF52 fibroblasts.  (A) CIB1 
overexpression increases PAK1 activation in a Rac/Cdc42-independent manner (in the 
presence of toxin B).  (B)  Knockdown of CIB1 decreases PAK1 activation at early 
time points (20 and 45 minutes) but not later time points (2.5 hours).  The panels in 
this figure are published in the following reference: Leisner, T.M., Liu, M., 
Jaffer, Z.M., Chernoff, J., and Parise, L.V. “Essential role of CIB1 in regulating 
PAK1 activaiton and cell migration.” JCB, 2005. 170: 3, 465-476.  They are 
reprinted with permission from The Rockefeller Unviersity Press. 
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3.3.5 Integrins 
 
Although the initial yeast-two hybrid classification of CIB1 suggested that it 
specifically bound to the αIIb cytoplasmic tail, and did not bind to any other integrin 
cytoplasmic tails (αv, α2, α5, β1, and β3)(5), recent NMR and ITC studies have revealed an 
association between CIB1 and α5 (Jun Qin, Holly Gentry, and Leslie Parise, unpublished 
data).  Furthermore, binding studies confirmed that αIIb contains a minimal binding sequence 
for CIB1 that extends beyond the cytoplasmic domain and into the αIIb putative 
transmembrane region(6;7).  This is important since only the cytoplasmic compartments of 
the αv, α2, and α5 integrins were used in the initial screen(5).  This prompted further studies 
using ITC, which showed that in addition to αIIb, CIB1 can in fact bind to other integrin α 
chains, including α2, α4, α5, αL, and αM.  All interactions between CIB1 and α integrins 
peptides were found to be of high affinity, with only αM occurring at a slightly lower affinity 
(binding of CIB1 to αv is still under investigation; Holly Gentry and Yi Wu, unpublished 
data).  These findings therefore suggest that CIB1 may be a global regulator of various types 
of α integrins, including ones that are critical for vascular homeostasis and angiogenesis.  
However still to be determined is whether CIB1 binding to these integrin subunits can affect 
their activation states and contribute to biological functions in vivo.   
 
3.4 Role of CIB1 in megakaryocytes and platelets 
 
When the αIIb integrin cytoplasmic domain or its cytoplasmic GFFKR motif (which 
partly comprises the CIB1 minimal binding sequence) are missing the αIIbβ3 integrin 
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becomes constitutively active(26).  Thus it was hypothesized that since CIB1 directly bound 
to the cytoplasmic domain of αIIb, it may be important for regulating αIIb activation and 
downstream signaling.  This mode of regulation has been shown to occur for multiple 
integrins via the β3 integrin subunit(27).  Naik and Naik provided the first evidence to 
demonstrate that CIB1 can functionally regulate platelet spreading and lamellipodia 
formation through its activation of FAK(9).    To validate and build upon these findings, 
Yuan et al. demonstrated that CIB1 competes with talin for αIIb integrin binding in order to 
regulate the activation state of αIIb in megakaryocytes(28).  Specifically, overexpression of 
CIB1 dramatically inhibited agonist-induced αIIb activation and binding to fibrinogen.  
While, in the converse experiment knockdown of CIB1 using RNAi demonstrated an 
increase in agonist-induced activation.  These findings suggested that in physiological 
situations, CIB1 can maintain the αIIbβ3 integrin in an inactive state, thus regulating platelet 
aggregation and hemostasis. 
 
To further clarify the role of CIB1 in platelet function and vascular biology a CIB1-
KO mouse was generated(29).  Despite an anticipated defect in platelet hemostasis, so far 
CIB1-KO mouse platelets appear to behave normally.  In fact, besides a sterility defect in 
CIB1-KO mice due to a disruption of the haploid phase of spermatogenesis(29), CIB1-KO 
mice reach all developmental milestones and progress to adulthood without any overt 
hematological or vascular phenotypes.  An explanation for this apparent discrepancy between 
in vitro and in vivo findings is yet to be proposed.  One probable explanation may be that 
molecular redundancies in megakaryocytes and platelets are compensating for the chronic 
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loss of CIB1 in CIB1-KO platelets.  Likely candidates that may compensate for the loss of 
CIB1 may include its newly identified homologs CIB3 and CIB4(11).   
 
3.5 Hypothesized role of CIB1 in ECs and Angiogenesis 
 
Beyond the role of CIB1 in megakaryocytes, platelets, and the testis, little else is 
know about the biological functions of CIB1.  Moreover, the potential role of CIB1 in other 
vascular tissue, in addition to platelets, has never been explored.  In an initial screen, we have 
found that CIB1 is expressed in different embryonic mouse vasculature structures and 
various types of ECs (see Chapter 4, Figure 4-1).  Since CIB1 also binds and regulate the 
activity of important angiogenic kinases like FAK(9) and PAK1(24), we hypothesized that 
CIB1 may play an important role in EC signaling and function.    Furthermore, although 
CIB1-KO mice demonstrate no obvious defect in vascular development, we postulated that 
pathological forms of angiogenesis in CIB1-KO mice may be altered. 
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CHAPTER 4 
 
 
 
CIB1 Regulates EC Signaling and Function 
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4.1 Abstract 
 
CIB1 is a 22kDa, EF-hand containing, regulatory protein that was originally 
identified to bind the platelet-specific integrin αIIb.  Subsequently, CIB1 was found to bind 
various other proteins, including proteins that can regulate EC function.  However, the role of 
CIB1 in vascular tissue has never been explored.  We found that CIB1 mRNA expression is 
highest in vascularized organs such as the testis, bone marrow, kidney, placenta, and the 
embryonic yolk sac.  CIB1 is also expressed in various species and types of ECs, including 
microvascular and macrovascular ECs.  We demonstrate here that when CIB1 is depleted 
from ECs by homologous recombination (CIB1-KO ECs), we observe attenuated adhesion-
induced PAK1 activation and ERK1/2 phosphorylation.  CIB1-KO ECs also have a 
significant decrease in growth factor-induced MMP2 expression and secretion.  Moreover, 
CIB1-depleted ECs demonstrate significantly decreased EC functions, including decreased 
migration, proliferation, tubule formation, and monolayer resistance.  Treatment with growth 
factors, such as VEGF or bFGF, did not rescue defects observed in CIB1-depleted ECs, but 
re-introduction of CIB1 in CIB1-KO ECs did restore haptotatic migration to normal levels.  
Thus, collectively our findings demonstrate that CIB1 can critically regulate various EC 
functions and is necessary for proper EC signaling.  This work identifies a previously 
unknown role for CIB1 in the vasculature, and suggests that it may have a role in 
angiogenesis.   
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4.2 Introduction 
 
CIB1, a 22kDa EF-hand-containing protein, was originally identified in a yeast-two-
hybrid screen as a binding partner for the cytoplasmic tail of the platelet integrin αIIb(2).  In 
vitro, CIB1 was found to compete with the cytoplasmic protein talin for binding of αIIb, and 
inhibit agonist-induced αIIbβ3 activation in megakaryocytes(3).  However, CIB1 is widely 
distributed, suggesting that it has roles in other cell types besides megakaryocytes, and 
contributes to cellular functions that are independent of αIIbβ3(4;5).  Thus far, CIB1 has 
been shown to associate with proteins such as the Alzheimer’s disease associated presenilin-
2(6), InsP3R(6;7), FAK(8), and PAK1(9).  Among these binding partners, FAK and PAK1 
have been shown in multiple studies to regulate EC signaling and function, thus prompting us 
to determine whether CIB1 has a role in ECs(10-12). 
 
The endothelium, which is comprised of a cohesive single-cell layer of ECs, covers a 
large surface area (4000-7000 m2 in an average sized human) and forms a metabolically 
active interface between blood and tissue(13).  Accordingly, ECs are pivotal in physiological 
processes such as controlling vasomotor tone, trafficking of cells and nutrients, maintaining 
blood fluidity, regulating permeability, and facilitating new blood vessel formation in healing 
and regenerating tissue(14).  Just as important however, dysfunction or aberrant activation of 
ECs can lead to a diverse set of diseases (such as atherosclerosis, thrombosis, or acute and 
chronic inflammation) that span various clinical disciplines including cardiology, 
pulmonology, infectious diseases, and oncology(15).    
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The formation of new blood vessels from pre-existing vasculature is an EC dependent 
biological process that is referred to as angiogenesis, and occurs in both physiological and 
pathological situations(16).  During the activation phase of angiogenesis, in response to 
various stimuli (i.e. hypoxia or inflammation), angiogenic growth factors (such as VEGF of 
bFGF) are typically secreted by stromal cells or liberated from the ECM through the action 
of ECM degrading MMPs(17;18).  In turn, these growth factors bind to their cognate 
receptors on the surface of ECs, activate intra-endothelial signaling cascades, induce 
expression of various genes, and ultimately alter various EC functions(19).  For example, 
growth factors can first stimulate ECs to undergo a remarkable increase in proliferation.  If a 
gradient has been established by the secreted growth factors, then newly formed ECs will 
also participate in directed migration toward areas of higher growth factor 
concentrations(20).  Migrating cells will also form a trail of ECs that can eventually envelop 
upon one another to form nascent tubular structures.  During the resolution phase of 
angiogenesis, these nascent tubules become remodeled into mature blood vessels that can 
facilitate blood flow(21).         
 
In recent years, much has been learned about the molecular regulation of EC 
angiogenic functions.  However, endothelial angiogenic signaling is highly complex and the 
molecular mechanisms that regulate ECs are still not fully elucidated.  In this study we 
demonstrate that in ECs, CIB1 regulates the activity of the angiogenic kinase PAK1, and 
affects downstream signaling events.  Furthermore, we also demonstrate that CIB1 is 
essential for proper EC functions such as migration, proliferation, tubule formation, and 
monolayer resistance.  Thus, we describe here the novel regulatory role of CIB1 in ECs, 
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which establishes the bases for later studies investigating the role of CIB1 in angiogenesis, in 
vivo. 
 
4.3 Methods 
 
Reagents, lysate preparation, and Western blotting.  MECs and BAECs were 
maintained in culture using high-glucose DMEM (Sigma, St. Louis, MO) supplemented with 
3% fetal bovine serum (FBS; Sigma).  HUVECs, HPAECs, and HCAECs were maintained in 
EBM culture media according to manufacture’s instructions (Cambrex, East Rutherford, NJ).  
MHECs and MLECs were isolated in isolation media (high-glucose DMEM with 20% FBS, 
20 U/mL penicillin/streptomycin antibiotic (Gibco, Carlsbad, CA), and 20 U/L Heparin 
(Sigma)) and were maintained in highly supplemented growth media (isolation media 
supplemented with 0.5X non-essential amino acids (Gibco), 0.5X sodium pyruvate (Gibco), 
0.5X L-glutamate (Gibco), 25 mM HEPES (Cellgro, Lawrence, KS),  and 100 µg/mL 
endothelial cell mitogen (ECGS; Biomedical Technologies, Stoughton, MA)).  Cells were 
serum starved in basal media (high-glucose DMEM supplemented with 0.1% BSA and 20 
U/L heparin).  For lysis of all EC types, 5 X 105 cells were pelleted and lysed in modified 
CHAPS buffer (20 mM Hepes, pH 7.4, 0.15 M NaCl, 10 mM CHAPS, 50 mM NaF, 10 mM 
β-glycerophosphate, 1 mM each of CaCl2 and MgCl2, and Protease Inhibitors Cocktail Set III 
(Calbiochem, San Diego, CA)) on ice for at least 30 minutes, and lysates were collected 
following centrifugation.  Total protein samples were then separated by SDS-PAGE, 
transferred to a PVDF membrane, and subjected to Western blotting.  As described 
previously(9;22), proteins were detected with CIB1 chicken polyclonal antibody, NH2-
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terminal-specific anti-PAK1 polyclonal antibody (Santa Cruz Biotechnology, Inc.), and anti-
total and anti-phospho-ERK1/2 polyclonal antibodies (Cell Signaling, Inc.).  Total MMP2 
was detected using anti-MMP2 specific goat IgG primary antibody (R&D Systems, 
Minneopolis, MN), and goat IgG secondary antibody (Sigma). 
  
Northern blotting.  Nitrocellulose blots of total adult mouse organ RNA and 
embryonic RNA were a generous gift from James Ferguson and Cam Patterson, UNC-CH.  A 
full-length CIB1 probe was constructed using Prime It Random kit (Stratagene, La Jolla, 
CA).  A CIB1 cDNA probe was labeled with 32P-dCTP and hybridized to nitrocellulose blots. 
 
Short hairpin RNA construction and transduction.  A lentiviral expression system 
was adopted as previously described(1).  For CIB1 knockdown, human 
(5’accggagcgaatctgcatggtcttcaagagagaccatgcagattcgctcctttttc3’) and mouse 
(5’accgtgcccttcgagcagattcttcaagagagaatctgctcgaagggcactttttc3’) CIB1 shRNA were cloned 
into a mammalian FG12 expression vector that separately expresses green florescent protein 
(GFP) via a separate promoter.   For control shRNA in murine ECs, human CIB1 shRNA 
was used since as previously reported(3), it has no homology to murine CIB1 or to any 
sequence in the mouse genome.  For control shRNA in human ECs, mouse R-Ras shRNA (5’ 
accgctcttcacacagatcctcttcaagagagaggatctgtgtgaagagctttttc 3’) was used since it has no 
homology to any sequence in the human genome. For CIB1 overexpression, the lentiviral 
vector was reconstructed to express CIB1 cDNA downstream of a cytomegalovirus (CMV) 
promoter.  A control cDNA vector was also constructed containing only the CMV promoter.  
HEK293 cells were transfected with lentivirus packaging vectors, as well as shRNA or the 
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cDNA construct of interest.  ECs were transduced with lentivirus collected from HEK293 
culture supernatant at multiplicity of infection (MOI) 10 – 25.  CIB1 knockdown or 
overexpression was confirmed via Western blotting.  Densitometry with the software 
Quantity One (Fluor-S Multimager; Bio-Rad Laboratories, Hercules, CA) was used to 
determine fold change in CIB1 expression. 
 
Isolation of primary endothelial cells.  Hearts and lungs of approximately 1-3 
month old WT and CIB1-KO mice were dissected from the mouse mediastinum.  Organs 
were gently minced, collagenase-digested, and strained.  The resulting cell suspension 
underwent positive cell sorting using PECAM-1 (BD Biosciences, San Jose, CA) anti-rat 
IgG-conjugated magnetic beads (Invitrogen, Carlsbad, CA).  Isolated cells were plated in 
tissue culture flasks coated with 5ng/mL fibronectin and cultured in growth media.  Heart 
and lung ECs were then purified with a second round of positive cell sorting using ICAM-2 
(BD Biosciences) coated magnetic beads.  The remaining ECs were cultured for up to 3 
passages. 
 
PAK1 kinase activation assay.  As previously described(9), serum starved ECs were 
held in suspension or seeded onto tissue culture plates coated with 10µg/mL fibronectin.  
Lysates were prepared by addition of cold lysis buffer supplemented with 10% glycerol and 
0.2mM pervanadate.  Equal amounts of lysate protein were subjected to SDS-PAGE and 
Western blotted for total and phospho-ERK1/2.  Lysates were also subjected to PAK1 
immunoprecipitation, and PAK1 kinase activity was assayed using myelin basic protein as 
substrate.  For each condition, experiments were repeated at least 3 times. 
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 Gelatin zymography.  The activity of MMP2 in conditioned medium was 
determined by gelatin zymography.  Briefly, ECs were serum starved for at least 24h, 
followed by addition of phenol-free high-glucose DMEM media supplemented with 
100ng/mL of VEGF or bFGF (R&D Systems, Minneopolis, MN), or 160ng/mL of PMA.  
Conditioned media was collected 18h later, filtered through 0.45µm Whatman filters, and 
concentrated using Vivaspin 10kDa concentrator (Sartorius, Edgewood, NY).  Equal protein 
concentrations were loaded under nonreducing conditions onto pre-made 10% zymograms 
and treated with renaturation and development buffers according to manufacture’s 
instructions (Biorad, Hercules, CA).  For each condition, experiments were repeated at least 
3 times. 
 
Boyden chamber haptotactic assay.  Haptotactic migration was performed using 
8µm pore polycarbonate transwell membranes (Corning, Corning, NY) coated underneath 
with 25µg/mL fibronectin (Calbiochem).  Cells were serum starved for at least 24h, and 2 X 
105 cells were added to the top chamber.  Cells migrated in basal media (0.1% BSA and 20U 
heparin) supplemented with or without 250ng/mL bFGF or VEGF.  After 6h, non-migrating 
cells were removed from the topside of the membrane, and membranes were isolated, fixed, 
and stained with Alexa Fluor 594-conjugated phalloidin (1:1000; Invitrogen).  To obtain 
counts of migrating cells expressing pre-transduced lentiviral vectors, both Texas red and 
GFP fluorescence images of at least 5 random digital frames were collected using a Nikon 
Eclipse TE300 inverted florescent microscope equipped with a CoolSnap Photometrics HQ 
camera from Media Cybernetics with Image-Pro Plus 5.0 software.  Images were transferred 
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to NIH ImageJ software (http://rsb.info.nih.gov/ij/), where total numbers of haptotactic cells 
were counted and reported as mean number of cells per imaged field.  For each condition, 
experiments were repeated at least 3 times. 
 
Monolayer wound healing culture assay.  EC cultures were grown to confluency in 
10 cm culture plates.  Cells were serum starved for at least 48 h and wounds were created in 
the monolayer culture with a medium sized pipette tip.  Growth media was then added and 
images were collected at approximately the same areas of the same wounds 0, 16, 20, and 
24h post-wound induction.  Percentage in wound area closure was measured using ImageJ 
software.  
 
Matrigel tubule formation assay.  Using a 48-well culture format, wells were coated 
with 150µL of GFR Matrigel (BD Biosciences).  Serum starved 5 x 104 cells were added on 
top of the polymerized GFR Matrigel.  Cells were then incubated in the presence of growth 
media, or basal media supplemented with 25ng/mL of bFGF or VEGF.  Images were 
collected 18 hours after incubation.  For tubules formed by ECs that had been pre-transduced 
with lentiviral vector, fluorescent images were also collected to confirm EC transduction 
efficiency.  Tubule number was analyzed from collected images using ImageJ software.  For 
each condition, experiments were repeated at least 3 times. 
 
ELISA.  For bromodeoxyuridine (BrdU) incorporation, 1 X 104 ECs were adhered in 
a 96-well culture format followed by serum starvation for at least 24h.  Growth media or 
basal media supplemented with 25ng/mL bFGF or VEGF was then added.  BrdU addition 
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and detection at 24h were performed according to manufacturer’s instructions (Roche, Basel, 
Switzerland).  For each condition, experiments were repeated at least 3 times and absorbance 
measured in a multi-well spectrophotometer at 450nm (Spetra MaxPlus, Molecular Devices, 
Sunnyvale, CA).  
 
Monolayer real-time cell electronic sensing (RT-CES).  Isolated ECs were cultured 
to 60% confluency and starved overnight in basal media.  ECs (2.5x104 cells) were seeded in 
fibronenctin-coated (5ug/mL) electronic microtiter plates (E-Plate, ACEA Biosciences Inc., 
San Diego, CA) and supplemented with growth media.  EC adhesion and ionic resistance 
across forming monolayers were monitored using a computerized RT-CES apparatus (ACEA 
Biosciences, Inc.).  For each cell type the assay was performed in replicates of 8.   
 
Statistical analysis.  We compared continuous variables with the Student’s t-test.  
We considered P < 0.05 to be significant.   
 
4.4 Results 
 
4.4.1 CIB1 is expressed in vascular structures and ECs.   
 
Northern blot using full-length CIB1 cDNA probe confirms CIB1 mRNA expression 
in adult mouse lung, kidney, and testis.  Additionally, we found that CIB1 mRNA is 
expressed in mouse ovary, spleen, and bone marrow.  CIB1 mRNA expression was highest in 
the testis, kidney, and bone marrow (Figure 4-1A).  Northern blotting also confirmed CIB1 
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mRNA expression in mouse embryonic tissue.  Specifically, we found that it is expressed at 
embryonic day (ED) 7.5, 8.5, and 9.5.  CIB1 mRNA was highly expressed in the primitive 
embryonic vascular structures such as the yolk sac and placenta of ED 8.5 and 9.5 mouse 
embryos (Figure 4-1B).  Furthermore, Western blot analysis reveled that CIB1 is expressed 
in various types of ECs including transformed (mouse intraembryonic endothelial cells; 
MECs(23), and bovine aortic endothelial cells; BAECs), primary (human aortic endothelial 
cells; HAECs, HUVECs, human coronary artery endothelial cells; HCAECs, and human 
pulmonary artery endothelial cells; HPAECs), embryonic (MECs), macrovascular (BAECs 
and HAECs), and microvascular ECs (HUVECs, HCAECs, and HPAECs; Figure 4-1C). 
 
4.4.2 Lentiviral mediated knockdown and overexpression of CIB1.   
 
Lentiviral transduction is more efficient than standard transfection techniques, and is a 
reliable method of gene transfer.  In order to test the role of CIB1 in EC signaling and 
function, we adopted this technique to stably knockdown and overexpress CIB1 in ECs.  To 
knockdown CIB1, cells were transduced with a vector that expresses shRNA specific for 
CIB1.  For overexpression, a vector that expresses CIB1 cDNA was instead used.  Figure 4-2 
illustrates a schematic of the CIB1 knockdown and overexpression vectors that were used as 
well as their respective controls.  At reasonable viral titers, lentiviral transduction efficiency  
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Figure 4-1.  CIB1 is expressed in various organs, mouse embryonic vascular structures, 
and EC types. (A) Northern blot using full-length CIB1 cDNA probe demonstrates CIB1 
mRNA expression in various adult mouse organs.  CIB1 mRNA expression is highest in the 
testis, kidney, and bone marrow.  (B) Northern blot also demonstrates CIB1 mRNA 
expression in mouse embryonic tissue at ED 7.5, 8.5, and 9.5.  CIB1 mRNA is highly 
expressed in primitive embryonic vascular structures such as the yolk sac and placenta of ED 
8.5 and 9.5 mouse embryos.  For panels (A) and (B), 28S rRNA loading equivalency does 
not account for differences in tissue expression of CIB1 mRNA (results not shown).  (C) 
Relative to 1ng of CIB1 (first lane), Western blot reveled that CIB1 is expressed in various 
types of ECs, including mouse, bovine, human, embryonic, macrovascular, and 
microvascular ECs.  MEC, mouse intraembryonic EC; BAEC, bovine aortic EC; HAEC, 
human aortic EC; HUVEC, human umbilical vein EC; HCAEC, human coronary artery EC; 
HPAEC, human pulmonary artery EC. 
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was >95% in different EC cell types such as MECs and HUVECs, as determined by GFP 
expression (Figures 4-3A & 4-3B).  Western blot analysis confirmed stable knockdown by up 
to 80%, and overexpression by up to 600% (Figures 4-3C & 4-3D). 
 
4.4.3 PAK1 and ERK1/2 activation in ECs is disrupted upon the loss of CIB1.   
 
Leisner et al. previously determined that CIB1 regulates PAK1 activation in fibroblasts and 
epithelial cells (see Chapter 3; Figure 3-2)(9).  Since various studies have demonstrated that 
proper PAK1 activation and signaling is essential for EC function and 
angiogenesis(10;11;24), we asked whether the loss of CIB1 in ECs can also alter PAK1 
activation.  We tested this in mouse lung ECs (MLECs) isolated from WT and CIB1-KO 
mice, and preliminarily in transduced MECs.  In agreement with previous findings, in vitro 
kinase assays demonstrated significantly decreased PAK1 activation in CIB1-KO ECs 
shortly after adhesion to fibronectin (20 and 45 minutes; Figure 4-4A).  At 180 minutes after 
adhesion, PAK1 activation in both WT and CIB1-KO ECs appeared to subside to minimal 
levels.  Both WT and CIB1-KO ECs also demonstrated minimal PAK1 activation when held 
in suspension, as demonstrated in other cell types.  Although MECs transduced with control 
shRNA or CIB1 shRNA did not demonstrate a decrease in PAK1 activation during 
suspension, we preliminarily observed a similar decrease in PAK1 activation at 20 and 45 
minutes after adhesion of cells (Figure 4-4B).  By 180 minutes, both cell types again 
demonstrated minimal PAK1 activation. 
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Figure 4-3.  Efficient lentiviral transduction of MECs and HUVECs.  (A) 
Confluent monolayers of MECs were transduced with lentivirus packaging one of 
four different vectors (CIB1 shRNA (vector 1), control shRNA (vector 2), CIB1 
cDNA (vector 3), or control cDNA (vector4)).  Three days after infection, GFP 
expression was detected in approximately 95% of cells.  (B) Similarly, HUVECs were 
transduced with lentivirus packaging either CIB1 shRNA (vector 1) or control shRNA 
(vector 2).  At high and low magnifications, approximately 100% of cells express 
GFP 3 days after infection.  Untransduced MECs and HUVECs do not express GFP, 
(A and B).  Short scale bars; 40µm, and long scale bars; 50µm. (C and D) Relative to 
5ng of CIB1, stable knockdown and overexpression in ECs was confirmed via 
Western blot.  In MECs and HUVECs, stable CIB1 knockdown was up to 80% and 
90%, respectively, and CIB1 overexpression in MECs was up to 600%. 
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Figure 4-4.  Loss of CIB1 disrupts PAK1 activation and ERK1/2 
phosphorylation.  (A) PAK1 activity in WT and CIB1-KO MLECs upon adhesion to 
fibronectin for 20, 45, and 180 minutes, as demonstrated by in vitro myelin basic 
protein phosphorylation ([32P]MBP).  Western blots of total PAK1 protein and 
coomassie stain of MBP serve as loading controls.  (B) PAK1 activity in control and 
CIB1-depleted MECs following adhesion.  Western blot of PAK1 protein serves as 
loading control.  (C) ERK1/2 phosphorylation as detected with a phospho-ERK1/2 
specific antibody, in WT and CIB1-KO MLECs held in suspension or following 
adhesion.  Western blots of total ERK1/2 and Rac serve as loading controls.  (D) 
ERK1/2 phosphorylation in WT and CIB1-KO MLECs treated with VEGF (25ng/mL) 
for 2, 10, and 20 minutes.  Blots are contributed by Dr. Tina Lisner.   
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Since various studies have underscored the importance of the downstream effectors of 
PAK1, ERK1/2, in EC angiogenic signaling(10;25-27), we asked whether ERK1/2 activation 
is also disrupted in ECs upon the loss of CIB1.  Although no significant difference was 
detected in transduced MECs (data not shown), CIB1-KO MLECs demonstrated a significant 
decrease in ERK1/2 phosphorylation levels compared to WT MLECs, at 20 and 45 minutes 
after adhesion to fibronectin (Figure 4-4C).  Similar to the kinetics observed for PAK1 
activation, no difference in ERK1/2 phosphorylation was detected at later time points (180 
minutes) after adhesion.  The decrease in ERK1/2 phosphorylation appeared to be unique 
since we did not detect any differences in the phosphorylated protein levels of Akt, p38, and 
protein kinase C (PKC; data not shown).  Furthermore, decreased ERK1/2 activation was 
also preliminarily observed in CIB1-KO ECs treated with VEGF for 2 and 10 minutes 
(Figure 4-4D). 
 
4.4.4 Loss of CIB1 in ECs decreases MMP2 expression.   
 
Numerous signaling cascades can become activated downstream of PAK1 (for review 
see(28)).  Among them, MAPKs are implicated in the production of MMPs(29;30).  Since 
the loss of CIB1 in ECs decreases responsiveness to angiogenic growth factors and leads to 
decreased PAK1 and ERK1/2 activation upon fibronectin adhesion, we asked whether MMP 
expression was also disrupted.  Enzymatic activity of MMPs was assessed by gelatin 
zymography, which revealed increased lytic zones only at the molecular mass of active 
(68kDa) and latent form of MMP2 (gelatinase A; faint band at 72kDa) in the conditioned 
media of growth factor-treated WT MLECs, but not CIB1-KO MLECs (Figure 4-5A).  
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Western blotting also demonstrated less growth factor-induced MMP2 expression in CIB1-
KO MLEC conditioned media (Figure 4-5B), and decreased MMP2 protein expression in 
CIB1-KO mouse heart ECs (MHECs; Figure 4-5C).  However, MMP9 (gelatinase B) 
secretion was undetectable in both WT and CIB1-KO ECs (data not shown).  Furthermore, 
no differences in the expression of the physiological activator and inhibitor of MMP2 (tissue 
inhibitor of metalloproteinases-2; TIMP-2, and MMP14; MT1-MMP, respectively(31;32)) 
were observed between both cell types (data not shown). 
 
4.4.5 Loss of CIB1 decreases EC migration.   
 
Disrupted PAK1 and ERK1/2 signaling may significantly affect EC function.  Since 
both CIB1 and PAK1 have been implicated in cellular migration, we first tested the role of 
CIB1 in EC migration.  Knockdown of CIB1 with short hairpin (sh) RNA decreased 
haptotaxis of MECs on fibronectin (38% relative to control MECs; Figure 4-6A).  Similarly, 
deletion of CIB1 by homologous recombination in CIB1-KO MLECs resulted in a similar 
decrease (24% decrease relative to WT and CIB1 heterozygous MLECs; Figure 4-6B). While 
angiogenic growth factors bFGF and VEGF increased haptotaxis in untransduced MECs 
(data not shown) and control MECs, they did not stimulate haptotaxis to the same level in 
CIB1 knockdown MECs (Figure 4-6A).  Interestingly, CIB1 overexpression in MECs did not 
elevate haptotaxis beyond control levels, suggesting that endogenous CIB1 is expressed 
maximally for this effect (data not shown).  Finally, re-introduction of CIB1 in CIB1-KO 
MLECs restored haptotatic migration to normal levels (Figure 4-6B).  These results suggest  
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Figure 4-5.  Loss of CIB1 decreases MMP-2 secretion and expression.  (A) 
Conditioned media of growth factor-treated and untreated WT and CIB1-KO MLECs 
was subjected to gelatin zymography.  Clear bands in de-stained gel represent MMP-
2.  Coomassie stained non-specific bands serve as a loading controls.    (B) Western 
blot of MMP-2 in conditioned media of growth factor-treated and untreated WT and 
CIB1-KO MLECs.  Coomassie stained non-specific bands serve as a loading controls.  
(C) Western blot of total MMP-2 and CIB1 protein in duplicate WT and CIB1-KO 
MHEC lysates.  Blot for GAPDH serves as a loading control.  Panel (C) is 
contributed by Dr. Weiping Yuan. 
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Figure 4-6.  Loss of CIB1 decreases EC haptotatic migration.  Loss of CIB1 
decreases EC function.  (A) Quantification of mean number of MECs transduced with 
CIB1 shRNA or control shRNA that migrated across fibronectin in a Boyden chamber 
in the presence or absence of bFGF or VEGF.  (B) Mean value of haptotactic cells in 
transduced or untransduced, WT, CIB1 heterozygous, and CIB1-KO MLECs.  CIB1 
heterozygous and CIB1-KO MLECs were transduced with either control cDNA or 
CIB1 cDNA vectors.  Error bars represent SEM (n = at least 3 for all conditions); * P 
< 0.05, ** P < 0.001.  
 
 
 
 
 
 129
that CIB1 is necessary for both growth factor-stimulated and unstimulated haptotactic EC 
migration. 
 
To further confirm these findings, we tested migration using a cell-culture monolayer 
wound healing assay(33).  Monolayer wounds in both CIB1 knockdown MEC and CIB1-KO 
MHEC resolved less rapidly, relative to control MECs and WT MHECs, respectively 
(Figures 4-7A & 4-7B).  These data provide further evidence that CIB1 expression is 
necessary for normal EC migratory behavior. 
 
4.4.6 Loss of CIB1 decreases EC proliferation.   
 
Proliferation of ECs is fundamental to angiogenesis (16).  Relative to control, MECs depleted 
of CIB1 by shRNA, and cultured in either growth media or in basal media supplemented with 
bFGF or VEGF, showed modest yet significantly decreased BrdU incorporation (Figure 4-
8A).  Consistent with this, CIB1-KO MHECs and MLECs cultured in growth media also 
demonstrated a 61% and 35% decrease, respectively, in BrdU incorporation compared to WT 
ECs (Figure 4-8B).  Direct cell-counts of cultured CIB1 knockdown MECs and CIB1-KO 
MHECs further confirmed a significant decrease in proliferation relative to control MECs 
and WT MHECs (data not shown).  Thus, in addition to migration, CIB1 is also necessary for 
normal rates of EC proliferation. 
 
4.4.7 Loss of CIB1 decreases EC tubule formation. 
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Figure 4-8.  Loss of CIB1 decreases EC proliferation.  (A) Quantification of BrdU 
incorporation as the fold difference in absorbance (O.D. 370) in MECs cultured in 
growth media, or in basal media supplemented with bFGF or VEGF.  (B)  Fold 
change in BrdU incorporation in CIB1-KO and WT MHECs and MLECs cultured in 
growth media.  Error bars represent SEM (n = at least 3 for all conditions); * P < 
0.05, ** P < 0.001. 
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 To determine whether loss of CIB1 affects other EC functions, we assessed tubule 
formation on growth factor reduced (GFR) Matrigel.  In the presense of growth media, CIB1 
knockdown MECs and CIB1-KO MHECs had a 26% and 44% reduction in nascent tubule 
formation, compared to their respective controls (Figure 4-9A & 4-9B).  Treatment of CIB1 
knockdown MECs and CIB1-KO MHECs with bFGF or VEGF did not stimulate tubule 
formation to the same extent as control cells (Figure 4-9A & 4-9B).  Hence, in addition to EC 
migration and proliferation, CIB1 may be required for efficient EC sprouting and invasion 
that also contribute to angiogenesis. 
 
4.4.8 Decreased monolayer resistance in CIB1-KO ECs 
 
In vivo, ECs inside blood vessels form a semi-permeable barrier that is selective for 
the transport of nutrients and macromolecules in and out of blood vessels.  This process is 
regulated by various factors including angiogenic growth factors, adhesion molecules, or 
cytotoxic angents.  Since in our pervious assays CIB1 appears to be an important regulator of 
EC function, we wanted to determine weather it also plays a role in EC barrier function.  
Using an RT-CES apparatus, we observed that both WT and CIB1-KO ECs reached near 
maximal adhesion to fibronectin by approximately 1.5 hours (Figure 4-10).  However, over a 
period of nearly 17 hours, we also observed a dramatic and consistent decrease in the ionic 
resistance generated across the CIB1-KO EC monolayer compared to the WT EC monolayer.  
This suggests that CIB1 is also critical for EC monolayer integrity – a function that may have 
serious manifestations in vivo.     
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Figure 4-9.  Loss of CIB1 decreases EC tubule formation on GFR Matrigel.  (A) 
DIC and GFP fluorescent images of CIB1 shRNA transduced MECs and control 
shRNA transduced MECs following treatment with growth media, bFGF, or VEGF.  
GFP images confirm MEC transduction and expression of vectors.  Scale bars, 
100µm. (B) Quantification of tubule formation in CIB1-KO and WT MHECs 
following treatment with growth media, bFGF, or VEGF treatment.  Error bars 
represent SEM (n = at least 3 for all conditions); * P < 0.05.  
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Figure 4-10.  Loss of CIB1 decreases EC monolayer ionic resistance.  Real-time 
assessment of ionic resistance across WT and CIB1-KO ECs demonstrates that both 
cell types adhere to fibronectin in approximately 1.5 hours.  CIB1-KO EC monolayers 
demonstrate decreased ionic resistance upon adhesion and for the following 17 hours 
thereafter.  Assay was performed in replicates of 8, and error bars represent SD. 
 
 
 
 
 
 
 
 
 135
4.5 Discussion 
 
CIB1 is an important regulatory molecule that is expressed in different tissue types 
and has various binding partners(34).  However, the role of CIB1 in ECs has never been 
explored.  In this study we demonstrate that CIB1 is expressed in ECs and various other 
vascular structures.  We also provide the first evidence to suggest that CIB1 plays an 
important regulatory role in ECs and can affect various EC functions such as migration, 
proliferation, nascent tubule formation, and monolayer resistance.   
 
Recent evidence suggests that CIB1 contributes to important intracellular signaling 
mechanisms. For example, Leisner et al. demonstrated that CIB1 can bind and regulate the 
activity of PAK1 in different cell types(9).  In that study knockdown of CIB1 in REF52 
fibroblasts decreased adhesion-induced PAK1 activation at early time points (20 and 45 
minutes), but not at later time points (150 minutes).  Similarly, here we observe that 
adhesion-induced PAK1 activation in CIB1-KO ECs is significantly reduced both at 20 and 
45 minutes.  Thus these findings confirm the dynamic interaction between CIB1 and PAK1, 
and demonstrate that it likely occurs in different cell types and tissues.  Interestingly, at later 
time points Leisner et al. demonstrated that CIB1-depleted REF52 cells had a rebound PAK1 
activation that was dependent on the Rho GTPases Rac and Cdc42(9).  However in our study 
we did not detect in CIB1-KO ECs a rebound activation of PAK1 at later time points (180 
minutes), suggesting that this mechanism is either not as profound in ECs or occurs at later 
time points.  These differences could reflect the variation in the pathways used by different 
cell types or an alteration in pathway usage upon the chronic loss of CIB1 in CIB1-KO ECs. 
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 In our laboratory we previously reported that overexpression of CIB1 in transformed 
cell lines inhibits migration (unpublished data;(9)).  However, in this study we observed that 
knockdown or deletion of CIB1 from ECs decreased haptotactic migration as well.  We also 
found that reintroduction of CIB1 in CIB1-KO ECs increased migration back to normal 
levels.  This apparent discrepancy can be explained in several ways.  First, our studies 
primarily focused on the role of CIB1 in ECs.  It is therefore conceivable that CIB1 has cell 
type-specific roles that can affect different cellular processes in different ways.  Second, 
previous studies primarily relied on transfection-mediated RNAi knockdown of CIB1.  Here 
we utilize a more efficient method of knockdown (using shRNA) and we also take advantage 
of CIB1-KO ECs.  It is possible that a complete loss of CIB1 alters pathway usage and 
therefore contributes to the observed discrepancies.  Third, PAK1 activation was previously 
shown to both increase and decrease migration through different signaling pathways.  
Therefore it is possible that in different settings or in response to different stimuli, CIB1-
regulated PAK1 activation can lead to different migratory phenotypes.   
 
Previous reports also show that PAKs can phosphorylate and activate c-Raf(35), 
MEK1(27), and the MAPKs ERK1/2(36) and p38(25).  In this study we demonstrate that 
CIB1-KO ECs have attenuated adhesion-induced ERK1/2 activation.  However, we observe 
no difference in the activation of other kinases such as p38, PKC, and Akt (data not shown).  
Furthermore, we observed that the activation pattern of ERK1/2 resembles the activation 
kinetics of PAK1 (decreased activation only at early time points).  This suggests that ERK1/2 
activation is a downstream event of CIB1-regulated PAK1 activation.  Since efficient 
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ERK1/2 activation is necessary for various EC functions, it is likely that disrupted ERK1/2 
phosphorylation in CIB1-KO ECs is at least in part responsible for the observed decrease in 
migration, proliferation, and nascent tubule formation upon the loss of CIB1. 
 
Additionally, studies have shown that ERK1/2 activation is necessary for 
transcriptional up-regulation of MMPs(29;30), which are key modulators of various 
pathophysiologcial events(37).  Constitutively expressed by various types of cells (including 
ECs), MMP2 degrades ECM and facilitates EC proliferation and migration(31).  In vivo it 
also mediates the release of heparin-bound growth factors (such as VEGF and bFGF) from 
the ECM, and regulates spermatogenesis(38) – a process that also requires CIB1(39).  Here 
we report that CIB1 null ECs express significantly less VEGF and bFGF-induced MMP2.  
This is a significant observation since MMP2 is detected at high levels in atherosclerotic 
plaques, aneurysms, and sites of myocardial infarctions(37).  A decrease in MMP2 in vivo 
has also been shown to prevent myocardial infarction-induced cardiac rupture(40), as well as 
tumor progression and angiogenesis(41).  Thus these findings suggest that CIB1 may be 
involved in a wide range of pathologies and cardiovascular disorders in vivo.     
 
The decrease in MMP2 expression in CIB1-KO ECs also suggests that perhaps the 
expression of other important genes is also disregulated upon the loss of CIB1.  Indeed, 
analyses of preliminary global gene expression microarrays suggest that there is a subset of 
genes that appears to be differentially expressed between WT and CIB1-KO ECs (Appendix 
A).  Most prominently we detect a significant decrease in the expression of the angiopoiten 
receptors Tie1 and Tie2, which suggests that in addition to VEGF and bFGF, CIB1-KO ECs 
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may also respond less efficiently to the Ang ligands (Ang1 and Ang2).  Furthermore, the 
expression of EC intracellular junction proteins (such as VE-Cadherin and PECAM-1) is also 
decreased in CIB1-KO ECs, suggesting that this may be the molecular basis for the observed 
decreased in CIB1-KO EC monolayer resistance.  
 
It is important to note that loss of CIB1, either by homologous recombination or by 
depletion via shRNA, did not completely inhibit EC functions.  Similarly, loss of CIB1 did 
not completely abolish in vitro PAK1 activation, ERK1/2 phosphorlyation, and MMP2 
expression.  This suggests that there are likely compensatory mechanisms that facilitate the 
rescue of EC signaling and function.  Although the mechanisms for such compensations are 
yet to be determined, likely candidates may include the CIB1 homologs CIB2, CIB3, and 
CIB4.  Studies are currently underway to determine whether the expression of any of these 
homologs is altered upon the loss of CIB1.  Another likely candidate for CIB1 compensation 
may also be calmodulin.  This regulatory calcium binding protein is highly homologous to 
CIB1 and was recently shown to be essential for normal EC function under hypoxic 
stress(42).  Compensatory mechanism may also help explain why CIB1-KO mice develop 
normally and reach adulthood inconsequentially.   
 
Thus, collectively our data demonstrate that CIB1 is a critical regulator of various EC 
functions.  CIB1 also appears to regulate PAK1 activation and its downstream ERK1/2 
signaling pathway in ECs.  Further, CIB1-KO ECs have attenuated growth factor-induced 
function and MMP2 expression.  These data suggest that although CIB1-KO mice develop 
normally, CIB1 may also play an important role in pathological forms of angiogenesis.  In 
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the following chapters we will explore the role of CIB1 in angiogenesis in various different 
in vivo murine angiogenesis models. 
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CHAPTER 5 
 
 
 
CIB1 is Necessary for Ischemia-Induced 
Pathological and Adaptive Angiogenesis 
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5.1 Abstract 
 
In Chapter 4 we demonstrate that CIB1 plays a critical role in EC signaling, function, 
and MMP2 expression.  Since these events are critical for a robust angiogenic response, we 
tested the role of CIB1 in different forms of angiogenesis in vivo.  Here we demonstrate that 
developmental vasculogenesis and angiogenesis are normal in the retinas of CIB1-KO mice.  
This is not surprising since, besides having male sterility, CIB1-KO mice develop normally 
and reach adulthood inconsequentially.  However, in response to ischemia, CIB1-KO retinas 
have significantly reduced pathological angiogenesis and retinal neovessel bud formation.  
Similarly, in a hind-limb ischemia-induced angiogenesis assay, CIB1-KO mice demonstrated 
reduced hind-paw perfusion, increased hind-paw gangrene and hind-limb muscle tissue 
damage, and decreased hind-limb adaptive angiogenesis.  The observed defects in 
angiogenesis appears to be specific, since CIB1-KO mice demonstrate no significant 
difference in other post-ischemic recovery mechanisms such as arteriogenesis.  Therefore, 
these studies provide the first evidence to show that CIB1 has an important role in adult 
pathological and adaptive forms of ischemia-induced angiogenesis.       
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5.2 Introduction 
 
Angiogenesis, the process of new blood vessel formation from pre-existing 
vasculature, occurs in both physiological and pathological situations(1).  During embryonic 
development and after birth, physiological angiogenesis promotes primitive vessel 
development and permits organ growth(2).  In adults, angiogenesis becomes tightly regulated 
by a balance of pro-angiogenic and anti-angiogenic growth factors and cytokines(1;3).  As a 
result angiogenesis is permitted to take place only in rare physiological situations such as 
during active wound healing or during tissue regeneration (i.e. in the corpus luteum and the 
uterine endometrial lining)(1;3-6).  However, pathological angiogenesis may also ensue due 
to imbalances in either angiogenic activators or inhibitors, which can manifest in 
inconvenient, debilitating, or even life-threatening clinical disorders(1).  Several molecular 
differences between physiological and pathological angiogenesis have so far been identified, 
suggesting that these two processes are differentially regulated and can arise from different 
molecular signals(7;8).  Identifying exactly which molecules contribute to pathological 
angiogenesis, but not physiological angiogenesis, will provide clinicians with better 
therapeutic targets to alleviate angiogenesis-dependent diseases and aid in our understanding 
of how pathological angiogenesis arises in the first place.    
 
Ischemia-induced angiogenesis is an example of both pathological and adaptive forms 
of angiogenesis and has a clear association with a subset of common disorders that can affect 
nearly all types of human tissue(1;9).  Among these disorders, age-related macular 
degeneration (AMD) and diabetic retinopathy are the two most common retinal disorders that 
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cause vision impairment in adults in the Western world(10;11).  Both diseases are believed to 
be initiated, by among other things, the reduction of oxygen concentrations in the retinal 
tissue(12).  This stimulates the expression and release of growth factors such as VEGF and 
IGF-1 by surrounding tissue which, in turn, leads to increased vascular permeability and 
excessive angiogenesis(13;14).  Conventional treatment for these disorders has remained the 
same for the past few decades, and has involved the use of laser photocoagulation-induced 
destruction of neovasculature(15).  Although this therapy is effective in reducing the risk of 
further vision loss, it does not address the basic biological processes that lead to these 
diseases and is typically applied after the onset of retinal damage.  Thus, identifying and 
inhibiting molecules that contribute to this pathological induction of angiogenesis may prove 
to be a more effective therapeutic option. 
 
On the other hand, in some ischemic diseases the desired outcome is to stimulate 
adaptive angiogenesis in order to facilitate revascularization of ischemic tissue(16).  Hence, 
in diseases like peripheral vascular disease (PVD; also known as peripheral artery occlusive 
disease) angiogenic therapy has been proposed as an alternative to conventional surgical 
interventions(17).  Such novel therapy would have a large impact since PVD is an extremely 
debilitating condition that occurs predominantly in elderly populations, and is estimated this 
year alone to affect nearly 7.4 million individuals – a 100,000 of whom will undergo lower-
limb amputation due to limb claudication(9;18).  Initial animal studies highlight the promise 
of this therapy by showing that angiogenic therapy can remarkably increase functional 
angiogenesis and arteriogenesis (the remodeling and expansion of collaterals between arteries 
of adjacent vascular beds) following ischemic injury of the limb (reviewed in (19)).  
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However, so far clinical trials that have focused on the use of non-specific angiogenic growth 
factors such as VEGF and bFGF, and have had limited success(20;21).  It is yet to be 
determined whether tissue-specific molecules that facilitate ischemia-induced angiogenesis 
are better candidates for angiogenic therapy.   
 
As demonstrated in Chapter 4, we have found that CIB1 is a critical regulator of ECs.  
Not only is CIB1 essential for proper activation of PAK1 in ECs, but it also important for 
various EC functions, including migration, proliferation, tubule formation, and monolayer 
resistance.  To expand upon these findings and to determine whether CIB1 plays a role in 
angiogenesis in vivo, we recently engineered a CIB1-deficient (CIB1-KO) mouse via 
homologous recombination in embryonic stem cells(22).  Although CIB1-KO mice reach all 
developmental milestones, we hypothesized that CIB1 may still have a role in pathological 
forms of angiogenesis, including ischemia-induced angiogenesis.  Here we demonstrate that 
although CIB1-KO mice have normal retinal developmental angiogenesis, upon ischemic 
injury in different tissue they demonstrate increased tissue damage, decreased recovery, 
reduced plasma VEGF levels, and impaired ischemia-induced angiogenesis.  However, 
arteriogenesis in CIB1-KO mice appears to be unaltered suggesting that CIB1 does not play a 
critical role in this process. Thus our findings identify CIB1 as a novel and specific regulator 
of pathological and adaptive forms of ischemia-induced angiogenesis. 
 
5.3 Methods 
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Retinal isolation.  Eyeballs were enucleated from euthanized mice and submerged in 
2% PFA, for at least 2 hours, at 4˚C.  Eyeballs were washed in PBS and microdissected as 
previously described.  Isolated retinas were permeablized in 70% ethanol and by 0.1% 
TritonX-100, prior to overnight staining at 4˚C with Alexa Fluor 594 conjugated Griffonia 
simplicifolia isolectin-1-B4 (GSL1-B4; Invitrogen, Carlsbad, CA).      
 
Oxygen-induced retinal angiogenesis.  Postnatal day 7 (P7) mice were placed in 
75% oxygen for five days (until P12), which induced central avascularity of both CIB1-KO 
and WT retinas.  Following hyperoxic incubation, we housed CIB1-KO and WT neonatal 
mice for five additional days (until P17) at normoxic conditions, after which mouse eyeballs 
were enucleated, briefly fixed in 2% PFA, and either micro-dissected  to obtain intact retinas 
or cryopreserved in O.C.T. (IMEB, San Marcos, CA).  Isolated retinas were flat-mounted, 
permeablized, and stained with isolectin GSL-1-B4 (1:100).  Fluorescent images of retinas 
collected with a Nikon inverted microscope were stitched (PhotoFit, TekMate, Anchorage, 
AK) and the number of neovessel buds (> 7µm) per retina counted (ImageJ; n = 8 mice per 
group).  Interrupted 6µm sections at 50µm intervals were obtained for cryopreserved eyeballs 
and stained with H&E.  Mean capillary area of vessels either directly under or invading the 
retinal ILM were measured from digitized images obtained from two randomly selected 
interrupted eyeball sections (n = 4 mice per group). 
 
Unilateral femoral artery ligation.   Male and female WT and CIB1-KO mice, at 
least 15 weeks old, were anesthetized with 1.125% isoflurane supplemented with 2:3 oxygen-
air.  Rectal temperature was closely maintained at 37.0 ± 0.5˚C.  Hair was removed from 
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hindquarters using depilating cream, with care to avoid erythema. The femoral artery, 
proximal to the bifurcation of the lateral caudal femoral artery, was aseptically exposed and 
ligated with 7-0 suture.  The wound was irrigated with sterile saline and then the incision was 
closed.   
 
Laser-Doppler perfusion imaging.  Superficial hind-paw plantar and hind-limb 
ventral adductor thigh regions were monitored with noninvasive measurements obtained 
using a scanning laser-Doppler perfusion imager (model LD12-IR, Moor Instruments, 
Wilmington, DE) modified for high resolution and depth of penetration (2mm) with an 
830nm-wavelenght infrared 2.5mW laser diode, 100µm beam diameter, and 15kHz 
bandwidth(23).  Prior to measurements, anesthesia, ventilation, and temperature were 
controlled using the same techniques as with femoral artery ligation.  Hind-paw and hind-
limb measurements of ischemic and non-ischemic limbs were performed before, and at 1, 7, 
14, and 21d after ligation.  Hind-paw and hind-limb regions of interest (ROIs) were drawn as 
previously described(23), to obtain average Doppler velocity in plantar and ventral adductor 
regions. Average velocity in a ROI was normalized to the area of the ROI, due to 
unavoidable variations in animal positioning during Doppler scanning.  Data were reported 
as a ratio of ligated-to-nonligated rate of Doppler blood perfusion (n = 11 mice per group). 
 
Hind-paw appearance and hind-limb use score assessments.  Appearance and use 
scores were performed as previously described(24). Appearance score was assessed based on 
scale; 0 = no change, 1-5 = the number of nails with color change or number of lost nails, and 
6-10 = the number of digits lost or digits with color change.  Use scores were assessed based 
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on a scale of; 0 = no change, 1 = no toe flexion, 2 = no hind-paw flexion, 3 = foot or limb 
dragging.  Scores were assessed before femoral artery ligation, and 1, 7, 14, and 21d after 
ligation (n = 11 mice per group).   
 
Assessment of atrophy, capillary density in gastrocnemius muscle, and X-ray 
angiography.  Twenty-one days after femoral artery ligation, mice were perfused and fixed 
as previously described with minor modifications(23).  Mouse infrarenal abdominal aortas 
were cannulated and mice were perfused at 100mmHg with phosphate buffered solution 
(PBS, pH 7.4) containing 3.7mM adenosine and 106µM papaverine.  PBS was followed by 
4% PFA for at least 20 minutes.  Mice were then perfused at 100mmHg for 30m with a 
barium sulfate (85% w/v; Liquid Barospere, Lafayette Pharmaceuticals) suspension of high 
viscosity that optimized arterial filling and minimized venous filling.  Arterial angiograms 
were obtained by exposing specimens to an X-ray source (Faxitron MX-20; Faxitron 
Corporation) for 6.8 seconds at 26kV.  As previously described, the number of arterial 
vessels in WT and CIB1-KO, ligated and non-ligated hind-limbs, was derived from the hind-
limb “mid-zone” (n = 5 for each group).  Following angiography, ligated and non-ligated 
hind-limbs were removed from animals and post-fixed in 4% PFA for 48h, with a solution 
change at 24h.  A section of the gastrocnemius muscle was removed en bloc, beginning at the 
Achilles tendon and extending 5mm rostrally.  Samples were rinsed in water, placed in 70% 
ethanol for 48h with shaking and a change of solution at 24h, followed by embedding in 
paraffin.  At least 5 interrupted sections, 50µm apart were obtained and H&E stained.  For 
each gastrocnemius, three 20X images were collected from two randomly selected sections 
using a Nikon D100 camera attached to a Nikon inverted microscope.  Using ImageJ, muscle 
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atrophy was determined by obtaining the average muscle fiber size within fascicles with a 
delineated area (n = 5 – 9 mice per group).  To assess capillary density, the plasma 
membrane of capillary ECs in tissue sections were labeled with isolectin GSL-1-B4 (1:100).  
Using a Nikon TE2000U inverted fluorescent microscope with an OrcaER, three 20X images 
were collected for two randomly selected sections.  Within delineated areas of muscle 
fascicles (quantified by ImageJ software), capillaries were identified as GSL-1-B4-positive 
vessels with diameter < 7µm.  Capillary density was reported as the ratio of capillary-to-
muscle fiber number (n = 5 – 9 mice per group). 
 
ELISA.  Quantitative sandwich ELISA was performed according to manufacturer’s 
instructions (R&D Systems) to detect VEGF in mouse plasma and tissue homogenates (n = 
8-11 per group).  
 
Animal regulations.  All housing, breeding, and experimental procedures performed 
with mice were in accordance with national guidelines and regulations, and were approved 
by the UNC-CH Institutional Animal Care and Use Committee (IACUC). 
 
Statistical analysis.  We compared continuous variables with either the Student’s t-
test or the non-parameteric Mann-Whitney U test.  We considered P < 0.05 to be significant.  
For animal studies, male and female mice demonstrated no differences; thus they were 
combined.  Statistical significance was determined by unpaired t-test for comparisons across 
animal groups. 
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 5.4 Results 
 
5.4.1 Vascular development in CIB1-KO mouse retinas is normal. 
 
Mice lacking CIB1 develop and reach adult reproductive age normally(25).  Despite 
this, an underlying defect in developmental angiogenesis may still exist in vivo in CIB1-KO 
mice, yet not manifest overtly.  The retina is one of the most highly vascularized tissues in an 
adult mouse, but is avascular at birth(26).  With physiological hypoxia and increased 
metabolic demand during the first week of development in the mouse, the retinal vasculature 
begins to emerge from the optic nerve on postnatal day 0 (P0) and its development is 
complete by P18(27).  To study whether developmental angiogenesis is at all affected in 
CIB1-KO mice, we assessed the extent of vascularization in isolectin GSL1-B4 stained WT 
and CIB1-KO retinal flatmounts. 
 
At 2 days post-partum (P2) WT and CIB1-KO had similar hyaloid vascular systems 
(Figure 5-1A).  These large and highly interconnected vessels emerge from the optic nerve 
prior to birth and supply the retina with nutrients and gases via diffusion.  At P4, the hyaloid 
vascular system is also observed in both WT and CIB1-KO mice, and appears to cover the 
entire surface of the retina.  However, at P4, the retinal vasculature starts to also emerge and 
extends in a radial fashion toward the periphery of the retina (Figure 5-1B).  These newly 
vascularized areas are approximately the same size in both WT and CIB1-KO retinas.  By 
P8, the retinal vasculature has nearly reached the periphery of WT and CIB1-KO retinas and 
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forms many interconnections to generate a two-dimensional vascular system (Figure 5-1C).  
At this point the hyaloid vasculature has also started to regress.  By P12, both WT and CIB1-
KO retinas are fully vascularized, and at this time the vasculature is multi-dimensional and 
complex (Figure 5-1D).  Evidence of vascular pruning can also be observed in WT and 
CIB1-KO retinas at this stage, with reorganization of retinal capillaries away from adjacent 
newly formed arterioles (Figure 5-1E).  Similarly, adult retinas in both groups are also nearly 
identical (Figure 5-1F).  Using laser-scanning confocal microscopy, all three retinal vascular 
layers are observed in both WT and CIB1-KO adult retinas (Figure 5-1G).  Thus these 
findings confirm that there is no defect in the development of the retinal vascular in CIB1-
KO mice. 
 
5.4.2 CIB1 deficiency leads to decreased oxygen-induced retinal angiogenesis. 
 
It has been repeatedly demonstrated that EC regulatory molecules that do not 
contribute to developmental angiogenesis, may still have a significant role in pathological 
and adaptive forms of angiogenesis(7;8).  We previously demonstrated that CIB1-KO ECs 
have disrupted signaling and angiogenic function.  Therefore we hypothesized that although 
CIB1-KO retinal vascular developmental appears normal, CIB1-KO mice may still have a 
significant defect in pathological retinal angiogenesis.  To study this we performed an 
oxygen-induced retinal angiogenesis assay that models the ischemic disease of retinopathy of 
prematurity(28).  In this assay, P7 WT and CIB1-KO littermate neonatal mice are exposed to 
elevated  inspired  oxygen  concentrations.   This  induces  obliteration  of  the  central retinal  
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capillaries, which then leads to hypoxia in the mouse neonatal retina.  Subsequent return of 
P12 neonates to normoxia induces exuberant angiogenesis, resulting in the formation of 
aberrant capillary neovessel buds that can be visualized in isolectin GSL1-B4 stained retinal 
flat-mounts.  Although examination of P17 WT and CIB1-KO retinas demonstrated no 
difference in vascularized versus non-vascularized retinal areas (visualized in Figure 5-2A), a 
significant difference was observed in the number of retinal neovessel buds that formed in 
each group.  CIB1-KO retinal flat-mounts demonstrated 22% fewer neovessel buds that were 
less clearly defined compared to WT littermate controls (Figure 5-2A, and quantified in 5-
2C).  Since these buds are composed of clusters of tortuous vessels that protrude through the 
retinal inner limiting membrane (ILM)(29), retinal cross-sections were also obtained to 
assess the size and morphology of these neovessels.  WT retinal cross-sections displayed 
large protruding microvessels that occasionally ruptured through the ILM,  whereas CIB1-
KO retinal cross-sections showed blood vessels directly under the ILM that were smaller in 
size and did not protrude through as frequently (Figure 5-2D; and quantified in Figure 5-2E).  
In CIB1-KO retinas, the ILM was also almost always intact (Figure 5-2E).   Thus, these data 
provide the first evidence that demonstrates that CIB1-KO mice have impaired pathological 
neovascularization in response to ischemia. 
 
5.4.3 CIB1 deficiency delays post-ischemia hind-limb re-perfusion and 
recovery 
 
A common mouse model for peripheral vascular disease is experimentally-induced 
hind-limb ischemia through unilateral femoral artery ligation(30).  In this model, blood flow  
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 Figure 5-2.  Oxygen-induced retinal neovascularization is decreased in CIB1-KO 
mice.  (A) Isolectin GSL1-B4 stained flat-mounted retinas from WT and CIB1-KO 
neonatal mice that have undergone oxygen-induced retinal angiogenesis (left panel).  
Vascular buds that formed in WT and CIB1-KO ischemic retinas are indicated by 
arrowheads in magnified retinal areas (right panel).  Scale bar, 25µm.  (B) 
Quantification of vascular buds per retina in WT and CIB1-KO mice (n = 8 per mouse 
genotype).  (C) Representative H&E stained cross-sections from WT and CIB1-KO 
retinas after exposure to hyperoxia (75% oxygen) followed by return to room air.  The 
WT retina shows microvessel protrusion (*) and rupture (arrow) through the ILM.  
Scale bar, 50µm.  (D) Quantification of mean capillary area of microvessels directly 
under the ILM in WT and CIB1-KO retinas following ischemic injury (n = 4 mice for 
each mouse genotype).  V, vitreous; ILM, inner limiting membrane; GCL, ganglion 
cell layer; IPL, inner plexiform layer.  Error bars represent SEM; * P < 0.05.  
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to the hind-limb is effectively eliminated, which rapidly induces ischemia and post-ischemic 
recovery mechanisms (i.e. angiogenesis and arteriogenesis).  To extend our observations 
from the oxygen-induced retinal angiogenesis assay, we performed this procedure to assess 
blood flow and tissue recovery in the hind-paw regions (plantar regions of the hind-limbs) of 
WT and CIB1-KO littermate mice. 
 
Using high-resolution, non-invasive, laser scanning Doppler velocimetry(23), we 
determined that following ligation, blood re-perfusion in the hind-paws of WT mice was 
nearly always greater than CIB1-KO littermates (Figure 5-3A).  By 14 days after femoral 
artery ligation, 90% of the perfusion was restored in WT mice but only 60% in CIB1-KO 
mice (Figure 5-3B).  Furthermore, ischemia-induced tissue damage was more severe in CIB1 
null mice.  Hind-paw toe regions of CIB1 null mice consistently presented with lower 
perfusion levels due to the onset of gangrene (Figure 5-3A).    
 
Incidence of nail and toe discoloration, toe loss, hind-paw cyanosis and edema, as 
well as impaired hind-limb function was assessed using previously described appearance and 
use scores(24).  At 14 days after femoral artery ligation, CIB1-KO mice presented with a 
nearly 3-fold increase in appearance score compared to WT littermates (Figure 5-4A).  
Similarly, use scores for CIB1-KO mice were elevated, indicating that CIB1-KO mice 
experienced significantly reduced hind-paw toe and hind-limb flexion (Figure 5-4B).  At 21 
days after liagation, WT mice regained full function of the ischemic hind-limb, but CIB1 null 
mouse hind-limbs never fully regained function, suggesting that muscle tissue damage in 
these mice was more severe. 
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Figure 5-4.  Reduced recovery in ischemic CIB1-KO hind-paws and hind-limbs.  
(A) As previously described, and as explained in the methods section, hind-paw and 
hind-limb appearance and use scores were obtained to assess the rate of recovery 
following ischemia in WT and CIB1-KO mice.  (n = 11 per mouse genotype; Mann-
Whitney U test, * P < 0.05, ** P < 0.01).  Error bars represent ± SEM.   
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Of the muscles in the distal hind-limb, the gastrocnemius muscle experiences the 
most significant amount of ischemia upon femoral artery ligation(31;32).  Decreased hind-
limb flexion, as demonstrated by elevated hind-limb use scores in CIB1-KO mice (Figure 5-
4B), suggests that these mice have increased gastrocnemius muscle tissue atrophy.  To 
determine the extent of this in WT and CIB1-KO mice, muscle tissue sections were obtained 
at 21 days from both ischemic and non-ischemic gastrocnemius muscles.  As previously 
reported, no significant difference in muscle fiber size or appearance was observed in WT 
ischemic and non-ischemic gastrocnemius muscles (Figure 5-5A).  This demonstrates that at 
21 days after femoral artery ligation WT mice are able to recover normally.  However, 
significant atrophy and fibrosis were detected in the gastrocnemius of CIB1-KO ischemic 
hind-limbs.  Average muscle fiber size in CIB1-KO ischemic gastrocnemius muscles was 
reduced by 23%, but in WT mice by only 6% (Figure 5-5B).  Thus, these data show that 
CIB1-KO mice experience more profound tissue damage following ischemic insult.    
 
5.4.4 CIB1-KO mice have decreased hind-limb ischemia-induced 
neovascularization. 
 
A deficiency in either or both angiogenesis or arteriogenesis (the remodeling of pre-
existing arteriole-to-arteriole collateral vessels) could explain the difference in tissue damage 
observed in WT and CIB1-KO mice following femoral artery ligation(33).  To first test the 
contributions of angiogenesis, we determined capillary densities in gastrocnemius muscles, 
which experience substantial ischemia immediately after femoral artery ligation(23).  
Compared to control, there was less of an increase in capillary density in CIB1-KO ischemic  
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Figure 5-5.  Decreased recovery in CIB1-KO mouse ischemic gastrocnemius 
muscles.  (A) Contrast enhanced H&E, and Masson’s trichrome (MT)-stained 
sections of WT and CIB1-KO mouse, ischemic and non-ischemic, hind-limb 
gastrocnemius muscles.  Scale bars, 50µm.  (B) Mean muscle fiber size (µm2) per 
muscle fascicle in ischemic and non-ischemic, WT and CIB1-KO gastrocnemius 
muscles.  Error bars represent SEM (n = 5-9 per mouse genotype; * P < 0.05). 
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tissue, as determined by isolectin GSL1-B4 staining (Figure 5-6A).   However, since the 
reduced muscle fiber size in CIB1-KO mice can confound this interpretation, capillary 
number-to-muscle fiber number ratio was determined(23).  The ratio was significantly 
elevated in WT ischemic gastrocnemi, yet virtually unchanged for CIB1-KO mice (Figure 5-
6B), thus providing evidence that CIB1-KO mice have reduced ischemia-induced adaptive 
angiogenesis.  This decreased angiogenic response likely contributes to the increase in 
muscle tissue damage and delayed recovery in ischemic CIB1-KO hind-limbs.   
 
The decreased angiogenesis in CIB1-KO mice following hind-limb ischemia could be 
due to either defects in CIB1-KO EC function and signaling (Chapter 3), or decreased 
availability of angiogenic growth factors from surrounding tissue.  Indeed, less VEGF was 
detected in the plasma of CIB1-KO mice 5 days after femoral artery ligation (Figure 5-7A).  
Initial assessments of CIB1-KO plasma using Luminex technology suggested that the 
difference in VEGF plasma levels was specific, since levels of other plasma proteins (i.e. 
fibrinogen, CD40 ligand, and haptoglobin) were not significantly affected (data not shown).  
Using ELISA, we also did not detect a difference in VEGF expression between ischemic and 
non-ischemic gastrocnemi of WT or CIB1-KO mice (Figure 5-7B).  Therefore, the decreased 
angiogenic response is likely due to a combination of reduced function and signaling of 
CIB1-KO ECs and perhaps low VEGF levels in plasma, but unlikely to be due to low VEGF 
levels in the gastrocnemi.   
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Figure 5-7.  Decrease in VEGF plasma levels in CIB1-KO mice but not in 
gastrocnemius muscles.  (A) VEGF levels in EDTA plasma pre- and 5 days post-
femoral artery ligation in WT and CIB1-KO mice, as determined by ELISA.  Error 
bars represent SEM (n = 4-10 mice per condition; * P < 0.05).  (B) No difference was 
observed in VEGF levels in gastrocnemius muscle tissue homogenates of WT and 
CIB1-KO mice (n = 8-10 mice per condition). 
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5.4.5 Ischemia-induced arteriogenesis in CIB1-KO mice is unaltered.   
 
Impaired arteriogenesis (expansion of collateral diameter) may also contribute to 
reduced recovery and perfusion in CIB1-KO ischemic hind-limbs, since it is initiated by 
flow-induced shear stress in pre-existing collaterals following arterial ligation(34).  To test 
this we used laser-Doppler velocimetry to measure perfusion in the middle of the hind-limb 
ventral adductor region, which contains the major collaterals capable of restoring blood flow 
to arterial trees below the point of the femoral artery ligation.  Following femoral artery 
ligation, increased perfusion was observed in these regions in both WT and CIB1-KO 
ischemic hind-limbs (Figure 5-8A; quantification in Figure 5-8B).  Consistent with other 
reports, perfusion in WT mice gradually increased and peaked at 7 days, followed by 
resolution by day 21(23).  However, in CIB1-KO mice an increase in perfusion in the 
collateral zone rose more slowly (Figure 5-8B).  This could reflect the decreased 
angiogenesis in the ischemic distal limb (Figure 5-6A & 5-6B), rather than impaired 
arteriogenesis.  This interpretation is supported by X-ray angiographic analysis 21 days post-
ligation, which indicated no significant difference in the number of vessels detected in the 
collateral zone (Figure 5-9A; and quantified in Figure 5-9B).  Angiography also revealed no 
difference in the number of vessels detected at baseline in the non-ligated WT and CIB1-KO 
hind-limbs (data not shown).  Thus, although the perfusion patterns are different for WT and 
CIB1-KO mice, positive collateral remodeling and formation appears unaltered. 
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Figure 5-8.  Hind-limb ischemia-induced collateral perfusion increased less 
rapidly in CIB1-KO mice.  (A) Scanning laser-Doppler perfusion images of the 
ventral surface of upper hind-limbs from the same mouse show a gradual increase 
then decrease in perfusion over time.  Wound suture line is identified by (*).  (B) 
Quantification of perfusion was performed as previously described, using areas 
marked in magenta (A), and expressed as the ratio of perfusion in ischemic-to-non-
ischemic hind-limb ventral adductor surfaces of WT and CIB1-KO mice.  Perfusion in 
WT mice peaked at 7d post-ligation, but in CIB1-KO mice it rose more slowly and 
peaked at 14d.   Values are means ± SEM (n = 11 for each mouse genotype; * P < 
0.05). 
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Figure 5-9.  Hind-limb ischemia-induced arteriogenesis is unaltered in CIB1-KO 
mice.  (A) Postmortem X-ray angiography of perforating collateral arteries in the 
adductor region 21d post-ligation.  Point of femoral artery (FA) ligation shows a 
disruption in the course of the femoral artery.  Examples of newly formed collaterals 
that connect the femoral artery to distal arteries are identified with arrowheads.  (B) 
Average number of newly formed collaterals in the adductor “mid-zone” is not 
significantly different between WT and CIB1-KO ischemic and non-ischemic hind-
limbs.  Error bars represent SEM (n = 5-7 per mouse genotype). 
 
 
 
 169
5.5 Discussion 
 
Mice deficient in CIB1 grow and develop normally, reach reproductive age, and have 
no overt vascular phenotype.  So far the only defect identified in CIB1-KO mice is male 
sterility due to a disruption of the haploid phase of spermatogenesis(22).  In Chapter 4 we 
show that CIB1-depleted ECs have attenuated signaling and decreased function.  
Furthermore, preliminary gene array studies in CIB1-KO ECs reveal decreased expression of 
genes that are critical for vasculogenesis and angiogenesis (i.e. Notch 1 and Tie2; Appendix 
A).  Not surprisingly however, we observe here that vasculogenesis, which facilitates blood 
growth in retinas of neonatal mice between P0 and P10, progresses normally in CIB1-KO 
mice.  This confirms that CIB1 does not affect the rate of vasculogenesis and is not essential 
for this process.  Furthermore, we do not observe a significant difference in the development 
of intermediate and deep capillary beds that form solely by angiogenesis between P8 and 
P18.   Thus, in lieu of our previous findings (described in Chapter 4), these observations 
suggest that compensatory mechanisms are likely taking place during developmental 
vasculogenesis and angiogenesis to override the loss of CIB1 and facilitate normal vessel 
growth.  Likely candidates for such compensation were previously mentioned in Chapter 4, 
and include the CIB1 homologs CIB2, CIB3, CIB4, and calmodulin.   
 
Although CIB1-KO mice have no defect in developmental angiogenesis, we observed 
in two different murine angiogenesis models (the oxygen-induced retinal angiogenesis assay 
and the hind-limb ischemia-induced angiogenesis assay) that CIB1-KO mice have impaired 
ischemia-induced pathological and adaptive angiogenesis.  Similarly, previous reports also 
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demonstrated that genes not essential for embryonic vasculogenesis and developmental 
angiogenesis, may still have significant roles in pathological and adaptive forms of 
angiogenesis (see Chapter 2, Table 2-3).  Prominent examples of this include KO mice for 
bFGF and the VEGF homolog P1GF(8;35).  Like CIB1-KO mice, embryonic angiogenesis 
and development is normal in both bFGF-KO and P1GF-KO mice.  However, deletion of 
bFGF or P1GF also leads to significantly impaired pathological angiogenesis in vivo during 
ischemia, inflammation, wound healing, and tumor growth (discussed in (7)).  Other 
examples of impaired ischemia-induced angiogenesis can also be observed in KO mice 
deficient in the intracellular non-receptor tyrosine kinase Etk (endothelial/epithelial tyrosine 
kinase)(7), MMP9(36), caveolin-1(37), ICAM-2(38), the prostaglandin E2 receptor(39), 
thrombopoietin (TPO)(40), and adiponectin(41).  Interestingly, some KO mice also 
demonstrate enhanced ischemia-induced angiogenesis despite having unaltered 
developmental angiogenesis, as is the case for integrin β3- and β5-KO mice(42).  Our study 
here indicates that CIB1 is another member of this growing group of genes that contribute to 
pathological and adaptive forms of angiogenesis but not to physiological forms of 
angiogenesis. 
 
In vivo, ischemia has several components, such as stasis of blood flow, decreased 
(acidic) pH, reduced glucose availability, accumulation of waste products (i.e. metabolites 
and lactic acid)(9).  However the primary feature of ischemia that affects vascular tissue is 
hypoxia.  This is demonstrated in vitro where induction of hypoxia alone in vascular cell 
cultures (i.e. cultures of ECs and vascular smooth muscle cells) can significantly alter gene 
expression and cellular behavior(43).  One key regulator of the hypoxic response is the 
 171
heterodimeric transcription factor HIF-1(44).  Under hyopoxic conditions HIF-1 induces the 
expression of EC mitogens such as VEGF(45).  In turn, secretion of VEGF activates ECs to 
facilitate further growth factor release (paracrine secretion of bFGF and PDGF), increase 
permeability, and induce further angiogenesis.  We show here that following hind-limb 
ischemia, VEGF plasma levels are reduced in CIB1-KO mice.  Pervious reports have 
demonstrated a direct-correlation between systemic VEGF plasma levels and the level of 
ischemia-induced angiogenesis(46).  Thus, decreased VEGF plasma levels in CIB1-KO mice 
may be one contributing factor to the observed decrease in angiogenesis in the ischemic 
gastrocnemius mucles of CIB1-KO mice. 
 
In addition, a robust angiogenic response following ischemic injury is highly 
dependent on EC signaling and function.  EC MMP2 expression is known to contribute to 
various forms of pathological angiogenesis, including ischemia-induced retinal 
angiogenesis(47).  MMP2 contributes to angiogenesis by degrading ECM proteins (i.e. 
collagen, fibronectin, and laminin) and proteolytically activating other proMMPs, such as 
proMMP9, which is also essential for mediating ischemia-induced angiogenesis(48).  
Accordingly, genetic deletion of MMP2 or MMP9 significantly reduces postnatal ischemia-
induced angiogenesis(36;49).  In Chapter 4, we demonstrated that CIB1-KO ECs have 
significantly attenuated adhesion-induced signaling and decreased growth factor-induced 
migration, proliferation, tubule formation, and MMP2 expression.  Thus it is very likely that 
these defects in CIB1-KO ECs contribute to a large extent to the blunted angiogenic response 
observed in both CIB1-KO ischemic retinas and hind-limb gastrocnemius muscles.    
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But CIB1-KO mice do not have a defect in arteriogenesis, which has also been show 
to involve EC function and MMP2-induced ECM degradation(33).  The differences in CIB1-
mediated angiogenesis and arteriogenesis likely arise from the different mechanisms that 
induce each process.  Previous reports demonstrate that ischemia-induced adaptive 
angiogenesis in the gastrocnemius is primarily driven by hypoxia in the surrounding 
tissue(50;51).  In contrast, arteriogenesis occurs independent of hypoxia (often at sites 
proximal to the hypoxic zone), and is instead induced by physical forces such as fluid shear 
stress(52).  These physical forces arise from a rapid change in blood pressure in a vascular 
bed following arterial occlusion and they force pre-existing collaterals to remodel in order to 
accommodate ischemic tissue demands.  X-ray angiography demonstrated no significant 
difference in neo-collateral formation in the adductor regions of CIB1-KO and WT hind-
limbs, therefore suggesting that this post-ischemic recovery mechanism is unaltered in CIB1-
KO mice. 
 
However, emerging reports argue that arteriogenesis is also an active growth process, 
rather than just a simple passive dilatation process caused by altered blood pressure(33).  In 
vitro evidence suggests that fluid shear stress can also activate ECs and alter their 
cytoskeletal dynamics(32).  It is also hypothesized that in vivo neo-collateral ECs can 
become activated and undergo increased proliferation and migration, thus ultimately 
facilitating an increase in collateral vessel diameter.  Bone marrow-derived macrophages, 
endothelial progenitor cells, and hemangiocytes can also contribute to the process of 
arteriogenesis(40).  Thus arteriogenesis obviously involves more than just one process and is 
regulated by multiple mechanisms that work in concert.  Hence, redundancies in these 
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mechanisms may help explain why CIB1-KO mice have unaltered arteriogenesis, 
eventhough CIB1-KO ECs demonstrate reduced function (Chapter 4). 
 
Therefore, collectively our study identifies a previously uncharacterized role for CIB1 
in the vasculature, and for the first time demonstrates that it has a role in angiogenesis in 
vivo.  Our study also demonstrates that CIB1 is critical for both pathological forms of 
ischemia-induced angiogenesis (in the retina) as well as adaptive forms of angiogenesis (in 
the hind-limb).  Finally, we provide evidence to show that CIB1 does not contribute to 
ischemia-induced arteriogenesis.  These are important findings since they suggest that CIB1 
can be a novel and specific therapeutic target for pathological angiogenesis in vivo.  
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CHAPTER 6 
 
 
 
Role of CIB1 in Growth Factor-Induced and 
Tumor-Induced Pathological Angiogenesis  
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6.1 Abstract 
 
In previous chapters we demonstrated that CIB1-KO ECs have a decrease in growth 
factor-induced migration, proliferation, tubule formation, monolayer resistance, and MMP2 
expression.  In this chapter we extend these findings further and demonstrate that CIB1-KO 
mouse tissue has attenuated growth factor-induced microvessel sprouting in ex vivo organ 
cultures, and in in vivo Matrigel plugs.  Since pathological angiogenesis is highly dependent 
on the expression and secretion of growth factors and MMPs, we hypothesized that in 
addition to reduced ischemia-induced angiogenesis (Chapter 5), CIB1-KO mice may also 
have a decrease in tumor-induced angiogenesis.  We tested this in two different xenograft 
tumor models, using either B16 melanoma or Lewis lung carcinoma tumor cells.   Melanoma 
tumors that developed in CIB1-KO mice were smaller in volume, had a distinct necrotic 
appearance, and reduced intratumoral microvessel density.  Similarly, carcinoma tumors that 
developed in CIB1-KO mice had decreased weight and volume, and had a different 
morphological appearance.  Preliminary evidence also demonstrates that CIB1-KO mice, also 
transgenic for the PyV-mT oncogene, have a decreased number of palpable breast cancer 
tumor nodules and a reduced tumor burden.  Thus, these findings emphasize the role of CIB1 
in adult pathological angiogenesis, and suggest that it has an important role in regulating 
tumor growth. 
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6.2 Introduction 
 
CIB1, is a 22kDa EF-hand-containing protein that was originally identified as a 
binding partner for the cytoplasmic tail of the platelet integrin αIIb(1).  In subsequent studies, 
CIB1 was found to inhibit agonist-induced αIIbβ3 activation in megakaryocytes(2).  But 
CIB1 is also widely expressed in various organs, tissues, and cell types, which suggests that 
it likely has additional roles independent of αIIb function(3;4).  Accordingly, CIB1 also binds 
and regulates the activity of various proteins including the transcription factor PAX3(5), the 
polo-like kianses Fnk and Snk(6), the inositol 1,4,5-triphosphate receptor(7), Rac3(8), 
PAK1(9), and FAK(10).  Among these binding partners, PAK1 and FAK have been show to 
regulate EC function in vitro, and contribute to angiogenesis in vivo(11-13).  Therefore this 
led us to investigate whether CIB1 can also play a role in EC function and angiogenesis.  
 
In previous chapters we demonstrate that CIB1 is essential for proper EC signaling 
and is required for various EC functions including migration, proliferation, nascent tubule 
formation, and monolayer resistance.  Loss of CIB1 in ECs also leads to an attenuated 
response to angiogenic growth factors such as VEGF and bFGF, which results in a decrease 
in the expression of the zinc-requiring matrix-degrading proteinase MMP2.  Furthermore, 
using different murine in vivo angiogenesis assays we demonstrate that although CIB1 is not 
essential for developmental retinal vasculogenesis and angiogenesis, CIB1-KO mice are 
nevertheless impaired in pathological as well as adaptive forms of ischemia-induced 
angiogenesis.  Although this data clearly shows that CIB1 facilitates tissue recovery after 
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ischemic injury and participates in angiogenesis in vivo, the role of CIB1 in the more 
complex angiogenic processes is still not defined.   
 
One such process is tumor-induced angiogenesis which is a hallmark of cancer and 
metastatic disease(14).  This pathological form of angiogenesis was first noticed a century 
ago, and was hypothesized by Folkman to be the process by which tumors grow and 
eventually invade surrounding tissue and distant sites(15).  It is now commonly accepted that 
neovascularization takes place in and around tumors in response to diffusible factors that 
tumor cells secret when they become hypoxic.  This occurs as tumors exceed 1-2 mm3 in size 
and O2 is unable to diffuse efficiently to the center of the tumor(16;17).  This hypoxic setting 
activates the heterodimeric transcription factor HIF-1 to induce expression of angiogenic 
growth factors and cytokines – a process that drastically alters the delicate balance between 
pro- and anti-angiogenic factors in the tumor microenvironment and tips the angiogenic 
switch in favor of angiogenesis(18;19).   Hence to a large extent, pathological tumor-induced 
angiogenesis ensues in a growth factor-dependent manner, and this dependency could be 
exploited to develop effective anti-tumor therapy.   
 
Recent successes in both pre-clinical and clinical studies have demonstrated that 
targeting the tumor vasculature is indeed a promising strategy for impeding tumor 
growth(20).  One such strategy that is still under development is the selective targeting of 
zinc-dependent matrix degrading proteinases such as the gelatinases MMP2 and 
MMP9(21;22).  Both MMP2 and MMP9 are secreted by most tumor cells as well as by 
activated tumor ECs(23).  They can also hydrolyze type IV collagen that is localized in the 
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basement membrane and is secreted in large amounts by malignant tumor cells(24).  To 
support this, studies have shown that MMP2 and MMP9 contribute to tumor progression and 
metastasis, and are essential for tumor-induced angiogenesis(25;26).  Furthermore, MMP2 
binds to the tumor EC-surface proteins MMP14 and integrin αvβ3 to perhaps modulate their 
activity and facilitate angiogenesis(27;28).  Although clinical trials that have tested anti-
MMP agents demonstrate that this treatment is associated with significant toxicities and 
untolerated side-effects, the efficacy and safety profile of selective anti-MMP2 agents has not 
yet been tested(22).  
 
Here we report that in addition to participating in ischemic recovery and ischemia-
induced angiogenesis (Chapter 5), CIB1 is also critical for mediating growth-factor induced 
angiogenesis ex vivo and in vivo.  Furthermore, we observe that in different murine tumor 
xenograft models, tumors that develop in CIB1-KO mice are smaller and are distinctly 
different in gross appearance compared to tumors that develop in WT controls.  Tumors in 
CIB1-KO mice are also more necrotic and have a decrease in intratumoral microvessel 
density.  These observations are corroborated by our preliminary findings that suggest that 
CIB1-KO mice, also transgenic for the PyV-mT oncogene(29), have less tumor formation 
and reduced tumor burden.  Thus our findings here demonstrate that CIB1 plays an important 
role in tumor growth and tumor-induced angiogenesis, and opens a new avenue of research in 
cancer biology. 
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6.3 Methods 
 
Aortic ring and tibialis anterior muscle ex vivo cultures.  Thoracic aortas were 
isolated from WT and CIB1-KO mice and placed in cold isolation media for at least 10 
minutes.  Aortas were microdissected into 1mm rings and placed between 2 layers of 250µL 
of GFR Matrigel (BD Biosciences) in a 24-well culture format.  Polymerized Matrigel was 
then overlaid with 300µL growth media, or basal media supplemented with 50ng/mL bFGF 
or VEGF (R&D Systems).  At 2, 5, and 8d, images of aortic rings and their newly formed 
blood vessels were collected and stitched together using PhotoFit Premium software 
(Tekmate, Tokyo, Japan).  In digitized images, the total number of sprouting microvessels at 
each time point, in WT and CIB1-KO aortic rings, was counted using ImageJ as described 
previously (n = 8 per group).  Identical procedures were used for the tibialis anterior muscle 
cultures, except that they were cultured only in growth media and images taken at 8d of 
culturing.  
 
Matrigel plug assay.  The in vivo Matrigel plug assay was performed as described 
previously with minor modifications(30;31).  WT and CIB1-KO mice were subcutaneously 
injected with approximately 300µL of GFR Matrigel mixed with 60 U/mL of heparin (Sigma, 
St. Louis, MO), or with heparin plus 250ng/mL bFGF or VEGF.  Fourteen days later, plugs 
were isolated along with adjacent skin and peritoneal muscle, fixed, and sectioned at 
interrupted intervals.  The total number of blood-vessels infiltrating four random interrupted 
sections was counted in H&E stained sections using a Nikon inverted microscope, and 
expressed as mean values of infiltrating blood vessels per plug (n = 3 per group). 
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 Tumor cell xenografts.  Male WT and CIB1-KO mice, at least 15 weeks old, were 
anesthetized with 1.125% isoflurane supplemented with 2:3 oxygen-air.  Rectal temperature 
was closely maintained at 37.0 ± 0.5˚C.  Hair was removed from the hind-limb ventral 
adductor thigh region using depilating cream, with care to avoid erythema.  Mice were given 
a single subcutaneous injection of either 5 x 105 B16 melanoma (purchased from UNC-CH 
Tissue Culture Facility) or 2.5 x 105 Lewis lung carcinoma cells (ATCC, Manassas, VA) that 
were impregnated in 50 uL of 50% growth factor reduced Matrigel (n = 8 - 11 mice per 
group). 
 
Assessment of necrosis and tumor microvessel density.  Fourteen days after tumor 
cell injection, tumors were isolated from animals and fixed in 2% PFA for 48h, with a 
solution change at 24h.  Tumors were rinsed in water, placed in 70% ethanol for 48h with 
shaking and another change of solution at 24h.   Four biopsies (~ 2-3 mm in size) were 
obtained from both the center and periphery of each tumor and embedded in paraffin.  At 
least 3 interrupted sections, 50µm apart were obtained and stained with H&E or Masson’s 
trichrome.  For each tumor, one interrupted section of all four biopsies was assessed for the 
incidence of blood lakes and necrosis (necrosis in more than 70% of the biopsy tissue). 
Representative images were captured at various magnifications using a Nikon D100 camera 
attached to a Nikon inverted microscope.  To assess capillary density, the plasma membrane 
of capillary ECs in tissue sections was labeled with Alexa Fluor 594 conjugated isolectin 
GSL-1-B4 (1:100; Invitrogen).  Using a Nikon TE2000U inverted fluorescent microscope 
with an OrcaER, four 20X images were collected for each biopsy to yield a total of 16 
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images per tumor.  The number of vessels with a clear lumen and < 7µm were counted by 
Weiping Yuan, who was blinded of animal group genotypes (n = 7 - 11 mice per group).  
Tumor microvessel density was reported as the average number of intratumoral microvessels.   
 
Laser-Doppler perfusion imaging.  Superficial hind-limb ventral adductor thigh 
regions where tumor cells were injection were monitored with noninvasive measurements 
using a scanning laser-Doppler perfusion imager (model LD12-IR, Moor Instruments) 
modified for high resolution and depth of penetration (2mm) with an 830nm-wavelenght 
infrared 2.5mW laser diode, 100µm beam diameter, and 15kHz bandwidth(32).  Prior to 
measurements, anesthesia, ventilation, and temperature were controlled using the same 
techniques as with tumor cell injection.  Blood perfusion measurements at the site of tumor 
injection were performed before, and at 1, 7, and 14 days after transplantation.  Regions of 
interest (ROIs) were drawn as previously described(32), to obtain average Doppler velocity 
at tumor site. To control for tumor size average velocity in a ROI was normalized to the 
tumor Feret diameter (√(4*Area)/π)(33;34).  Data were reported in normalized mean blood 
perfusion units (n = 8 - 9 mice per group). 
 
Generation of PyV-MT transgenic mice and tumor assessment.  PyV-MT 
transgenic mice and PCR primers used to verify geneotype were a generous gift from 
Victoria Bautch, UNC-CH.  PyV-MT male mice were crossed with CIB1-KO female mice to 
yield CIB1-HT/PyV-mT F1 offspring.  CIB1-HT/PyV-mT male mice were then crossed a 
second time with either CIB1-KO or WT females to yield CIB1-KO/PyV-mT and WT/PyV-
mT F2 offspring.  Mice were weaned into separate cages and monitored for tumor growth. 
 187
Two to three weeks after tumor onset mice were sacrificed and the number of palpable tumor 
nodules was assessed.    
 
Animal regulations.  All housing, breeding, and experimental procedures performed 
with mice were in accordance with national guidelines and regulations, and were approved 
by the UNC-CH Institutional Animal Care and Use Committee (IACUC). 
 
Statistical analysis.  We compared continuous variables using the Student’s t-test.   
For all animal studies, statistical significance was determined by an unpaired t-test for 
comparisons across animal groups (Wt versus CIB1-KO mice).  We considered P < 0.05 to 
be significant.   
 
6.4 Results 
 
6.4.1 CIB1 deficiency diminishes bFGF and VEGF-induced microvessel 
sprouting ex vivo.   
 
Expression of bFGF and VEGF is elevated several fold in ischemic tissue and in this 
setting they are major angiogenesis-stimulating factors(35).  In Chapter 4 we showed that 
CIB1-KO ECs have decreased bFGF and VEGF -induced migration, proliferation, tubule 
formation, and MMP2 expression.  In Chapter 5 we also demonstrated that CIB1-KO mice 
have decreased ischemia-induced angiogenesis in vivo.  Thus to determine whether CIB1-KO 
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ECs have a specific defect in growth factor-induced angiogenesis we performed two types of 
ex vivo organ culture assays. 
 
The ex vivo aortic ring organ culture assay is a commonly used technique that allows 
investigators to assess microvessel sprouting upon treatment with different types of 
angiogenic stimuli(36).  In this case, aortic rings of WT and CIB1-KO mice were isolated 
and cultured for 8 days in the presence of growth media, bFGF, or VEGF.  At 2 days of 
culturing both WT and CIB1-KO aortic rings produce microvessel sprouts.  However, by 5 
days of culturing a clear difference starts to emerge in the extent of microvessel sprouting 
from WT and CIB1-KO aortic rings.  Treatment with growth media, bFGF, and VEGF all 
yielded fewer microvessel sprouts in CIB1-KO aortic rings (Figure 6-1A, and quantified in 
Figure 6-1B).    This trend is even more dramatic at 8 days where CIB1-KO aortic rings 
cultured in growth media produced ~50% fewer microvessels, relative to WT aortic rings.  
Similarly, CIB1-KO aortic rings cultured in the presence of bFGF and VEGF produced 
~60% fewer microvessels.  At nearly all time points, WT and CIB1-KO aortic rings treated 
with growth media produced more microvessel sprouting than cultures that were treated with 
just bFGF or VEGF.  This is likely because fetal bovine serum in growth media contains high 
concentrations of various growth factors. 
 
We further assessed microvessel sprouting in WT and CIB1-KO mice by performing 
an ex vivo tibialis anterior muscle culture assay.  In this assay microvessels produced upon 
angiogenic growth factors stimulation are microvascular in nature – thus more closely 
resembling angiogenesis in vivo.  In this assay we observed a similar trend to that  
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Figure 6-1.  CIB1-KO aortic ring cultures demonstrate reduced growth factor-
induced microvessel sprouting ex vivo.  (A) Photo-stitched low-magnification DIC 
images of WT and CIB1-KO ex vivo aortic ring cultures show newly formed 
microvessels 8 days following treatment with growth media, bFGF, or VEGF.  Scale 
bar, 0.2mm.  (B) Quantification of microvessel sprouts of WT (solid line) and CIB1-
KO (dotted line) aortic rings cultured in growth media, or basal media supplemented 
with bFGF or VEGF.  Error bars are ± SEM (done in replicates of at least 4, n = 6-8 
aortas per genotype).  (C) High-magnification DIC images of microvessel sprouts in 
WT and CIB1-KO tibialis anterior muscle sections cultured in growth media for 8d 
(done in replicates of at least 2, n = 3 muscles per genotype).  Scale bar, 100µm.   
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found using the aortic ring assay.  At 8 days of culturing, CIB1-KO muscles cultured in 
growth media consistently form less microvessel sprouts (~50 - 60% less) compared to their 
WT controls (Figure 6-1C).  Thus this suggests that CIB1-KO tissue have a defect in growth-
factor induced angiogenesis. 
 
6.4.2 CIB1 deficiency diminishes bFGF and VEGF-induced microvessel 
sprouting in vivo. 
 
To determine whether CIB1-KO mice also have decreased growth-factor induced new 
blood vessel formation in vivo, we performed a subcutaneous Matrigel plug angiogenesis 
assay.  In this assay WT and CIB1-KO mice were injected with both untreated Matrigel plugs 
as well as plugs that were impregnated with either bFGF or VEGF.  Non-invasive Doppler 
flowmetery indicates that by 14 days after subcutaneous injection of plugs an increase in 
blood perfusion was clearly detectable (Appendix B).  Accordingly, 14 days after injection of 
plugs, histological examination confirmed a dramatic neovascularization of the growth 
factor-impregnated plugs in WT mice.  Although we observed cells in the growth factor-
impregnated plugs subcutaneously injected in CIB1-KO mice, overall the there were ~80% 
less microvessels in these plugs compared to WT controls (Figure 6-2A, and quantified in 
Figure 6-2B). 
 
6.4.3 Subcutaneous B16 melanoma tumors in CIB1-KO mice have increased 
necrosis and decreased angiogenesis. 
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Figure 6-2.  Growth factor containing Matrigel plugs have reduced microvessel 
sprouting in CIB1-KO mice. (A) Representative images of bFGF and VEGF 
reconstituted Matrigel plugs that were subcutaneously injected in WT and CIB1-KO 
mice for 14 days.  Newly formed microvessels are indicated by arrowheads.  Scale 
bar, 25µm. (B) Quantification of microvessels infiltrating untreated, or bFGF or 
VEGF reconstituted, Matrigel plugs subcutaneously injected in WT and CIB1-KO 
mice.  Error bars represent SEM (n = 3-7 plugs per group); * P < 0.05, ** P < 0.001. 
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Almost all tumor cells secrete angiogenic growth factors and MMPs to stimulate the 
growth of new blood vessels(14;16;23).  Since CIB1-KO mouse tissue demonstrates reduced 
growth factor-induced angiogenesis, we asked whether CIB1-KO mice also have a defect in 
tumor-induced angiogenesis.  To examine this we xenografted WT and CIB1-KO mice with 
B16 melanoma tumor cells, which are known to secrete angiogenic growth factors such as 
VEGF, bFGF, and PDGF, but only very low levels of gelatinases MMP2 and MMP9(25;37).  
These rapidly dividing tumor cells were injected subcutaneously in the adductor region of the 
mouse hind-limb since laser Doppler flowmetery suggested that this area has relatively low 
blood perfusion (Appendix B).  At 14 days after tumor cell injection, signs of tumor necrosis 
were observed in a large subset of CIB1-KO mice (Figure 6-3A).  This prompted us to 
immediately terminate the study.  The incidence of morphologically apparent melanoma 
tumor necrosis in CIB1-KO mice was nearly double that observed for WT mice (Figure 6-
3B).  Furthermore, dissection of melanoma tumors that developed in CIB1-KO reveled that 
they were less dense, fluid-laden, and surrounded by pockets of bleeding.  Although the 
tumors isolated from WT and CIB1-KO mice demonstrate no significant difference in tumor 
weight, the melanoma tumor volume in CIB1-KO mice was reduced by 32%.  
 
Higher incidence of tumor necrosis was observed in biopsies obtained from the center 
and periphery of tumors isolated from CIB1-KO mice compared to WT mice (Figure 6-4A, 
and quantified in Figure 6-4B).  However this difference was not statistically different.  
Tumors isolated from CIB1-KO mice also had a slightly higher incidence of hemorrhage 
(observed in the form of intratumoral blood lakes) compared to WT mice,  
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Figure 6-3.  Higher incidence of morphological necrosis in B16 melanoma tumors 
that developed in CIB1-KO mice (A) Representative images of melanoma tumors 
that developed in WT and CIB1-KO mice.  Study was terminated 14 days after the 
subcutaneous injection of tumor cells in the hind-limb adductor regions due to onset 
of tumor necrosis in CIB1-KO mice.  (B) Summarizes the incidence of necrosis in 9 
WT and 11 CIB1-KO mice.  Sixty-seven percent of the CIB1-KO mice studied in this 
ssay demonstrated tumor necrosis, while only 33.3% of WT mice had some signs of 
 
a
necrosis. 
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Figure 6-4.  Increased necrosis and bleeding in CIB1-KO melanoma tumors.  (A) 
Representative images of H&E (i and iii) and Masson’s trichrome (MT; ii and iv) 
stained sections of melanoma tumors that developed in WT (i and ii) and CIB1-KO (iii 
and iv) mice.  Necrosis (indicated by N) is observed in H&E-stained sections of tumors 
isolated from both WT and CIB1-KO mice, but appeared more common in tumors that 
developed in CIB1-KO mice.  Bleeding in the form of blood lakes (BL) is also evident 
in H&E and MT-stained sections of tumors isolated from both groups.  Blood lakes in 
tumors that developed in CIB1-KO mice appeared larger.  MT-stained melanoma 
tumors isolated from CIB1-KO mice had scattered foci of fibrosis identified by arrows 
(iv). Scale bars, 50µm.  (B) The incidence of necrosis in 4 biopsies per tumors per 
animal is elevated in CIB1-KO mice, P = 0.06.  (C) A slightly increased incidence of 
blood lakes was also observed in tumors isolated from CIB1-KO mice, P = 0.13.  Error 
bars represent SEM (n = 8-11 mice per group). 
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however this difference was also not statistically significant (Figure 6-4A, and quantified in 
Figure 6-4C).  Isolectin GSL1-B4 stained microvessels were observed in tissue sections of 
biopsies of melanoma tumors isolated from both WT and CIB1-KO.  At high magnification 
we observed that the microvessel density in melanoma tumors in CIB1-KO mice was 30% 
less than that observed in tumors isolated from WT mice (Figure 6-5A, and quantified in 
Figure 6-5B).  Therefore, not only do xenografted melanoma tumors in CIB1-KO mice have 
increased necrosis, but they also have significantly reduced intratumoral neovascularization. 
 
6.4.4 Subcutaneous Lewis lung carcinoma tumors in CIB1-KO mice have 
reduced tumor growth. 
 
To expand our findings, we carried out another xenograft tumor model and 
subcutaneously injected WT and CIB1-KO mice with Lewis lung carcinoma tumor cells.  
Like B16 melanoma tumor cells, these cells secrete a variety of growth factors.  However, 
unlike B16 melanoma tumor cells, Lewis lung carcinoma tumor cells can secrete MMP2 and 
MMP9 in vivo(25).  In this assay we observed that carcinoma tumors that developed in CIB1-
KO mice were decreased in weight as well as volume compared to tumors that developed in 
WT mice (Figure 6-6A & Figure 6-6B).  Moreover, compared to carcinoma tumors that 
developed in WT mice, tumors that developed in CIB1-KO mice appeared paler, suggesting 
that there is a difference in tumor blood perfusion between the two groups (Figure 6-6C).   
To test this we performed non-invasive Doppler flowmetery on tumors that developed in WT 
and CIB1-KO mice.  Although this technique revealed high levels of perfusion in specific 
intratumoral areas, we did not observe any significant difference between WT and CIB1-KO  
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Figure 6-5.  Decreased intratumoral microvessel density in melanoma tumors isolated 
from CIB1-KO mice.  (A) Representative Isolectin GSL1-B4-stained melanoma tumor 
sections in three different WT and CIB1-KO mice.  Scale bars, 50µm.  (B) Quantification 
of microvessel density from 16 randomly collected digital frames from each tumor.  Data is 
presented as the average number of vessels per digital frame.  Error bars represent SEM (n 
= 5-9 per mouse genotype; * P < 0.001). 
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Figure 6-6.  Decreased Lewis lung carcinoma tumor weight and volume in CIB1-KO 
mice.   (A, B) Weight and volume of tumors that formed in CIB1-KO mice were 
decreased by approximately 33%.  Error bars represent SEM (n = 5-9 per mouse 
genotype; * P < 0.05).  (C) Representative images of carcinoma tumors that developed in 
WT and CIB1-KO mice, 14 days after subcutaneous injection of tumor cells in the 
adductor region of the hind-limb. 
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carcinoma tumor perfusion (Figure 6-7A, and quantified in Figure 6-7B).  Nevertheless, we 
found that this technique was extremely useful in providing a real-time assessment of 
intratumoral blood perfusion (Appendix B). 
 
6.4.5 CIB1-KO mice preliminarily demonstrate a reduced capacity to form PyV-
mT driven breast cancer tumors.  
 
Mice transgenic for the PyV-mT oncogene have been widely used to study mammary 
tumorigenesis and metastasis(38).  Since our findings using subcutaneous xenograft tumor 
models suggest that CIB1-KO mice have reduced tumor-induced angiogenesis, increased 
tumor necrosis, and decreased tumor growth, we hypothesized that these features would 
render CIB1-KO mice more resistant to spontaneous tumor growth.  To test this we crossed 
CIB1-KO mice with PyV-mT transgenic mice.  From this cross, F2 generation WT/PyV-mT 
and CIB1-KO/PyV-mT transgenic mice were isolated and monitored for tumor growth.  
Preliminary evidence suggests that although time to tumor onset in female CIB1-KO/PyV-
mT mice (~3 months) was unaffected, CIB1-KO/PyV-mT mice had smaller and less 
numerous breast tumors (Figure 6-8A).  Approximately 14 days after tumor onset the number 
of palpable breast tumor nodules in CIB1-KO/PyV-mT female mice is nearly two-fold less 
than that observed in WT/PyV-mT mice (Figure 6-8B).  These findings suggest that loss of 
CIB1 may inhibit aggressive breast tumor growth and decrease overall tumor burden. 
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Figure 6-7.  Lewis lung carcinomas growing in WT and CIB1-KO mice both 
demonstrated an increase in tumor blood perfusion.   (A) Scanning laser-Doppler 
perfusion images of the ventral surface of upper hind-limbs where tumor cells are 
subcutaneously injected.  Growing tumors are outlined in brown.   (B) Quantification 
of perfusion was performed and corrected to Feret’s diameter as described in the 
methods section.  Data is expressed in arbitrary perfusion units (PU).  Error bars are ± 
SEM (n = 8-9 mice per group). 
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Figure 6-8.  Decreased tumor formation in CIB1/PyV-mT transgenic mice.  (A) 
Representative images of breast tumors that developed over 14 days after tumor onset 
in WT and CIB1-KO female littermate mice that are also transgenic for PyV-mT.  
CIB1-KO mice form less tumor nodules compared to WT mice.  (B) Number of 
palpable breast cancer tumor nodules in CIB1/PyV-mT mice was reduced. Total 
breast tissue weight and volume is significantly reduced in CIB1-KO mice. Error bars 
are ± SEM (n = 2-3 mice per group). 
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6.5 Discussion 
 
It is widely accepted that angiogenesis proceeds when the net balance between pro-
angiogenic and anti-angiogenic molecules is tipped in favor of angiogenesis(14).  
Pathological ischemia- and tumor-induced angiogenesis are both facilitated by the local 
release of various angiogenic growth factors and MMPs(39;40).  Surrounding tissues respond 
excessively to these stimuli and induce the aberrant formation of new blood vessels.  In 
previous chapters we demonstrated that CIB1-KO ECs have decreased VEGF- and bFGF-
induced function and signaling.  We also observed a significant decrease in ischemia-induced 
pathological and adaptive angiogenesis in CIB1-KO mice.  Therefore these findings suggest 
that CIB1 may have an important role in growth factor-induced angiogenesis.  To test this 
more specifically we performed two different ex vivo organ culture assays and an in vivo 
Matrigel plug assay.  In all these assays, CIB1-KO mouse tissue had an attenuated response 
to VEGF- and bFGF-induced microvessel formation, suggesting once again that CIB1 is 
necessary for growth factor-induced angiogenesis and angiogenesis in vivo.  
 
Previous reports have demonstrated that in addition to angiogenic growth factors, 
MMP2 expression and secretion is essential for ischemia- and tumor-induced 
angiogenesis(23;40).    We demonstrate (in Chapter 4) that CIB1 can regulate VEGF- and 
bFGF-induced MMP2 expression.  Therefore, to test whether this defect can affect tumor-
induced angiogenesis in vivo, we subcutaneously injected CIB1-KO mice with tumor cells 
that endogenously expression very low levels of MMP2 (B16 melanoma tumor cells) or with 
tumor cell that express MMP2 at high levels (Lewis lung carcinoma cells)(25;37).  Our 
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observations clearly demonstrate that in an MMP2 deficient environment, B16 melanoma 
tumors that develop in CIB1-KO mice are smaller in volume, and morphologically and 
histologically more necrotic.  In addition, melanoma tumors that developed in CIB1-KO 
mice demonstrate reduced microvessel density, thus providing evidence that CIB1-KO mice 
have reduced tumor-induced angiogenesis.  On the other hand, Lewis lung carcinoma tumors 
that developed in CIB1-KO mice did not present with gross tumor necrosis.  Perhaps 
endogenous expression of MMP2 by the carcinoma tumor cells is able to compensate for 
defects in MMP2 expression by CIB1-KO ECs, therefore enhancing tumor survival.  
Nevertheless, carcinoma tumors that develop in CIB1-KO mice are smaller (have decreased 
weight and volume), suggesting that other mechanisms in addition to EC expression of 
MMP2 contribute to xenograft tumor growth.  In Chapter 4 we demonstrate that CIB1-KO 
ECs have attenuated PAK1 activation and decreased migration, proliferation, and tubule 
formation.  It is possible that any or all of these defects also contribute to the decrease in 
xenograft tumor growth in CIB1-KO mice.   
 
Another possible mechanism that may have contributed to our observations in the 
xenograft tumor assays is the reduced capacity for CIB1-KO ECs to efficiently form 
intracellular junctions.  In Chapter 4 we observed decreased monolayer resistance in CIB1-
KO ECs, suggesting that CIB1 was necessary for proper EC monolayer permeability.  Here 
we observe that B16 melanoma tumors in CIB1-KO mice are more fluid-laden and are 
surrounded by pockets of hemorrhage and bleeding.  Although it is not statistically 
significant, intratumoral blood lakes also occur at a slightly higher incidence in melanoma 
tumors that develop in CIB1-KO mice.  These observations imply that tumor permeability is 
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increased in CIB1-KO mice.  Related to this, we also observed in preliminary gene 
expression arrays of CIB1-KO ECs a decrease in expression of EC adhesion molecules such 
as PECAM1 and VE-Cadherin (Appendix A).  Not only are these molecules important for 
maintaining EC monolayer integrity and regulating other EC functions (such as migration 
and tubule formation), but they can also affect tumor growth(41-43).  For example, local 
administration of anti-murine antibodies for PECAM1 and VE-Cadherin can inhibit both 
growth factor- and tumor-induced angiogenesis in vivo(41;44).  Thus, like PECAM1-KO 
mice (which are fertile and viable(45)) CIB1-KO mice may also have an underlying 
endothelial permeability defect that does not manifest overly.  Depending on its severity it 
can decrease tumor permeability and growth, as well as tumor-induced angiogenesis.  An 
extensive study to determine whether or not CIB1-KO mice have altered endothelial 
permeability is currently underway. 
 
We also preliminarily observe a decreased in tumor growth in the breast tissue of 
CIB1-KO/PyV-mT transgenic mice.  These observations support our findings in the B16 
melanoma and Lewis lung carcinoma xenograft tumor assays.  Since our previous findings 
also demonstrate that CIB1-KO mice have decreased pathological angiogenesis, it is possible 
that we observe reduced tumor burden in CIB1-KO/PyV-mT mice as a result of decreased 
tumor-induced angiogenesis.  However, we acknowledge that there may be other factors that 
contribute to our observations in CIB1-KO/PyV-mT mice.  For example, it is possible that 
CIB1 has a direct role in breast cancer tumor cells.  Recently, our laboratory has identified 
important roles for CIB1 in epithelial, prostate, and neuroblastoma tumor cells (Tina Leisner, 
Bin Zhou, and Cassandra Moran, unpublished data).  CIB1 was also recently found to bind 
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and regulate PDK1, which can activate the AGC protein kinase family, and regulate tumor 
cell growth, survival, and cell cycle progression.  In prostate cancer cells CIB1 was found to 
mediate cell survival, and upon depletion of CIB1 in these cells, apoptosis was increased in 
response to damaging agents (Bin Zhou, unpublished data).  Thus, it is possible that the lack 
of CIB1 may be directly affecting the rate of proliferation, invasiveness, and metastatic 
potential of CIB1-KO/PyV-mT breast cancer cells.   
 
Therefore, in conclusion, we describe here a previously uncharacterized role for CIB1 
in tumor growth and breast cancer.  We also provide additional evidence demonstrating the 
crticial role of CIB1 in growth factor- and tumor-induced pathological angiogenesis.  These 
findings, along with our observations from previous chapters, indicate that CIB1 may serve 
as a novel selective drug target for inhibiton of pathological angiogenesis in vivo.  
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7.1 Conclusion 
 
One of the surprises of modern science arose from the human genome project.  
Compared to an estimated 14,000 genes in the Drosophila, the human genome has only a 
mere 30,000 genes(1).  This indicates that the complexity of human physiology is surely not 
in scale with the number of genes that regulate it.  This discordance is in part attributed to the 
complex translational machinery in humans which facilitates more alternative splicing and 
post-translational modifications.  However, more importantly the complexity in all 
mammalian tissue is also likely due to a high level of molecular interplay between cellular 
proteins.  These interactions give rise to sophisticated regulatory networks that are 
interconnected and affect cells and tissues in multiple ways. 
 
This thesis represents substantial efforts to try to understand the biological function of 
the regulatory protein CIB1.  Previously, CIB1 had only been studied in platelets, 
megakaryocytic, and transformed cell lines.  The work presented in this thesis shows that 
CIB1 also plays a novel and important role in vascular ECs.  In vitro, ex vivo, and in vivo 
complementary analysis, described herein, demonstrate the critical roles of CIB1 in EC 
function and angiogenesis.  Furthermore, we show that CIB1 can affect the activation of 
signaling molecules such as PAK1, which regulate the angiogenic response of ECs.  We also 
demonstrate that although CIB1 is not essential for developmental vasculogenesis and 
angiogenesis, it plays an important role in pathological and adaptive forms of ischemia-
induced angiogenesis, as well as pathological tumor-induced angiogenesis.   Thus, these 
findings give rise to various new insights about the biological functions of CIB1, its role in 
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neovasculature, as well as the process of angiogenesis in general.  A summary of these 
considerations follows below. 
 
7.2 CIB1 is ubiquitously expressed but is not essential for tissue growth and 
development. 
 
CIB1 is expressed to a high degree in platelets(2), and megakaryocytes(3), as well as 
various transformed cell lines such as REF52 fibroblasts(4), HeLa ovarian epithelial cancer 
cells (Tina Lesiner, unpublished data), SK-N-SK neuroblastoma cells (Cassandra Moran, 
unpublished data), PC3 prostate cancer cells (Bin Zhao, unpublished data), and cells of 
megakaryocytic/erythrocytic linage (DAMI, Meg 01, K562, and HEL)(5).  CIB1 mRNA and 
protein is also detected in nearly all human and mouse organs, and between the two species it 
is found in the testis, heart, brain, lung, liver, skeletal muscle, kidney, pancreas, and bone 
marrow(5;6).   We expand this list further and demonstrate here that CIB1 mRNA is also 
expressed in the mouse embryo and is present in primitive mouse embryonic structures such 
as the yolk sac and placenta.  For the first time, we also demonstrate that CIB1 is expressed 
in various species and types of vascular ECs.  Thus collectively these findings clearly 
demonstrate that CIB1 is ubiquitously expressed in human and mouse tissue, and implies that 
CIB1 may have greater roles than previously thought. 
 
Mice that are deficient in CIB1 are viable and reach adulthood(7).  In fact, besides a 
male sterility defect, CIB1-KO mice appear to be phenotypically normal.   This argues that 
CIB1 is not essential for normal growth and development, which is intriguing but certainly is 
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not a unique finding.  Like CIB1-KO mice, many knockout mouse models for important 
regulatory proteins do not induce a lethal phenotype, and at times can yield mice that are 
completely normal (Chapter 2, Table 2-3).  There are several reasonable explanations for 
why this can happen.  As mentioned earlier, intracellular molecular signals in mammalian 
tissue are highly complex, and have numerous interconnections that work in concert with one 
another.  Thus, redundancies in molecular signaling pathways may easily mask defects in 
pathways that are in parallel.  This was shown to be the case for mice deficient in either 
MMP2 and/or MT1-MMP.  MMP2 and MT1-MMP work in concert to activate other MMPs 
to facilitate angiogenesis, blood vessel remodeling, as well as organ growth(8).  When either 
gene is deleted the mouse survives with only mild defects(9;10).  However, when both genes 
are deleted a lethal phenotype results immediately following birth suggesting that MMP2 and 
MT1-MMP behave similarly and that at least one is required for survival(11).  It is possible 
that CIB1 is not essential for survival, development, and growth, because other molecules 
that behave like CIB1 are able to mask its deficiency.     
 
So far, various CIB1 homologs have been identified.  These include the CIB1 family 
members CIB2 (59% similarity), CIB3 (62% similarity), and CIB4 (64% similarity)(12).  
Other CIB1 homologs also include calcineurin B (58% similarity) and calmodulin (56%)(2), 
as well as the primarily neuronally expressed KChIP1 (46% similarity), neurocalcin (46% 
similarity), and frequenin (43% similarity)(12).  It is highly likely therefore that at least one 
of these proteins can compensate for the loss of CIB1 in CIB1-KO mouse tissue.  Studies are 
currently underway to determine if the expression of any of these homologs is altered in 
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CIB1-KO mouse tissue.  Preliminary results indicate that at least CIB3 and CIB4 mRNAs are 
overexpressed in CIB1-KO megakaryocytes (Jan DeNofrio, unpublished data). 
 
7.3 Depletion of CIB1 significantly decreases various EC functions. 
 
Various investigators have demonstrated that CIB1 can regulate the activity of a 
number of proteins that contribute to a diverse set of physiological functions (including 
DNA-repair, apoptosis, transcription, integrin activation, and adhesion; reviewed in (13)).  
The effects of CIB1 on cellular functions is variable.  In certain situations, CIB1 has been 
found to dramatically alter cell function (~90% inhibition of agonist-induced αIIbβ3 
activation in megakaryocytes(3)), while in other situations the effects of CIB1 are more 
modest (~25% inhibition of InsP3R channel activation; measured in the form of channel open 
probability(14)).  Here, for the first time, we show that CIB1 also plays a functional role in 
microvascular ECs.  Although most of the CIB1 functions are partial (loss of CIB1 does not 
completely abrogate EC function), they are nevertheless significant relative to controls.  Thus 
we conclude from our findings that CIB1 critically regulates EC functions such as migration, 
proliferation, tubule formation, and monolayer permeability. 
 
7.4 CIB1 regulates PAK1 and ERK1/2 activation in ECs, but likely affects other EC 
signals. 
 
In addition to altering EC function, CIB1 can also regulate PAK1 activation in ECs.  
This confirms a pervious report that also shows a similar association between CIB1 and 
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PAK1(4).  We also found that ERK1/2 activation, which is downstream of PAK1, is 
attenuated in CIB1-KO ECs.  Therefore, from these results we conclude that the observed 
decrease in CIB1-KO EC function maybe at least in part affected by decreased PAK1 
activation.  However, we also acknowledge that additional studies are needed to confirm this 
signaling pathway.  For example, constitutively active PAK1 should be expressed CIB1-KO 
ECs to determine whether any signaling or functional defects are normalized. 
 
Furthermore, in addition to PAK1 and ERK1/2, we also acknowledge that altered 
CIB1-KO functions may be influenced by other signaling pathways.  This is probable since 
CIB1 binds to various types of proteins that influence different signaling pathways(13).  
Studies are currently underway to determine if the known interactions between CIB1 and 
FAK as well as integrin α chains, can contribute to the phenotypes we observe in CIB1-KO 
ECs and CIB1-KO mice, in vitro and in vivo, respectively.  Moreover, preliminary gene 
expression arrays indicate that CIB1-KO ECs have altered expression of various important 
genes that can greatly affect EC function and angiogenesis in vivo (i.e. Tie1, Tie2, PECAM1, 
VE-Cadherin, VEGF, fibronectin; Appendix A).  Confirmations of these preliminary results 
are currently underway, and understanding their contributions to our observations is certainly 
a high priority.  
 
7.5 CIB1 may also have a role in other cell types that contribute to angiogenesis. 
 
The basic angiogenesis model primarily focuses on ECs (Figure 2-1), and proposes 
that EC functions such as proliferation, migration, and nascent tubule formation play a 
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central role in angiogenesis in vivo.  However, it is becoming increasingly clear that other 
cell types such as fibroblasts, pericytes, and smooth muscle cells are also necessary for 
angiogenesis to proceed(15).  For example, PDGF-β-KO mice are embryonically lethal due 
decreased pericyte recruitment to newly formed vessels(16;17).  This in turn leads to the 
formation of excessive aneurisms and results in hemorrhage.  Similarly, mice deficient in 
endoglin are embryonically lethal as a result of defective smooth muscle cell differentiation 
which severely limits the extent of vascular remodeling(18).  A few reports have already 
implicated CIB1 in fibroblast migration and proliferation(4;7).  Therefore, it is possible that 
other cell types in addition to ECs are affected by the loss of CIB1 and are contributing to the 
angiogenesis defects we observe in CIB1-KO mice.  Since these contributions are not yet 
fully defined, this topic is certainly still open for further investigation.  
 
7.6 Developmental angiogenesis is fundamentally different from adult pathological 
angiogenesis. 
 
Our results show that CIB1 is required for pathological as well as adaptive forms of 
angiogenesis.  However, our studies also confirm that the developing retinal vasculature in 
CIB1-KO mice demonstrates no significant defects in vasculogenesis and developmental 
angiogenesis.  Therefore, CIB1 joins a growing number of genes that are not important for 
developmental and physiological angiogenesis, but are necessary for pathological forms of 
angiogenesis(19;20).  We postulate that these differences occur because of the following 
reasons: i) Genes are differentially expressed between the developing embryonic vasculature 
and the adult endothelium, ii) Physiological angiogenesis is far more regulated than 
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pathological angiogenesis, and depends on the spatial and temporal expression of growth 
factors and angiogenesis mediators, and iii) Physiological angiogenesis is much more critical 
for survival, and therefore may have built in redundancies to overcome any defects that can 
occur during this process.  Therefore, it is apparent that there are important molecular and 
functional differences between physiological and pathological angiogenesis.  In the future, it 
may become increasingly popular to exploit these differences in order to enhance drug 
selectivity and decrease toxicities of anti-angiogenic therapies.   
 
7.7 Angiogenesis is a graded phenomenon 
 
Our data also adds to a growing body of evidence that shows that angiogenesis occurs 
in a graded fashion(21).  In CIB1-KO mice we observed that pathological angiogenesis is 
significantly reduced.  However, CIB1-KO mice always demonstrate a partial angiogenic 
response in each in vivo assay we performed.  The same was also observed in knockout 
mouse models for a large set of genes, which include bFGF(22), MMP2(10), integrin α2(23), 
ICAM1(24), PKG(25), etc (see Table 2-3).  Thus, this suggests that instead of an ‘angiogenic 
switch’, which implies either an ‘on’ or ‘off’ state, pathological angiogenesis could be better 
described as an ‘angiogenic seesaw,’ which more appropriately implies a graded angiogenic 
effect that depends on the extent of the imbalance between pro- and anti-angiogenic factors. 
 
7.8 CIB1 is a candidate for pro-angiogenic treatment as well as anti-angiogenic 
treatment. 
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Finally our studies propose CIB1 as a novel target for pro- and anti-angiogenic 
therapy.  In conditions such as ischemic heart disease and peripheral vascular disease, 
overexpression of CIB1 may facilitate an increase in angiogenesis, thus alleviating ischemia-
associated tissue damage, morbidity, and mortality.  On the other hand, in growing tumors, 
and in conditions such as diabetic retinopathy and age-related macular degeneration, 
inhibition of CIB1 may decrease neovascularization, thus reducing the severity and 
progression of the disease.  One hypothetical advantage of CIB1 therapy may be that it will 
have little effect on physiological angiogenesis, and will instead be more selective to 
pathological or adaptive forms of angiogenesis.  On the other hand, the challenge of 
delivering such therapy will to a large extent depend on our ability to selectively target the 
endothelium.  This is because CIB1 is expressed in various cell types and tissues.  Thus non-
specific CIB1-targeting therapy may yield unwanted side effects.  Strategies for selective 
targeting of the endothelium are slowly emerging and over the coming years may yield new 
and exciting opportunities for pro- and anti-angiogenic therapy. 
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APPENDIX A 
Preliminary Gene Expression Analysis of CIB1-KO ECs 
 
Gene 
Name Description % Change 
Ghr Growth hormone receptor -77.25 
Cdh5 Cadherin 5 -59.81 
Kitl Kit ligand -53.82 
Tie1 Tyrosine kinase receptor 1 -52.33 
Tek Endothelial-specific receptor tyrosine kinase -45.62 
Itga4 Integrin alpha 4 -43.05 
Pecam1 Platelet/endothelial cell adhesion molecule 1 -42.63 
Fn1 Fibronectin 1 -40.40 
Esam1 Endothelial cell-specific adhesion molecule -38.87 
Ccnl1 Cyclin L1 -36.04 
Vegfa Vascular endothelial growth factor A -30.78 
Hif1an Hypoxia-inducible factor 1, alpha subunit inhibitor  -28.94 
Bmp1 Bone morphogenetic protein 1 -28.59 
Efnb2 Ephrin B2 -26.85 
Ctgf Connective tissue growth factor -25.37 
Igf1r Insulin-like growth factor I receptor -25.35 
Eng Endoglin -22.93 
Tgfb2 Transforming growth factor, beta 2 -22.48 
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Tgfa Transforming growth factor alpha -21.77 
Notch1 Notch gene homolog 1 (Drosophila) -20.30 
Itga5 Integrin alpha 5 (fibronectin receptor alpha) -17.26 
Timp1 Tissue inhibitor of metalloproteinase 1 -17.13 
Hif1a Hypoxia inducible factor 1, alpha subunit -15.87 
Angpt1 Angiopoietin 1 -15.78 
Mmp9 Matrix Metallopeptidase 9 -15.57 
Bmpr2 bone morphogenic protein receptor, type II (serine/threonine kinase) 45.50 
Mmp2  Matrix metallopeptidase 2 45.88 
Notch2 Notch gene homolog 2 (Drosophila) 46.61 
Tgfbr2 Transforming growth factor, beta receptor 46.66 
Tgfb3 Transforming growth factor, beta 3 47.56 
Thbs2 Thrombospondin 2 47.57 
Vcam1 Vascular cell adhesion molecule 1  50.05 
Pdgfb Platelet derived growth factor, B polypeptide 54.02 
Plat Plasminogen activator, tissue 63.73 
Itgb3bp Integrin beta 3 binding protein (beta3-endonexin) 65.81 
Vegfc Vascular endothelial growth factor C 80.88 
Thbs3 Thrombospondin 3 85.75 
Flt1 FMS-like tyrosine kinase 1 90.31 
Plat Plasminogen activator, tissue 90.59 
Angpt4 Angiopoietin 4 98.63 
Bmpr1a Bone morphogenetic protein receptor, type 1A 103.14 
Pdgfra Platelet derived growth factor receptor, alpha  112.75 
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Egfr Epidermal growth factor receptor 113.07 
Fgf10 Fibroblast growth factor 10 128.68 
Cdh11 Cadherin 11 148.13 
Tnc Tenascin C 226.09 
Ptn Pleiotrophin 1324.54 
 
Percent change represents the relative level of gene expression from male CIB1-KO 
MHECs versus male WT MHECs.  Total RNA was isolated using a Qiagen RNeasy Mini 
Kit (Qiagen, Austin, TX) from serum starved duplicate MHEC cultures.  RNA purity and 
quality were confirmed, and labeled by RNA amplification method at UNC-CH Genomics 
Core Facility.    Labeled RNA was hybridized to 4x44K mouse genome microarrays 
(Aglient, Santa Clara, CA) and scanned with an Aglient scanner.  Normalized single channel 
ratios were obtained and averaged for each gene.  Percent change in gene expression in 
CIB1-KO MHECs was calculated, and a subset of the most dramatically changed genes is 
presented above.  A negative value indicates lower gene expression and a positive value 
indicates higher gene expression.  Also provided are the common gene name, and the 
description of the gene product.   
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